

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 956 360 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
14.06.2006 Bulletin 2006/24

(21) Application number: 97946609.1

(22) Date of filing: 07.11.1997

(51) Int Cl.:

<i>C12P 21/06</i> ^(2006.01)	<i>C12N 15/00</i> ^(2006.01)
<i>C12N 7/00</i> ^(2006.01)	<i>C12N 7/04</i> ^(2006.01)
<i>A61K 39/21</i> ^(2006.01)	<i>A61K 39/12</i> ^(2006.01)
<i>A61K 39/275</i> ^(2006.01)	<i>A01N 63/00</i> ^(2006.01)
<i>C07K 14/155</i> ^(2006.01)	

(86) International application number:
PCT/US1997/020430

(87) International publication number:
WO 1998/021354 (22.05.1998 Gazette 1998/20)

(54) **POXVIRUS-BASED EXPRESSION VECTORS CONTAINING HETEROLOGOUS INSERTS
DERIVED FROM LENTIVIRUSES**

AUF POCKENVIREN BASIERENDE EXPRESSIONSVEKTOREN, WELCHE HETEROLOGE DNA-
EINFÜGUNGEN AUS LENTIVIREN ENTHALTEN

VECTEURS D'EXPRESSION A BASE DE POXVIRUS CONTENANT DES INSERTS
HETEROLOGUES DERIVES DE LENTIVIRUS

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: 14.11.1996 US 746668

(43) Date of publication of application:
17.11.1999 Bulletin 1999/46

(73) Proprietor: Connaught Technology Corporation
Greenville,
DE 19807 (US)

(72) Inventors:
• TARTAGLIA, James
Schenectady, NY 12303 (US)
• PAOLETTI, Enzo
Delmar, NY 12054 (US)

(74) Representative: Vossius, Volker et al
Dr. Volker Vossius,
Patentanwaltskanzlei - Rechtsanwaltskanzlei,
Geibelstrasse 6
81679 München (DE)

(56) References cited:

- GONIN P. ET AL.: "Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus." VETERINARY MICROBIOLOGY, vol. 45, no. 4, 1995, pages 393-401, XP002231897 ISSN: 0378-1135
- BEATTY J. A ET AL: "A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction." JOURNAL OF VIROLOGY, vol. 70, no. 9, 1996, pages 6199-6206, XP002231898 ISSN: 0022-538X
- AIDS RES. HUMAN RETRO., 1995, Vol. 11, No. 8, FRANCHINI et al., "Highly Attenuated HIV Type 2 Recombinant Poxviruses, but not HIV-2 Recombinant Salmonella Vaccines, Induce Long-Lasting Protection in Rhesus Macaques", pages 909-920.
- VIROL., 1993, Vol. 195. COX et al., "Induction of Cytotoxic T Lymphocytes by Recombinant Canarypox (ALVAC) and Attenuated Vaccinia (NYVAC) Viruses Expressing the HIV-1 Envelope Glycoprotein", pages 845-850.
- J. GEN. VIROL., 1992, Vol. 73, WARDLEY et al., "The Use of Feline Herpesvirus and Baculovirus as Vaccine Vectors for the Gag and Env Genes of Feline Leukaemia Virus", pages 1811-1818.

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 956 360 B1

- BIOLOGICALS, 1995, Vol. 23, PINCUS et al., "Poxvirus-Based Vectors as Vaccine Candidates", pages 159-164.
- AIDS RES. HUMAN RETRO, 1995, Vol. 11, No. 8, OKUDA et al., "Induction of Potent Humoral and Cell-Mediated Immune Responses Following Direct Injection of DNA Encoding the HIV Type 1 Env and Rev Gene Products", pages 933-943.
- VIRUS RES., 1994, Vol. 32, GONDA et al., "Bovine Immunodeficiency Virus: Molecular Biology and Virus-Host Interactions", pages 155-181.
- PROC. NATL. ACAD. SCI. U.S.A., April 1989, Vol. 86, OLMSTED et al., "Molecular Cloning of Feline Immunodeficiency Virus", pages 2448-2452.
- J. VIROL., December 1990, Vol. 64, No. 12, WHETTER et al., "Equine Infectious Anemia Virus Derived from a Molecular Clone Persistently Infects Horses", pages 5750-5756.

- VIROL., 1993, Vol. 193, ANDRESSON et al., "Nucleotide Sequence and Biological Properties of a Pathogenic Proviral Molecular Clone of Neurovirulent Visna Virus", pages 89-105.
- VIROL., 1990, Vol. 179, SALTARELLI et al., "Nucleotide Sequence and Transcriptional Analysis of Molecular Clones of CAEV which Generate Infectious Virus", pages 347-364.

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description**STATEMENT OF POSSIBLE GOVERNMENT RIGHTS**

- 5 **[0001]** Some work reported herein may have been supported by a NIH/NIAID grant (R01-AI30904) and a Virogenetics Corp./University of Florida collaborative grant. The government may have certain rights (without prejudice or admission).

RELATED APPLICATIONS

- 10 **[0002]** Reference is made to U.S. application Serial No. 08/417,210 filed April 5, 1995 as a continuation-in-part of application Serial No. 08/223,842, filed April 6, 1994 which in turn is a continuation-in-part of application Serial No. 07/897,382, filed June 11, 1992 (now U.S. application Serial No. 08/303,275, filed September 7, 1994), which in turn is a continuation-in-part of application Serial No. 07/715,921, filed June 14, 1991. Application Serial No. 08/417,210 is also a continuation-in-part of application Serial No. 08/105,483, filed August 13, 1993, now U.S. Patent No. 5,494,807, 15 which in turn is a continuation of application Serial No. 07/847,951, filed March 6, 1992, which in turn is a continuation-in-part of application Serial No. 07/713,967, filed June 11, 1991, which in turn is a continuation in part of application Serial No. 07/666,056, filed March 7, 1991 (now U.S. Patent No. 5,364,773). Mention is also made of co-pending allowed application serial No. 08/184,009, filed January 19, 1994 as a continuation-in-part of application Serial No. 08/007,115, filed January 20, 1993.

FIELD OF THE INVENTION

- 20 **[0003]** The present invention relates: to certain product(s) from lentivirus, retrovirus and/or immunodeficiency virus, e.g., HIV, SIV, EIAV, BIV, FIV, comprising certain epitope(s) of interest, preferably Env, Gag, Pol, and accessory gene products, e.g. Tat, Rev, more preferably of Gag and Pol or Env, Gag and Pol and most preferably Gag and protease; 25 to certain nucleic acid molecule(s), e.g., RNA, DNA, encoding the product(s); to a vector, preferably a mammalian vector system, comprising the nucleic acid molecule(s) and preferably expressing the product(s) as exogenous to the vector; to the product(s) obtained or obtainable from expression by the vector; to immunological, immunogenic and/or vaccine compositions comprising the vector and/or the product(s); to methods for preparing the product(s); to methods for preparing the vector; to methods for preparing the compositions; and to methods for using the product(s), vector and compositions, including methods for obtaining an immunological response such as by immunization regimens wherein the product(s), vector and/or compositions are administered alone or in a prime/boost configuration with inactivated lentivirus, retrovirus or recombinant subunit preparations, e.g., in a prime/boost configuration with an inactivated infected cell vaccine or immunological or immunogenic composition (ICV).

- 30 **[0004]** The invention especially relates to recombinant immunological, immunogenic or vaccine compositions and their utility in stimulating a response, such as providing protection against a lentivirus challenge exposure, including exposure to a heterologous strain. The recombinant composition is preferably comprised of a mammalian vector system expressing lentivirus gene products used in effective immunization regimens alone or in a prime/boost configuration with inactivated lentivirus preparations (e.g., ICV) or recombinant subunit preparations.

- 35 **[0005]** Several documents are referenced in this application. Full citation to these documents is found at the end of the specification immediately preceding the claims or where the document is mentioned; and each of these documents is hereby incorporated herein by reference.

BACKGROUND OF THE INVENTION

- 40 **[0006]** The patent and scientific literature includes various mammalian vector systems such as mammalian virus-based vector systems and mammalian DNA-based vector systems, and how to make and use these vector systems, for instance for cloning of exogenous DNA and expression of proteins, as well as uses for such proteins and uses for products from such proteins.

- 45 **[0007]** For instance, recombinant poxvirus (e.g., vaccinia, avipox virus) and exogenous DNA for expression in this viral vector system can be found in U.S. Patent Nos. 4,603,112, 4,769,330, 5,174,993, 5,505,941, 5,338,683, 5,494,807, 5,503,834, 4,722,848, 5,514,375, U.K. Patent GB 2 269 820 B, WO 92/22641, WO 93/03145, WO 94/16716, PCT/US94/06652, and allowed U.S. application Serial No. 08/184,009, filed January 19, 1994. See generally Paoletti, "Applications of pox virus vectors to vaccination. An update," PNAS USA 93:11349-11353, October 1996; Moss, "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety," PNAS USA 93:11341-11348, October 1996, and Pincus et al (1995).

- 50 **[0008]** Baculovirus expression systems and exogenous DNA for expression therein, and purification of recombinant proteins therefrom can be found in Richardson, C.D. (Editor), Methods in Molecular Biology 39, "Baculovirus Expression

Protocols" (1995 Humana Press Inc.) (see, e.g., Ch.18 for influenza HA expression, Ch.19 for recombinant protein purification techniques), Smith et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Molecular and Cellular Biology, Dec., 1983, Vol. 3, No. 12, p. 2156-2165; Pennock et al., "Strong and Regulated Expression of *Escherichia coli* β -Galactosidase in Infect Cells with a Baculovirus vector," Molecular and Cellular Biology Mar. 1984, Vol. 4, No. 3, p. 399-406; EPA 0 370 573 (Skin test and test kit for AIDS, discussing baculovirus expression systems containing portion of HIV-1 env gene, and citing U.S. application Serial No. 920,197, filed October 16, 1986 and EP Patent publication No. 265785).

[0009] U.S. Patent No. 4,769,331 relates to herpesvirus as a vector. Wandley describes the use of feline herpesvirus and baculovirus as vaccine vectors for the Grg and Env genes of feline leukemia virus. See also Roizman, "The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors," PNAS USA 93:11307-11312, October 1996; Andreansky et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors," PNAS USA 93:11313-11318, October 1996. Epstein-Barr virus vectors are also known. See Robertson et al. "Epstein-Barr virus vectors for gene delivery to B lymphocytes," PNAS USA 93:11334-11340, October 1996. Further, there are alphavirus-based vector systems. See generally Frolov et al., "Alphavirus-based expression vectors: Strategies and applications," PNAS USA 93:11371-11377, October 1996.

[0010] There are also poliovirus and adenovirus vector systems (see, e.g., Kitson et al., J. Viral. 65, 3068-3075, 1991; Grunhaus et al., 1992, "Adenovirus as cloning vectors," Seminars in Virology (Vol. 3) p. 237-52, 1993; Ballay et al. EMBO Journal, vol. 4, p. 3861-65; Graham, Tibtech 8, 85-87, April, 1990; Prevec et al., J. Gen Virol. 70, 429-434). See also U.S. applications Serial Nos. 08/675,556 and 08/675,566, filed July 3, 1996 (adenovirus vector system, preferably CAV2) and PCT WO91/11525 (CAV2 modified to contain a promoter-gene sequence within the region from the SmaI site close to the end of the inverted terminal repeat region up to the promoter for the early region 4 (E4)).

[0011] There are also DNA vector systems. As to transfecting cells with plasmid DNA for expression therefrom, reference is made to Felgner et al. (1994), J. Biol. Chem. 269, 2550-2561. As to direct injection of plasmid DNA as a simple and effective method of vaccination-against a variety of infectious diseases reference is made to Science, 259: 1745-49, 1993. See also McClements et al., "Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease," PNAS USA 93:11414-11420, October 1996.

[0012] In 1983, human immunodeficiency virus type 1 (HIV1) was identified as the causative agent of AIDS and was subsequently classified into the lentivirus subfamily of the retrovirus family (Hardy, 1990). Other members of the lentivirus subfamily are equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), Simian immunodeficiency virus (SIV) and HIV-2. Much attention within the field of medical virology has been focused on the AIDS pandemic caused by infection with HIV. This lentivirus system has been scrutinized with respect to its molecular biology, immunobiology and pathogenesis in an effort to develop safe and effective vaccines and antiviral therapies. To date, HIV, as well as other lentiviral vaccine studies using different vaccine types have encountered varying degrees of success (Heeney et al., 1994; Daniel et al., 1992; Fultz et al., 1992; Girard et al., 1991; Issel et al., 1992). Further, knowledge is still lacking on the relevance of specific HIV immune responses on vaccine efficacy in humans. Thus, after many years, despite a massive, worldwide effort, an effective HIV1 vaccine is still not available.

[0013] Infection of cats with feline immunodeficiency virus (FIV) causes persistent infection and AIDS-like immunosuppressive diseases similar to the HIV infection. As such, FIV infection of cats provides a model for investigating lentivirus immunopathogenicity and vaccine development (Pedersen et al., 1987; Johnson et al., 1994). Similar to HIV, heterogeneity exists, such that multiple FIV subtypes exist (Sadora et al., 1994; Okada et al., 1994). Indeed, like HIV, FIV strains have been classified into four subtypes (A-D) based on genetic differences predominantly in the env and, to a lesser extent gag coding regions.

[0014] Beatly et al., describes a longitudinal study of feline immunodeficiency virus-specific T lymphocytes in experimentally infected cats, using antigen-specific induction.

[0015] Thus, while inactivated whole FIV vaccines and inactivated FIV-infected cell vaccines (ICV) have obtained protection against homologous and slightly heterologous FIV (Hosie et al., 1995; Johnson et al., 1994; Yamamoto et al., 1991, 1993), these same vaccines failed to induce protective immunity against distinctly heterologous FIV strains of other subtypes such that induction of protective immunity against a broad range of FIV subtypes may call for a modified or different vaccine approach. This obviously raises concerns relevant to vaccine development. It must also be noted that the FIV prevalence in the cat population is greater than HIV is in man (Verschoor et al., 1996). The development of an FIV vaccine or immunogenic composition is not only useful in providing a model for an HIV vaccine or immunogenic composition but is also therefore of importance from a veterinary health perspective.

[0016] More particularly, from the previous FIV studies (Hosie et al., 1995; Johnson et al., 1994; Yamamoto et al., 1991, 1993) it was observed that only cats with significant FIV Env-specific serum reactivity were likely to be protected against homologous challenge exposure. In no case were vaccine-administered animals lacking such a response observed to be protected against FIV challenge (Johnson et al., 1994; Yamamoto et al., 1991, 1993). Together, these results coupled to the observations, to date, that subunit immunogens have not been shown to elicit a protective immune

response in target species bring to the forefront several important points relevant to the state-of-the-art for FIV and lentivirus, vaccine development in general. Grouiy et al. describes an immunization trial of cats with a replication-defective-adenovirus type 5 expressing the Env gene of feline immunodeficiency virus. One exception perhaps is with the simian immunodeficiency virus (SIV)/macaque system where certain recombinant subunit preparations (including vaccinia-based recombinants) or combinations of these recombinant subunits have conferred, at least, partial protection from SIV challenge exposure (Hu, 1992; 1994; 1995). This data is somewhat limited in scope since complete protection from infection was not observed and challenge studies were not performed with a distinctly heterologous SIV strain. Moreover, no level of protection was afforded by recombinant subunits devoid of an SIV Env component (Hu et al., 1994).

[0017] Relevant to FIV vaccine development, no sub-unit based vaccine candidate has been taught or suggested; there is no teaching as to how to develop a subunit vaccine; and, it is not obvious as to how to develop a subunit-based vaccine candidate.

[0018] Secondly, a different or perhaps modified approach, as compared to the inactivated conventional vaccines, needs to be developed to afford protection against heterologous strains (Hosie et al., 1995; Johnson et al., 1994).

[0019] Lastly, Env-specific immune responses in protective immunity may be important (Johnson et al., 1994; Yamamoto et al., 1991, 1993). Indeed, in Flynn et al., "ENV-specific CTL Predominate in Cats Protected from Feline Immunodeficiency Virus Infection by Vaccination," *The Journal of Immunology*, 1996, 157:3658-3665, at 3664 the authors conclude "that FIV Env-specific CTL may be more effective in protective immunity to FIV infection of domestic cats" such that "future vaccine strategies should be aimed at eliciting both humoral and cell-mediated immune responses that are long-lived, recognize appropriate epitopes on the viral envelope glycoprotein, and are targeted to tissues known to sequester virus."

[0020] It can thus be appreciated that provision of a feline immunodeficiency virus recombinant subunit immunogenic, immunological or vaccine composition which induces an immunological response against feline immunodeficiency virus infections when administered to a host, e.g., a composition having enhanced safety such as NYVAC- or ALVAC- based recombinants containing exogenous DNA coding for an FIV epitope of interest, such as of FIV Env, Gag, or Pol, especially in an immunogenic configuration, or any combination thereof, for instance, FIV Gag-protease, Gag-Pol, or Gag and a portion of Pol (such as a portion of Pol including protease) or all of Env, Gag and Pol or a portion of Pol, in combination, would be a highly desirable advance over the current state of technology. Further, use of such recombinants or compositions containing such recombinants in a prime-boost regimen, e.g., wherein the recombinant composition is used in an initial immunization and a subsequent immunization is with an inactivated FIV, or ICV, or other recombinant subunit preparation would be a highly desirable advance over the current state of technology.

[0021] And more generally, it can thus be appreciated that provision of a lentivirus, retrovirus or immunodeficiency virus recombinant subunit immunogenic, immunological or vaccine composition which induces an immunological response against the lentivirus, retrovirus or immunodeficiency virus infections when administered to a host, e.g., a composition having enhanced safety such as NYVAC- or ALVAC- based recombinants containing exogenous DNA coding for a lentivirus, retrovirus, or immunodeficiency virus epitope of interest, such as Env, Gag, or Pol, especially in an immunogenic configuration, or any combination thereof, for instance, Gag-protease, Gag-Pol or Gag and a portion of Pol (such as a portion including protease) all of Env, Gag and Pol or a portion of Pol, in combination such as Env, Gag-protease, in combination, would be a highly desirable advance over the current state of technology. Further, use of such recombinants or compositions containing such recombinants in a prime-boost regimen, e.g., wherein the recombinant composition is used in an initial immunization and a subsequent immunization is with an inactivated lentivirus, retrovirus or immunodeficiency virus, or ICV, or other recombinant subunit preparation, such as a respective inactivated virus, ICV or other recombinant subunit preparation would be a highly desirable advance over the current state of technology (As to "respective", if the recombinant is, for example an FIV recombinant, inactivated FIV or an FIV ICV preparation may be "respective").

OBJECTS AND BDNARY OF THE INVENTION

[0022] It is therefore an object of the invention to provide certain product(s) from lentivirus, retrovirus and/or immunodeficiency virus, e.g., HIV, SIV, EIAV, BIV, FIV, visna virus, carpine arthritis-encephalitis virus, comprising certain epitope(s) of interest, preferably Env, Gag, Pol or epitopes thereon, with optional accessory functions or proteins or epitope(s) of interest thereon e.g. Tat and/or Rev, more preferably Gag and Pol, or Env, Gag and Pol, or Gag and a portion of Pol, or Env, Gag and a portion of Pol, especially such a portion including protease, and most preferably Gag and protease, or Env, Gag and protease, or epitopes thereon, with optional accessory functions or proteins, e.g., Tat and/or Rev or other such functions/proteins, or epitopes thereon.

[0023] The first object of the invention is a vector comprising exogenous DNA encoding at least one FIV epitope, characterized in that the vector is a canarypox virus.

[0024] In one embodiment of the first object of the invention the vector is characterized in that the canarypox virus is the ALVAC strain, or is a Rentschler vaccine strain obtained by (a) attenuation of a Rentschler vaccine strain through

more than 200 serial passages on chick embryo fibroblasts, (b) subjecting a master seed therefrom to four successive plaque purifications under agar, and (c) amplifying a plaque clone through five additional passages.

[0025] In a further embodiment the vector is characterized in that the DNA encoding the at least one FIV epitope encodes all or part of (a) Gag-Pol, (b) Gag-protease, (c) Env, Gag-Pol, or (d) Env, Gag-protease.

[0026] In a third embodiment the vector is characterized in that the DNA encoding the at least one FIV epitope encodes all or part of Gag-Pol or Gag-protease.

[0027] In even a fourth embodiment the vector is characterized in that the DNA encoding the at least one FIV epitope encodes all or part of Env, Gag-Pol, or Env, Gag-protease.

[0028] In a fifth embodiment of the first object of the invention the vector is vCP242, vCP253, vCP255, or vCP329, said vector comprising exogenous DNA encoding at least one FIV epitope, wherein vCP242, vCP253, vCP255, or vCP329 are recombinants of the ALVAC strain, wherein vCP242 comprises DNA encoding Env, vCP253 comprises DNA encoding Gag-protease, vCP255 comprises DNA encoding Env, Gag-protease and wherein vCP329 comprises DNA encoding 97TM, Gag-protease.

[0029] The second object of the invention is the use of the vector of the first object of the invention or the first three embodiments thereof in admixture with a suitable carrier for the preparation of an antigenic, immunological or vaccine composition for inducing an antigenic or immunological or protective response in a feline animal.

[0030] The third object of the invention is the use of the vector of the fourth and fifth embodiments of the first object of the invention in admixture with a suitable carrier for the preparation of an antigenic, immunological or vaccine composition for inducing an antigenic or immunological or protective response in a feline animal.

[0031] The fourth object of the invention is the use of the vector of the first object of the invention or the first three embodiments thereof for the preparation of a therapeutic composition for treatment of seropositive feline animals in need of therapy to stimulate or boost the immune system against a homologous or heterologous strain of FIV.

[0032] The fifth to seventh object of the invention are compositions for inducing an immunological response comprising: a vector of the first object of the invention or the first three embodiments thereof, a vector of the fourth, or a vector of the fifth embodiment of the first object of the invention, respectively in admixture with a suitable carrier.

[0033] The eighth object of the invention is a method for expressing a gene product in a cell cultured *in vitro* comprising introducing into the cell a vector of the first object of the invention or the first five embodiments thereof.

[0034] Other accessory functions or proteins which can be included in the product(s) or epitope(s) of interest include any or all of net, vpu, vit, vpr, and vpx or epitope(s) thereon, *inter alia*; see Trono, D., Cell, 82:189-192, July 28, 1995.

Such accessory functions or proteins may be considered non-envelope functions or proteins which can be included in the product(s) or epitope(s) of interest, e.g. for induction of a cellular response. For instance, for a given lentivirus, retrovirus or immunodeficiency virus pathogen, that pathogen's accessory function(s) or protein(s) or epitope(s) thereon can be included; for example, the product(s) could thus include Gag-Pro plus accessory function(s) or protein(s) or epitope(s) thereon.

[0035] Certain nucleic acid molecule(s), e.g., RNA, DNA, encoding the product(s), e.g., encoding certain epitope(s) of interest such as Gag and protease or all of Env, Gag and Pol, are described.

[0036] A vector, preferably a mammalian vector system, comprising the nucleic acid molecule(s) and preferably expressing the product(s) as exogenous to the vector, e.g., a poxvirus, baculovirus, herpesvirus, Epstein-Barr, alphavirus, poliovirus, adenovirus or DNA vector system is disclosed, as well as the product(s) obtained or obtainable from expression by the vector. An immunological, immunogenic and/or vaccine composition comprising the vector and/or the product(s) is described, as well as methods for preparing the product(s) or preparing the vector, or preparing the compositions.

[0037] Furthermore, methods for using the product(s), vector and compositions, including methods for obtaining an immunological response such as by immunization regimens wherein the product(s), vector and/or compositions are administered alone or in a prime/boost configuration with inactivated lentivirus, retrovirus or recombinant subunit preparations, e.g., in a prime/boost configuration with an inactivated infected cell vaccine or immunological or immunogenic composition (ICV), such as a respective ICV, are disclosed.

[0038] The present invention thus relates to recombinant immunological, immunogenic or vaccine compositions and their utility in eliciting a response such as by providing protection against lentivirus, retrovirus or immunodeficiency virus challenge exposure in a target species.

[0039] More in particular, the invention relates to a mammalian vector system for the insertion and expression of foreign genes for use as safe immunization vehicles to elicit a response such as a protective immune response against lentiviruses, retroviruses or immunodeficiency viruses.

[0040] A mammalian vector system, which expresses gene products (e.g., a gene product including an epitope of interest) of a lentivirus, retrovirus or immunodeficiency virus such as EIAV, FIV, BIV, HIV, or SIV, with feline immunodeficiency virus (FIV) presently preferred is described as well as an immunogenic and/or immunological and/or vaccine compositions which induce an immunological and/or protective response against a lentivirus, retrovirus or immunodeficiency virus such as EIAV, FIV, BIV, HIV, or SIV exposure when administered to the target host, e.g., FIV and a feline, such as a domesticated cat or kitten.

[0041] In one aspect, a mammalian vector (e.g., poxvirus, baculovirus, herpesvirus, Epstein-Barr, alphavirus, poliovirus, adenovirus or DNA vector system, preferably a poxvirus) expressing a lentivirus, retrovirus or immunodeficiency virus epitope of interest, e.g., EIAV, FIV, BIV, HIV, or SIV, preferably FIV is disclosed, and, the epitope of interest is preferably Gag/protease. The vector is useful in the protection of the target species (e.g., feline) against a highly homologous challenge exposure; and accordingly, an immunological, immunogenic or vaccine composition comprising the vector and optionally an acceptable carrier or diluent is disclosed

[0042] In another aspect, a method for inducing an immunological response, preferably a protective response comprising administering the vector or composition comprising the vector to a host as disclosed. The method can be an immunizing regimen, e.g., priming with the vector or composition comprising the vector (and expressing the lentivirus, retrovirus or immunodeficiency virus (e.g., FIV) epitope(s) of interest gene products) and boosting with a respective lentivirus, retrovirus or immunodeficiency subunit preparation (e.g., FIV inactivated whole cell (ICV) preparation) or with a respective lentivirus, retrovirus or immunodeficiency recombinant subunit preparation (e.g., FIV epitope(s) of interest from isolating such from expression of a recombinant containing exogenous nucleic acid molecule(s) encoding the same) to elicit an immunological response such as conferring protection to the host (e.g., cats) against homologous and heterologous lentivirus, retrovirus or immunodeficiency virus isolates.

[0043] Additional a recombinant poxvirus antigenic, vaccine or immunological composition having an increased level of safety compared to known recombinant poxvirus vaccines are described as well as a modified vector for expressing a gene product in a host, wherein the vector is modified so that it has attenuated virulence in the host. Furthermore a method for expressing a gene product in a cell cultured *in vitro* using a modified recombinant virus or modified vector having an increased level of safety is disclosed.

[0044] In a further aspect, a vector, preferably a modified recombinant virus having inactivated virus-encoded genetic functions so that the recombinant virus has attenuated virulence and enhanced safety is disclosed. The functions can be non-essential, or associated with virulence (e.g., essential). The virus is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus and canarypox virus. The vector which is preferably a modified recombinant virus can include, within an essential or nonessential region of the virus genome, a heterologous DNA sequence which encodes an antigen or epitope derived from a lentivirus, retrovirus or immunodeficiency virus, e.g., EIAV, FIV, BIV, HIV, or SIV, preferably feline immunodeficiency virus, such as, e.g., Env, Gag, Pol, accessory functions (e.g. Tat, Rev), or any combination thereof, such as Gag-Pol or Env, Gag, and Pol or Gag and a portion of Pol or Env, Gag and a portion of Pol, such as a portion of Pol including protease, or Gag-protease or Env, Gag, and protease.

[0045] In another aspect, an antigenic, immunological, immunogenic or vaccine composition or a therapeutic composition for inducing an antigenic or immunological or protective response in a host animal such as a feline, e.g., domesticated cat or kitten, inoculated with the composition is disclosed, the composition can include a carrier and an inventive vector which is preferably a modified recombinant virus having inactivated nonessential virus-encoded genetic functions so that the recombinant virus has attenuated virulence and enhanced safety; or the expression product of such a vector or modified recombinant virus. The virus used in the composition (or for expressing a product for use in a composition) is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus and canarypox virus. The modified recombinant virus can include, within an essential or nonessential region of the virus genome, a heterologous DNA sequence which encodes an antigenic protein, e.g., an epitope of interest derived from a lentivirus, retrovirus or immunodeficiency virus, e.g., EIAV, FIV, BIV, HIV, or SIV, preferably feline immunodeficiency virus, such as an antigen, e.g., Env, Gag, protease, or any combination thereof, such as Gag-protease or Env, Gag, and protease.

[0046] In yet another aspect a method for inducing an antigenic, immunological, immunogenic, vaccine (protective), and/or therapeutic response in a host animal such as a feline, e.g., domesticated cat or kitten, for instance, a host animal in need of such a response is disclosed comprising administering an amount of the aforementioned composition effective to obtain the response, either alone or as part of a prime-boost regimen (e.g., administering the composition or administering either or both of an inactivated lentivirus, retrovirus or immunodeficiency virus or ICV or IWV either before or after administering the composition).

[0047] In a further aspect, a method for expressing a gene product in a cell *in vitro* by introducing into the cell an inventive vector, such as a modified recombinant virus having attenuated virulence and enhanced safety is described. The vector or modified recombinant virus can include, within a nonessential or essential region of the virus genome, a heterologous DNA sequence which encodes an epitope of interest such as an antigenic protein, e.g. derived from a retrovirus, lentivirus or immunodeficiency virus, e.g., EIAV, FIV, BIV, HIV, or SIV, preferably feline immunodeficiency virus, such as, e.g., Env, Gag, Pol, accessory functions (e.g. Tat, Rev), or any combination thereof, such as Gag-Pol, or Env, Gag and Pol, or Gag and a portion of Pol or Env, Gag or a portion of Pol wherein the portion can include protease, or Gag-protease or Env, Gag, protease. The gene product can be harvested from the cells, or the cells can then be reinfused directly into an animal or used to amplify specific reactivities for reinfusion (*Ex vivo* therapy).

[0048] Thus, in a specific further aspect, a method for expressing a gene product in a cell cultured *in vitro* by introducing into the cell a vector or preferably a modified recombinant virus having attenuated virulence and enhanced safety is disclosed. The vector or modified recombinant virus can include, within an essential or nonessential region of the virus

genome, a heterologous DNA sequence which encodes an epitope of interest or an antigenic protein, e.g., derived from a lentivirus, retrovirus, or immunodeficiency virus, e.g., EIAV, FIV, BIV, HIV, or SIV, preferably feline immunodeficiency virus, such, e.g., Env, Gag, Pol, accessory functions (e.g. Tat, Rev), or any combination thereof, such as Gag-Pol, or Env, Gag and Pol, or Gag and a portion of Pol, or Env, Gag and a portion of Pol, wherein the portion can include a

protease, or Gag-protease or Env, Gag, protease. The product can then be administered to a host to stimulate a response. **[0049]** Antibodies can be raised by compositions including the vectors or recombinants or expression products of the vectors or recombinants. The antibodies raised can be useful in a host for the prevention or treatment of a lentivirus, retrovirus or immunodeficiency virus such as feline immunodeficiency virus. The antibodies or the expression products of the inventive vectors or recombinants can be used in diagnostic kits, assays or tests to determine the presence or absence in a sample such as sera of lentivirus, retrovirus or immunodeficiency virus, e.g., feline immunodeficiency virus, or antigens thereof or antibodies thereto or of recombinants of the present invention.

[0050] In a still further aspect, a modified recombinant virus having nonessential or essential virus-encoded genetic functions inactivated therein so that the virus has attenuated virulence, and wherein the modified recombinant virus further contains DNA from a heterologous source in an essential or nonessential region of the virus genome is disclosed. The DNA can code for an antigen or epitope of interest of a lentivirus, retrovirus or immunodeficiency virus, e.g., EIAV, FIV, BIV, HIV, or SIV, preferably feline immunodeficiency virus, e.g., Env, Gag, Pol, accessory functions, or any combination thereof, such as Gag-Pol or Env, Gag and Pol, or Gag and a portion of Pol or Env, Gag and a portion of Pol, wherein the portion of Pol can include protease, or Gag-protease or Env, Gag, protease. In particular, the genetic functions are inactivated by deleting or disrupting an open reading frame encoding a virulence factor, e.g., an essential region, or by utilizing naturally host restricted viruses, especially naturally host restricted viruses displaying attenuated virulence from having been serial passages and/or plaque purification (with or without subsequent passages). The virus used is advantageously a poxvirus, particularly a vaccinia virus or an avipox virus, such as fowlpox virus and canarypox virus.

[0051] Advantageously, the open reading frame is selected from the group consisting of J2R, B13R + B14R, A26L, A56R, C7L - K1L, and I4L (by the terminology reported in Goebel et al., 1990a,b); any combination thereof and, preferably the combination thereof. In this respect, the open reading frame comprises a thymidine kinase gene, a hemorrhagic region, an A type inclusion body region, a hemagglutinin gene, a host range gene region or a large subunit, ribonucleotide reductase; or, any combination thereof and preferably the combination thereof. The modified Copenhagen strain of vaccinia virus is identified as NYVAC (Tartaglia et al., 1992). NYVAC and NYVAC variations have essential regions deleted or disrupted therein, and for a subsequent publication to Tartaglia et al., 1992 which like Tartaglia et al., 1992 relates to deletion of essential regions of vaccinia virus (and therefore relates to NYVAC, NYVAC variations, or viruses taught by or obvious from viruses of Tartaglia et al., 1992 such as NYVAC and NYVAC variations) e.g., NYVAC.1, NYVAC.2, reference is made to PCT WO 95/30018. With respect to NYVAC and NYVAC variations, reference is also made to U.S. Patents Nos. 5,364,773 and 5,494,807. However, other vaccinia virus strains, such as the COPAX strain, can also be used.

[0052] The vector can be an attenuated canarypox virus, such as a canarypox virus which is not a mixed population. For instance, a Rentschler vaccine strain which was attenuated through more than 200 serial passages on chick embryo fibroblasts, a master seed therefrom was subjected to four successive plaque purifications under agar, from which a plaque clone was amplified through five additional passages. Such a canarypox is called ALVAC.

[0053] Results of restriction digests of plaque derived from Kanapox is as follows: Genomic DNA isolated from plaque isolates number 1, 4, and 5 cloned from canarypox virus (Kanapox). DNA from these plaques and from the uncloned canarypox virus was digested with restriction enzymes HindIII, BamHI and EcoRI and run on a 0.8% agarose gel. The gel was stained with ethidium bromide and photographed under UV light (see Fig. 1). The lanes are labeled v = uncloned canarypox virus, 1 = plaque 1, 4 = plaque 4, and 5 = plaque 4. A 1 kb molecule weight marker was run on the far left lane. The restriction profiles show distinct differences between the various plaque isolates. Plaque 1 was chosen as ALVAC (CP_{pp}).

[0054] In the restriction patterns of the uncloned canarypox virus (lanes = v) several submolar bands can be observed. However, when plaqued cloned, these submolar bands (lanes labeled 1, 4 and 5) become molar species in at least some of the plaque-cloned isolates. This indicates that the uncloned canarypox virus (Kanapox) represents a mixture of genomic variants which differ in restriction profiles.

[0055] Thus, ALVAC is different from, has unique properties over, and is superior to Kanapox; and therefore, ALVAC is a preferred vector in the practice of the invention. In particular, the Rentschler strain canarypox virus (Kanapox), from restriction analyses, represents a mixture of viral variants; that is, Kanapox, from which ALVAC was derived, was a mixed population. It is not unprecedented for a vaccine preparation, such as Kanapox, to contain multiple variants. ALVAC is not a mixed population. As such, ALVAC has several unique properties which are not shared by Kanapox; for instance:

[0056] ALVAC has a uniform genetic background. This property provides ALVAC with consistency; a unique feature of being useful for preparing vector-based vaccines. Consistency is useful for quality control and regulatory considera-

tions. This property of consistency of ALVAC provides ALVAC with the ability to pass quality control and regulatory considerations, i.e., be useful in the development of vector-based vaccines with predicted genetic properties.

[0057] Biological consistency is controlled using ALVAC to derive recombinants. Kanapox does not provide biological consistency. Indeed, Kanapox cannot consistently provide an effective recombinant product. Biological consistency and a consistently effective recombinant product are useful; for instance, for a consistent biological profile with respect to virulence, with regard to virus/host interactions, and ultimately for use as an immunization vehicle. ALVAC achieves biological consistency and consistently effective recombinant products. When Kanapox is used in deriving recombinants, there is no control over the virus background into which the foreign gene is inserted; and therefore, the properties of the resultant recombinant remain in question (cf. studies with vaccinia virus which illustrate that not all vaccinia genetic backgrounds are equivalent as immunization vehicles). ALVAC provides certainty with respect to its virus background, its properties related to virulence, and its functioning as an immunization vehicle.

[0058] Although the present invention has primarily been described using a canarypox virus (ALVAC)-based vector, it should be understood that also the expression of specific lentivirus, retrovirus or immunodeficiency virus gene products and their utility for conferring an immune response such as a protective immune response is disclosed. Hence, also alternative mammalian vector systems are disclosed. Examples of such vector systems include other poxviruses, adenoviruses, herpesviruses, alphavirus-based systems, bacterial expression systems, and DNA-based immunogen formulations.

[0059] Although the present invention has primarily been described using the lentivirus FIV, it should be understood that also the expression of functional homologs of the FIV gene products from other lentivirus and retrovirus and immunodeficiency virus systems are disclosed, e.g., Env, Gag/protease (i.e., Env, Gag and Pol or a portion of Pol, or Gag and Pol or a portion of Pol wherein the portion of Pol can include protease (without Env), or Env, Gag, protease or Gag-protease (without Env) or Env, Gag, Pol or a portion of Pol and accessory functions (e.g. Tat, Rev) or Gag, Pol or a portion of Pol wherein the portion of Pol can include protease and accessory functions (without Env) or Env, Gag protease and accessory functions or Gag-protease and accessory functions (without Env), of EIAV, FIV, BIV, HIV, or SIV, *inter alia*). Hence, also other lentivirus systems including human immunodeficiency virus -1, -2 (HIV-1,-2), bovine immunodeficiency virus (BIV), equine infectious anemia virus (EIAV), as well as other mammalian lentiviruses are disclosed.

[0060] These and other embodiments are disclosed or are obvious from and encompassed by the following detailed description.

DEPOSITS

[0061] The following have deposited with the ATCC under the terms of the Budapest Treaty.

<u>Material</u>	<u>Accession Number</u>	<u>Deposit Date</u>
ALVAC	VR-2547	NOV, 14, 1996
Plasmid MM 138 (pMM138) (containing FIV env. gag/pro)	97795	NOV, 14, 1996
Plasmid KM 129 (pMM129) (containing FIV gag/pro)	97796	NOV, 14, 1996

[0062] The invention thus comprehends nucleic acid molecules, including encoding product(s) having sequences as in the Deposited Material, as well as nucleic acid molecules having substantial homology thereto (e.g., at least 85% homology).

BRIEF DESCRIPTION OF THE DRAWINGS

[0063] The following detailed description, given by way of example, but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings, incorporated herein by reference, in which:

FIG. 1 shows the results of plaque purifying Kanapox, as described above;

FIG. 2 shows the nucleotide sequence of FIV env from Rhone Merieux (SEQ ID NO:1) (The FIV env start codon is at position 1 and the stop codon is at position 2569. Plasmid ptg6184, containing the FIV env coding sequence, was from Rhone Merieux(Lyon, France). The FIV env coding sequence in ptg6184 was sequenced and the following differences with the sequence below were observed: position 1218 T is G in ptg6184 changing phe to leu; position 1220 G to A changes gly to glu; and position 2201 C to A change ala to glu);

FIG. 3 shows the nucleotide sequence of FIV gag/pol coding sequences from Rhone Merieux (SEQ ID NO:2) (The gag start codon is at position 1 and the gag stop codon is at position 1414. The ribosomal frameshift site is near position 1255. The frameshift is -1 in relation to the gag open reading frame. The frameshift goes into the pol open

reading frame. The pol stop codon is at position 4614. Plasmid ptg8133 from Rhone Merieux contains the FIV gag/pol coding sequences. Part of ptg8133 has been sequenced and the CG at positions 577-578 below is GC in ptg8133, changing the codon from arg to ala);

FIG. 4 shows the ALVAC-nucleotide sequence comprised in the C6 donor plasmid pC6L (SEQ ID NO:3) (Plasmid pC6L contains the C6 insertion sites SmaI (position 409) and EcoRI (position 425));

FIG. 5 shows the predicted nucleotide sequence of the vCP242 insertion (SEQ ID NO:4) (The H6 promoter starts at position 55. The FIV env start codon is at position 179, and the FIV env stop codon is at position 2749). Positions 1 through 54 and positions 2750 through 2879 flank the H6/FIV env expression cassette);

FIG. 6 shows the predicted nucleotide sequence of I3L promoted FIV gag/protease expression cassette and flanking regions in vCP253 (SEQ ID NO:5) (The I3L promoter begins at position 135. The gag start codon is at position 235 and the protease stop codon is at position 1648);

FIG. 7 shows the predicted nucleotide sequence of the H6 promoted FIV env/I3L promoted FIV gag/protease expression cassette and flanking regions in vCP255 (SEQ ID NO:6) (The H6 promoter starts at position 129, the FIV env start codon is at position 253, and the FIV env stop codon is at position 2823. The I3L promoter starts at position 2830, the FIV gag start codon is at position 2930 and the FIV gag stop codon is at position 4282. The ribosomal frameshift site is near position 4184. The frameshift is -1 in relation to the gag open reading frame. The frameshift goes into the pol open reading frame. The stop codon for the protease gene is at position 4641. Positions 1 through 128 and positions 4642 through 4727 flank the H6 FIV env/I3L FIV gag/protease expression cassette); and

FIG. 8 shows the predicted nucleotide sequence of vCP329 insertion (SEQ ID NO:7) (The H6 promoter starts at position 2146. The coding sequence for FIV 97TM is from position 2022 to position 42. The I3L promoter starts at position 2253. The FIV gag start codon is at position 2353 and the pol stop codon is at position 3766).

DETAILED DESCRIPTION OF THE INVENTION

[0064] As discussed above, disclosed are : vector-based lentivirus, retrovirus, or immunodeficiency virus, e.g., EIAV, FIV, BIV, HIV, or SIV, preferably feline immunodeficiency virus (FIV) recombinants, preferably recombinants containing DNA

[0065] In another aspect of the invention the vector is cCP242, vCP253, vCP255, or vCP329, wherein vCP242, vCP253, vCP255, or vCP329 are recombinants of the ALVAC strain, wherein vCP242 comprises DNA encoding Env, vCP253 comprises DNA encoding Gag-protease, vCP255 comprises DNA encoding Env, Gag-protease and wherein vCP329 comprises DNA encoding 97TM, Gag-protease.

[0066] Thus, in a general way, the invention provides a vector comprising exogenous DNA encoding at least one lentivirus epitope. The epitope can be from a lentivirus other than SIV. More preferably, the epitope is of Gag and Pol or Env, Gag and Pol or Env, Gag and a portion of Pol or Gag and a portion of Pol or Gag-protease, or Env, Gag, and protease; and, most preferably the epitope is Gag and protease or epitope(s) on Gag and protease which elicit a response which is the same as or similar to Gag and protease. And, the vector preferably induces an immune response, more preferably a protective immune response, when administered to a target species (a target species is a host susceptible to the lentivirus; for instance, felines such as domesticated cats and kittens are a target species with respect to-FIV).

[0067] The methods for making a vector or recombinant can be by or analogous to the methods disclosed in U.S. Patent Nos. 4,603,112, 4,769,330, 5,174,993, 5,505,941, 5,338,683, 5,494,807, 5,503,834, 4,722,848, 5,514,375, U.K. Patent GB 2 269 820 B, WO 92/22641, WO 93/03145, WO 94/16716, PCT/US94/06652, allowed U.S. application Serial No. 08/184,009, filed January 19, 1994, Paoletti, "Applications of pox virus vectors to vaccination: An update," PNAS USA 93:11349-11353, October 1996, Moss, "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety," PNAS USA 93:11341-11348, October 1996, Richardson, C.D. (Editor), Methods in Molecular Biology 39, "Baculovirus Expression Protocols" (1995 Humana Press Inc.), Smith et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Molecular and Cellular Biology, Dec., 1983, Vol. 3, No. 12, p. 2156-2165; Pennock et al., "Strong and Regulated Expression of *Escherichia coli* B-Galactosidase in Infect Cells with a Baculovirus vector," Molecular and Cellular Biology Mar. 1984, Vol. 4, No. 3, p. 399-406; EPA 0 370 573, U.S. application Serial No. 920,197, filed October 16, 1986, EP Patent publication No. 265785, U.S. Patent No. 4,769,331, Roizman, "The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors," PNAS USA 93:11307-11312, October 1996, Andreansky et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors," PNAS USA 93:11313-11318, October 1996, Robertson et al. "Epstein-Barr virus vectors for gene delivery to B lymphocytes," PNAS USA 93:11334-11340, October 1996, Frolov et al., "Alphavirus-based expression vectors: Strategies and applications," PNAS USA 93:11371-11377, October 1996, Kitson et al., J. Virol. 65, 3068-3075, 1991; Grunhaus et al., 1992, "Adenovirus as cloning vectors," Seminars in Virology (Vol. 3) p. 237-52, 1993, Ballay et al. EMBO Journal, vol. 4, p. 3861-65, Graham, Tibtech 8, 85-87, April, 1990, Prevec et al., J. Gen Virol. 70, 429-434, U.S. applications Serial Nos. 08/675,556 and 08/675,566, filed July 3, 1996, PCT WO91/11525, Feigner et al. (1994), J. Biol. Chem. 269, 2550-2561, Science, 259:1745-49, 1993 and McClements et

al., "Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease," PNAS USA 93:11414-11420, October 1996.

[0068] vaccinia virus and more recently other poxviruses have been used for the insertion and expression of foreign genes. A basic technique of inserting foreign genes into live infectious poxvirus involves recombination between pox DNA sequences flanking a foreign genetic element in a donor plasmid and homologous sequences present in the rescuing poxvirus (Piccini et al., 1987).

[0069] Specifically, recombinant poxviruses can be constructed in two steps known in the art and analogous to the methods for creating synthetic recombinants of poxviruses such as the vaccinia virus and avipox virus described in U.S. Patent Nos. 4,769,330, 4,772,848, 4,603,112, 5,110,587, 5,179,993, 5,505,941, and 5,494,807.

[0070] First, the DNA gene sequence to be inserted into the virus, e.g., an open reading frame from a non-pox source, is placed into a plasmid construct such as an *E. coli* plasmid construct into which DNA homologous to a section of DNA of the poxvirus has been inserted. Separately, the DNA gene sequence to be inserted can be ligated to a promoter. The promoter-gene linkage is positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA; for instance, pox DNA containing a nonessential locus (although an essential locus may also be used). The resulting plasmid construct is then amplified, e.g., by growth within *E. coli* bacteria (Clewell, 1972) and isolated (Clewell et al., 1969; Maniatis et al., 1982). Alternatively, the DNA gene sequence can, without separate ligation to a promoter, merely be placed within the plasmid construct so that the DNA gene sequence is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA; for instance, a region downstream from an endogenous promoter-such that expression of the gene sequence is under control of the promoter and the promoter and coding portion of the DNA gene sequence are thus adjacent.

[0071] Second, the isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g. chick embryo fibroblasts, along with the poxvirus. Recombination between homologous pox DNA in the plasmid and the viral genome respectively gives a poxvirus modified by the presence, e.g., in a nonessential region of its genome, of foreign DNA sequences. The term "foreign" DNA designates exogenous DNA, particularly DNA from a non-pox source, that codes for gene products not ordinarily produced by the genome into which the exogenous DNA is placed.

[0072] However, the foregoing is not meant to limit means for obtaining vectors or recombinants, as any means for obtaining a vector or recombinant e.g. a poxvirus-lentivirus, retrovirus, and/or immunodeficiency virus, e.g., feline immunodeficiency virus, recombinant may be used.

[0073] Thus, genetic recombination is in general the exchange of homologous sections of DNA between two strands of DNA. In certain viruses RNA may replace DNA. Homologous sections of nucleic acid are sections of nucleic acid (DNA or RNA) which have the same sequence of nucleotide bases.

[0074] Genetic recombination may take place naturally during the replication or manufacture of new viral genomes within the infected host cell. Thus, genetic recombination between viral genes may occur during the viral replication cycle that takes place in a host cell which is co-infected with two or more different viruses or other genetic constructs. A section of DNA from a first genome is used interchangeably in constructing the section of the genome of a second co-infecting virus in which the DNA is homologous with that of the first viral genome.

[0075] However, recombination can also take place between sections of DNA in different genomes that are not perfectly homologous. If one such section is from a first genome homologous with a section of another genome except for the presence within the first section of, for example, a genetic marker or a gene coding for an antigenic determinant inserted into a portion of the homologous DNA, recombination can still take place and the products of that recombination are then detectable by the presence of that genetic marker or gene in the recombinant viral genome. Accordingly, additional strategies have recently been reported for generating recombinant poxviruses such as recombinant vaccinia virus; and, these strategies may be employed in the practice of this invention.

[0076] Successful expression of the inserted DNA genetic sequence by the modified infectious virus can occur under two conditions. First, the insertion may be into a nonessential region of the virus in order that the modified virus remain viable, or into an essential region whereby the essential function is not disturbed or the function is not necessary for viability under all conditions. A second condition for expression of inserted DNA is the presence of a promoter in the proper relationship to the inserted DNA. The promoter can be located upstream from the coding portion of the DNA sequence to be expressed.

[0077] Vaccinia virus has been used successfully to immunize against smallpox, culminating in the worldwide eradication of smallpox in 1980. In the course of its history, many strains of vaccinia have arisen. These different strains demonstrate varying immunogenicity and are implicated to varying degrees with potential complications, the most serious of which are post-vaccinal encephalitis and generalized vaccinia (Behbehani, 1983).

[0078] With the eradication of smallpox, a new role for vaccinia became important, that of a genetically engineered vector for the expression of foreign genes. Genes encoding a vast number of heterologous antigens have been expressed in vaccinia, often resulting in protective immunity against challenge by the corresponding pathogen (reviewed in Tartaglia et al., 1990a).

[0079] The genetic background of the vaccinia vector has been shown to affect the protective efficacy of the expressed

foreign immunogen. For example, expression of Epstein Barr Virus (EBV) gp340 in the Wyeth vaccine strain of vaccinia virus did not protect cottontop tamarins against EBV virus induced lymphoma, while expression of the-same gene in the WR laboratory strain of vaccinia virus was protective (Morgan et al., 1988).

[0080] A fine balance between the efficacy and the safety of a vaccinia virus-based recombinant vaccine candidate is extremely important. The recombinant virus must present the immunogen(s) in a manner that elicits a protective immune response in the vaccinated animal but lacks any significant pathogenic properties. Therefore attenuation of the vector strain would be a highly - desirable advance over the current state of technology.

[0081] A number of vaccinia genes have been identified which are non-essential for growth of the virus in tissue culture and whose deletion or inactivation reduces virulence in a variety of animal systems.

[0082] The gene encoding the vaccinia virus thymidine kinase (TK) has been mapped (Hruby et al., 1982) and sequenced (Hruby et al., 1983; Weir et al., 1983). Inactivation or complete deletion of the thymidine kinase gene does not prevent growth of vaccinia virus in a wide variety of cells in tissue culture. TK⁻ vaccinia virus is also capable of replication *in vivo* at the site of inoculation in a variety of hosts by a variety of routes.

[0083] It has been shown for herpes simplex virus type 2 that intravaginal inoculation of guinea pigs with TK⁻ virus resulted in significantly lower virus titers in the spinal cord than did inoculation with TK⁺ virus (Stanberry et al., 1985). It has been demonstrated that herpesvirus encoded TK activity *in vitro* was not important for virus growth in actively metabolizing cells, but was required for virus growth in quiescent cells (Jamieson et al., 1974).

[0084] Attenuation of TK⁻ vaccinia has been shown in mice inoculated by the intracerebral and intraperitoneal routes (Buller et al., 1985). Attenuation was observed both for WR neurovirulent laboratory strain and for the Wyeth vaccine strain. In mice inoculated by the intradermal route, TK⁻ recombinant vaccinia generated equivalent anti-vaccinia neutralizing antibodies as compared with the parental TK⁺ vaccinia virus, indicating that in this test system the loss of TK function does not significantly decrease immunogenicity of the vaccinia virus vector. Following intranasal inoculation of mice with TK⁻ and TK⁺ recombinant vaccinia virus (WR strain), significantly less dissemination of virus to other locations, including the brain, has been found (Taylor et al., 1991a).

[0085] Another enzyme involved with nucleotide metabolism is ribonucleotide reductase. Loss of virally encoded ribonucleotide reductase activity in herpes simplex virus (HSV) by deletion of the gene encoding the large subunit was shown to have no effect on viral growth and DNA synthesis in dividing cells *in vitro*, but severely compromised the ability of the virus to grow on serum starved cells (Goldstein et al., 1988). Using a - mouse model for acute HSV infection of the eye and reactivatable latent infection in the trigeminal ganglia, reduced virulence was demonstrated for HSV deleted of the large subunit of ribonucleotide reductase, compared to the virulence exhibited by wild type HSV (Jacobson et al., 1989).

[0086] Both the small (Slabaugh et al., 1988) and large (Schmidt et al., 1988) subunits of ribonucleotide reductase have been identified in vaccinia virus. Insertional inactivation of the large subunit of ribonucleotide reductase in the WR strain of vaccinia virus leads to attenuation of the virus as measured by intracranial inoculation of mice (Child et al., 1990).

[0087] The vaccinia virus hemagglutinin gene (HA) has been mapped and sequenced (Shida, 1986). The HA gene of vaccinia virus is nonessential for growth in tissue culture (Ichihashi et al., 1971). Inactivation of the HA gene of vaccinia virus results in reduced neurovirulence in rabbits inoculated by the intracranial route and smaller lesions in rabbits at the site of intradermal inoculation (Shida et al., 1988). The HA locus was used for the insertion of foreign genes in the WR strain (Shida et al., 1987), derivatives of the Lister strain (Shida et al., 1988) and the Copenhagen strain (Guo et al., 1989) of vaccinia virus. Recombinant HA⁻ vaccinia virus expressing foreign genes have been shown to be immunogenic (Guo et al., 1989; Itamura et al., 1990; Shida et al., 1988; Shida et al., 1987) and protective against challenge by the relevant pathogen (Guo et al., 1989; Shida et al., 1987).

[0088] Cowpox virus (Brighton red strain) produces red (hemorrhagic) pocks on the chorioallantoic membrane of chicken eggs. Spontaneous deletions within the cowpox genome generate mutants which produce white pocks (Pickup et al., 1984). The hemorrhagic function (u) maps to a 38 kDa protein encoded by an early gene (Pickup et al., 1986). This gene, which has homology to serine protease inhibitors, has been shown to inhibit the host inflammatory response to cowpox virus (Palumbo et al., 1989) and is an inhibitor of blood coagulation.

[0089] The u gene is present in WR strain of vaccinia virus (Kotwal et al., 1989b). Mice inoculated with a WR vaccinia virus recombinant in which the u region has been inactivated by insertion of a foreign gene produce higher antibody levels to the foreign gene product compared to mice inoculated with a similar recombinant vaccinia virus in which the u gene is intact (Zhou et al., 1990). The u region is present in a defective nonfunctional form in Copenhagen strain of vaccinia virus (open reading frames B13 and B14 by the terminology reported in Goebel et al., 1990a,b).

[0090] Cowpox virus is localized in infected cells in cytoplasmic A type inclusion bodies (ATI) (Kato et al., 1959). The function of ATI is thought to be the protection of cowpox virus virions during dissemination from animal to animal (Bergoin et al., 1971). The ATI region of the cowpox genome encodes a 160 kDa protein which forms the matrix of the ATI bodies (Funahashi et al., 1988; Patel et al., 1987). Vaccinia virus, though containing a homologous region in its genome, generally does not produce ATI. In WR strain of vaccinia, the ATI region of the genome is translated as a 94 kDa protein (Patel et al., 1988). In Copenhagen strain of vaccinia virus, most of the DNA sequences corresponding to the ATI region

are deleted, with the remaining 3' end of the region fused with sequences upstream from the ATI region to form open reading frame (ORF) A26L (Goebel et al., 1990a,b).

[0091] A variety of spontaneous (Altenburger et al., 1989; Drillien et al., 1981; Lai et al., 1989; Moss et al., 1981; Paez et al., 1985; Panicali et al., 1981) and engineered (Perkus et al., 1991; Perkus et al., 1989; Perkus et al., 1986) deletions have been reported near the left end of the vaccinia virus genome. A WR strain of vaccinia virus with a 10 kb spontaneous deletion (Moss et al., 1981; Panicali et al., 1981) was shown to be attenuated by intracranial inoculation in mice (Buller et al., 1985). This deletion was later shown to include 17 potential ORFs (Kotwal et al., 1988b). Specific genes within the deleted region include the virokinin N1L and a 35 kDa protein (C3L, by the terminology reported in Goebel et al., 1990a,b). Insertional inactivation of N1L reduces virulence by intracranial inoculation for both normal and nude mice (Kotwal et al., 1989a). The 35 kDa protein is secreted like N1L into the medium of vaccinia virus infected cells. The protein contains homology to the family of complement control proteins, particularly the complement 4B binding protein (C4bp) (Kotwal et al., 1988a). Like the cellular C4bp, the vaccinia 35 kDa protein binds the fourth component of complement and inhibits the classical complement cascade (Kotwal et al., 1990). Thus the vaccinia 35 kDa protein appears to be involved in aiding the virus in evading host defense mechanisms.

[0092] The left end of the vaccinia genome includes two genes which have been identified as host range genes, K1L (Gillard et al., 1986) and C7L (Perkus et al., 1990). Deletion of both of these genes reduces the ability of vaccinia virus to grow on a variety of human cell lines (Perkus et al., 1990).

[0093] To develop a new vaccinia vaccine strain, NYVAC (vP866), the Copenhagen vaccine strain of vaccinia virus was modified by the deletion of six nonessential regions of the genome encoding known or potential virulence factors. The sequential deletions are detailed in U.S. Patents Nos. 5,364,773 and 5,494,807. All designations of vaccinia restriction fragments, open reading frames and nucleotide positions are based on the terminology reported in Goebel et al., 1990a,b.

[0094] The deletion loci were also engineered as recipient loci for the insertion of foreign genes.

[0095] The regions deleted in NYVAC are listed below. Also listed are the abbreviations and open reading frame designations for the deleted regions (Goebel et al., 1990a,b) and the designation of the vaccinia recombinant (vP) containing all deletions through the deletion specified:

- (1) thymidine kinase gene (TK; J2R) vP410;
- (2) hemorrhagic region (\bar{u} ; B13R + B14R) vP553;
- (3) A type inclusion body region (ATI; A26L) vP618;
- (4) hemagglutinin gene (HA; A56R) vP723;
- (5) host range gene region (C7L - K1L) vP804; and
- (6) large subunit, ribonucleotide reductase (I4L) vP866

(NYVAC).

[0096] NYVAC is a genetically engineered vaccinia virus strain that was generated by the specific deletion of eighteen open reading frames encoding gene products associated with virulence and host range. NYVAC is highly attenuated by a number of criteria including i) decreased virulence after intracerebral inoculation in newborn mice, ii) inocuity in genetically (nu^+/nu^+) or chemically (cyclophosphamide) immunocompromised mice, iii) failure to cause disseminated infection in immunocompromised mice, iv) lack of significant induration and ulceration on rabbit skin, v) rapid clearance from the site of inoculation, and vi) greatly reduced replication competency on a number of tissue culture cell lines including those of human origin. Nevertheless, NYVAC based vectors induce excellent responses to extrinsic immunogens and provided protective immunity.

[0097] Two additional vaccine vector systems involve the use of naturally host-restricted poxviruses, avipox viruses. Both fowlpoxvirus (FPV) and canarypoxvirus (CPV) have been engineered to express foreign gene products. Fowlpox virus (FPV) is the prototypic virus of the Avipox genus of the Poxvirus family. The virus causes an economically important disease of poultry which has been well controlled since the 1920's by the use of live attenuated vaccines. Replication of the avipox viruses is limited to avian species (Matthews, 1982) and there are no reports in the literature of avipox virus causing a productive infection in any non-avian species including man. This host restriction provides an inherent safety barrier to transmission of the virus to other species and makes use of avipox virus based vaccine vectors in veterinary and human applications an attractive proposition.

[0098] FPV has been used advantageously as a vector expressing antigens from poultry pathogens. The hemagglutinin protein of a virulent avian influenza virus was expressed in an FPV recombinant (Taylor et al., 1988a). After inoculation of the recombinant into chickens and turkeys, an immune response was induced which was protective against either a homologous or a heterologous virulent influenza virus challenge (Taylor et al., 1988a). FPV recombinants expressing the surface glycoproteins of Newcastle Disease Virus have also been developed (Taylor et al., 1990; Edbauer et al., 1990).

[0099] Despite the host-restriction for replication of FPV and CPV to avian systems, recombinants derived from these

viruses were found to express extrinsic proteins in - cells of nonavian origin. Further, such recombinant viruses were shown to elicit immunological responses directed towards the foreign gene product and where appropriate were shown to afford protection from challenge against the corresponding pathogen (Tartaglia et al., 1993a,b; Taylor et al., 1992; 1991b; 1988b).

[0100] The ALVAC recombinants can be by the methods detailed in Piccini et al. 1983; Perkus et al. 1995, e.g., recombination, which is novel and nonobvious with respect the present invention as a novel and nonobvious product results therefrom.

[0101] TROVAC refers to an attenuated fowlpox that was a plaque-cloned isolate derived from the FP-1 vaccine strain of fowlpoxvirus which is licensed for vaccination of 1 day old chicks. TROVAC is a unimolar fowlpox virus species.

[0102] ALVAC is an attenuated canarypox virus-based vector that was a plaque-cloned derivative of the licensed canarypox vaccine, Kanapox (Tartaglia et al., 1992). ALVAC has some general properties which are the same as some general properties of Kanapox. ALVAC is a unimolar canarypox virus species.

[0103] ALVAC-based recombinant viruses expressing extrinsic immunogens have also been demonstrated efficacious as vaccine vectors (Tartaglia et al., 1993a,b). This avipox vector is restricted to avian species for productive replication. On human cell cultures, canarypox virus replication is aborted early in the viral replication cycle prior to viral DNA synthesis. Nevertheless, when engineered to express extrinsic immunogens, authentic expression and processing is observed *in vitro* in mammalian cells and inoculation into numerous mammalian species induces antibody and cellular immune responses to the extrinsic immunogen and provides protection against challenge with the cognate pathogen (Taylor et al., 1992; Taylor et al., 1991).

[0104] Recent Phase I clinical trials in both Europe and the United States of a ALVAC recombinants, e.g., canarypox/ rabies glycoprotein recombinant (ALVAC-RG), demonstrated that ALVAC vaccines are safe and well tolerated and, for instance, induced protective levels of rabies virus neutralizing antibody titers (Fries et al., 1996; Pialoux et al., 1994; Cadoz et al., 1992). Additionally, peripheral blood mononuclear cells (PBMCs) derived from the ALVAC-RG vaccinees demonstrated significant levels of lymphocyte proliferation when stimulated with purified rabies virus (Fries et al., 1996).

[0105] NYVAC, ALVAC and TROVAC have also been - recognized as unique among all poxviruses in that the National Institutes of Health ("NIH") (U.S. Public Health Service), Recombinant DNA Advisory Committee, which issues guidelines for the physical containment of genetic material such as viruses and vectors, i.e., guidelines for safety procedures for the use of such viruses and vectors which are based upon the pathogenicity of the particular virus or vector, granted a reduction in physical containment level: from BSL2 to BSL1. No other poxvirus has a BSL1 physical containment level. Even the Copenhagen strain of vaccinia virus - the common smallpox vaccine - has a higher physical containment level; namely, BSL2. Accordingly, the art has recognized that ALVAC has a lower pathogenicity than other poxvirus.

[0106] ALVAC-based recombinant viruses have been shown to stimulate *in vitro* specific CD8⁺ CTLs from human PBMCs (Tartaglia et al., 1993a). Mice immunized with ALVAC recombinants expressing various forms of the HIV-1 envelope glycoprotein generated both primary and memory HIV specific CTL responses which could be recalled by a second inoculation (Tartaglia et al., 1993a; Cox et al., 1993). ALVAC-env recombinants (expressing the HIV-1 envelope glycoprotein) stimulated strong HIV-specific CTL responses from peripheral blood mononuclear cells (PBMC) of HIV-1 infected individuals (Tartaglia et al., 1993a; Cox et al., 1993). Acutely infected autologous PBMC were used as stimulator cells for the remaining PBMC. After 10 days incubation in the absence of exogenous IL-2, the cells were evaluated for CTL activities. ALVAC-env stimulated high levels of anti-HIV activities in mice. These and similar studies (see USSN 08/417,210) show a utility of ALVAC- based recombinants, especially with respect to immunodeficiency viruses. In particular, the highly attenuated character of ALVAC has been demonstrated in both immunocompetent and immunocompromised animal models in such studies; and, the safety of ALVAC-based recombinants has also been demonstrated.

[0107] Thus, in the present invention, the canarypox virus-based ALVAC vector is preferred.

[0108] Clearly, based on the attenuation profiles of the ALVAC vectors and its demonstrated ability to elicit both humoral and cellular immunological responses to extrinsic immunogens (Tartaglia et al., 1993a,b; Taylor et al., 1992) such recombinant viruses offer a distinct advantage over previously described vaccinia based recombinant viruses.

[0109] Perhaps more related to FIV (as felines are involved), an ALVAC-based recombinant virus expressing the FeLV (Subgroup A) env and gag gene products (ALVAC-FL; vCP97) was shown to afford complete protection of cats against an oronasal FeLV challenge exposure (Tartaglia et al., 1993). Significantly, protection was afforded in the absence of detectable FeLV-specific serum neutralizing activity prior to challenge.

[0110] In certain embodiments of the present invention, Applicants have engineered several ALVAC-FIV recombinants and assessed their ability to afford protection of cats against experimental FIV exposure. In summary, Applicants have demonstrated protection from homologous FIV challenge exposure by vaccination of cats with an ALVAC-FIV Gag-protease recombinant. Recombinants expressing FIV Env alone or in combination with Gag-protease did not afford significant levels of protection. However, vaccination regimens consisting of priming with ALVAC-FIV env/gag-protease and boosting with an adjuvanted inactivated whole cell vaccine preparation provided complete protection, demonstrating utility for the recombinants expressing Env alone or in combination with Gag-protease, despite these recombinants not per se affording significant levels of protection (and further, these recombinants can be used e.g., to express products

which can nonetheless be useful, for instance to obtain useful antibodies, or in kits, tests, assays and the like).

[0111] Interestingly, levels of FIV-specific humoral responses measured by ELISA and western blot were not necessarily predictive of protection. Furthermore, Env-specific humoral responses were not associated with the observed protection.

[0112] Furthermore, the data herein shows the efficacy of recombinants of the present invention against heterologous FIV challenge in cats, especially in a prime/boost protocol involving an inventive recombinant (e.g., an ALVAC-FIV recombinant) and an ICV.

[0113] Moreover, the data herein with respect to FIV and cats is capable of extension to other lentiviruses, retroviruses, and immunodeficiency viruses, e.g., e.g., EIAV, FIV, BIV, HIV, or SIV. Thus, knowledge in the art of nucleic acid molecules encoding epitope(s) of interest from these other viruses, e.g., Env, Gag, protease, can be utilized for making and using recombinants expressing epitope(s) of interest analogous to the exemplified FIV data herein. More in particular, using the knowledge in the art of nucleic acid molecules encoding Env, Gag, Pol, or a portion of Pol, such as a portion including protease, accessory functions/proteins, or epitope(s) thereof, for other lentiviruses, retroviruses, and immunodeficiency viruses, e.g., EIAV, FIV, BIV, HIV, or SIV, and using the knowledge in the art of vector systems, the skilled artisan can make vectors or recombinants expressing Env, Gag and Pol or a portion of Pol, or Gag and Pol or a portion of Pol, or Env, Gag and protease, or Gag and protease, with optionally accessory functions/proteins, or expressing epitope(s) thereof, of these other viruses, and can use the vectors or recombinants in an immunization regimen, such as a prime/boost regimen, as herein exemplified with respect to FIV, without any undue experimentation. Accordingly, vectors or recombinants of lentiviruses, retroviruses and immunodeficiency viruses in addition to FIV (as FIV is a model for other lentiviruses, retroviruses and immunodeficiency viruses), and methods of making and using those vectors or recombinants are disclosed.

[0114] The expression product generated by inventive vectors or recombinants can also be isolated from infected or transfected cells and used to inoculate hosts in a subunit vaccine configuration (composition, or an antigenic or immunological composition). The proteins generated by the vectors or recombinants and antibodies elicited therefrom can also be used in assays to detect the presence or absence of a lentivirus, retrovirus or immunodeficiency virus, e.g., FIV.

[0115] Accordingly, immunogens or epitope(s) of interest such as lentivirus, retrovirus or immunodeficiency virus immunogen(s) or epitope(s) of interest, e.g., EIAV, FIV, BIV, HIV, or SIV immunogens or epitopes of interest are disclosed. Such as from lentiviruses, including but not limited to HIV-1,-2, EIAV, BIV. All lentiviruses express functional homologs of the FIV Env, Gag-protease. Techniques for identifying, cloning and utilizing nucleic acid sequences encoding these functional homologs are known in the art and do not require any undue experimentation to practice in the light of this disclosure.

[0116] With respect to the state-of-the-art, mention is particularly made of: Gonda et al. (1990). -Development of bovine immunodeficiency-like virus as a model of lentivirus disease. *Dev. Biol. Stand.* 72:97-110; Garvey et al. (1990) Nucleotide sequence and genome organization of biologically active bovine immunodeficiency-like virus. *Virology* 175: 391-409; Gonda et al. (1987). Characterization and molecular cloning of a bovine lentivirus related to human immunodeficiency virus. *Nature* 330:388-391; Ball et al. (1988). EIAV genomic organization: further characterization by sequencing of purified glycoproteins and cDNA. *Virology* 165: 601-605; Kawakami et al. (1987) Nucleotide sequence analysis of equine infectious anemia virus proviral DNA. *Virology* 158: 300-312; Yaniv et al. (1986) Molecular cloning and physical characterization of integrated equine infectious anemia virus: molecular and immunologic evidence of its close relationship to ovine and caprine lentiviruses. *Virology* 154: 1-8; Stephens et al. (1986). Equine infectious anemia virus gag and pol genes: relatedness to visna and AIDS virus. *Science* 231:589-594; Chiu et al. (1985). Nucleotide evidence for relationship of AIDS retrovirus to lentiviruses. *Nature* 317:366-368; as well as a number of reviews in *Retrovirus Biology and Human Disease*, Gallo, R.C. and Wong-Stall, F. eds. Marcel Dekker, Inc. New York, 1990.

[0117] Further, DNA encoding such immunogens or epitopes of interest from inventive vectors or recombinants can be administered through immunization using alternate appropriately engineered mammalian expression systems including but not limited to other poxviruses, herpesviruses, adenoviruses, alphavirus-based strategies, and naked or formulated DNA-based immunogens. Techniques for engineering such recombinant subunits are known in the art.

[0118] With respect to techniques for these immunization vehicles and state-of-the-art knowledge - mention is particularly made of: Hormaeche and Kahn, Perkus and Paoletti, Shiver et al. all in *Concepts in Vaccine Development*, Kaufman, S.H.E., ed., Walter deGruyter, New York, 1996, and vectors described in *Viruses in Human Gene Therapy*, Vos, J.-M.H., ed, Chapman and Hall, Carolina Academic Press, New York, 1995, and in *Recombinant Vectors in Vaccine Development*, Brown, F., ed., Karger, New York, 1994.

[0119] The invention still further provides an antigenic, immunogenic, immunological or vaccine composition containing the recombinant virus or expression product thereof, and a acceptable carrier or diluent. An immunological composition containing the vector or recombinant virus (or an expression product thereof) elicits an immunological response - local or systemic. The response can, but need not be, protective. An immunogenic composition containing the vector or recombinant virus (or an expression product thereof) likewise elicits a local or systemic immunological response which can, but need not be, protective. An antigenic composition similarly elicits a local or systemic immunological response

which can, but need not be, protective. A vaccine composition elicits a local or systemic protective response. Accordingly, the terms "immunological composition", "antigenic composition" and "immunogenic composition" include a "vaccine composition" (as the three former terms can be protective compositions). A protective response is understood to be a response, such as a humoral and/or secretory and/or cell-mediated response which confers an immunity, with immunity understood to comprise the ability to resist or overcome infection or to overcome infection more easily as compared to a subject not administered the inventive composition, or to better tolerate infection as compared to a subject not administered the inventive composition, e.g., increased resistance to infection.

[0120] As to epitopes of interest, one skilled in the art can determine an epitope or immunodominant region of a peptide or polypeptide and ergo the coding DNA therefor from the knowledge of the amino acid and corresponding DNA sequences of the peptide or polypeptide, as well as from the nature of particular amino acids (e.g., size, charge, etc.) and the codon dictionary, without undue experimentation.

[0121] A general method for determining which portions of a protein to use in an immunological composition focuses on the size and sequence of the antigen of interest. "In general, large proteins, because they have more potential determinants are better antigens than small ones. The more foreign an antigen, that is the less similar to self configurations which induce tolerance, the more effective it is in provoking an immune response." Ivan Roitt, Essential Immunology, 1988.

[0122] As to size: the skilled artisan can maximize the size of the protein encoded by the DNA sequence to be inserted into the mammalian vector (keeping in mind the insertion limitations of the vector). To minimize the DNA inserted while maximizing the size of the protein expressed, the DNA sequence can exclude introns (regions of a gene which are transcribed but which are subsequently excised from the primary RNA transcript).

[0123] At a minimum, the DNA sequence can code for a peptide at least 8 or 9 amino acids long. This is the minimum length that a peptide needs to be in order to stimulate a CD4+ T cell response (which recognizes virus infected cells or cancerous cells). A minimum peptide length of 13 to 25 amino acids is useful to stimulate a CD8+ T cell response (which recognizes special antigen presenting cells which have engulfed the pathogen). See Kendrew, *The Encyclopedia of Molecular Biology* (Blackwell Science Ltd 1995). However, as these are minimum lengths, these peptides are likely to generate an immunological response, i.e., an antibody or T cell response; but, for a protective response (as from a vaccine composition), a longer peptide is preferred.

[0124] With respect to the sequence, the DNA sequence preferably encodes at least regions of the peptide that generate an antibody response or a T cell response. One method to determine T and B cell epitopes involves epitope mapping. The protein of interest "is fragmented into overlapping peptides with proteolytic enzymes. The individual peptides are then tested for their ability to bind to an antibody elicited by the native protein or to induce T cell or B cell activation. This approach has been particularly useful in mapping T-cell epitopes since the T cell recognizes short linear peptides complexed with MHC molecules. The method is less effective for determining B-cell epitopes" since B cell epitopes are often not linear amino acid sequence but rather result from the tertiary structure of the folded three dimensional protein. Janis Kuby, Immunology, pp. 79-80 (1992).

[0125] Another method for determining an epitope of interest is to choose the regions of the protein that are hydrophilic. Hydrophilic residues are often on the surface of the protein and are therefore often the regions of the protein which are accessible to the antibody. Janis Kuby, Immunology, p. 81 (1992).

[0126] Yet another method for determining an epitope of interest is to perform an X-ray crystallographic analysis of the antigen (full length)-antibody complex. Janis Kuby, Immunology, p. 80 (1992).

[0127] Still another method for choosing an epitope of interest which can generate a T cell response is to identify from the protein sequence potential HLA anchor binding motifs which are peptide sequences which are known to be likely to bind to the MHC molecule.

[0128] The peptide which is a putative epitope of interest, to generate a T cell response, should be presented in a MHC complex. The peptide preferably contains appropriate anchor motifs for binding to the MHC molecules, and should bind with high enough affinity to generate an immune response. Factors which can be considered are: the HLA type of the patient (vertebrate, animal or human) expected to be immunized, the sequence of the protein, the presence of appropriate anchor motifs and the occurrence of the peptide sequence in other vital cells.

[0129] An immune response is generated, in general, as follows: T cells recognize proteins only when the protein has been cleaved into smaller peptides and is presented in a complex called the "major histocompatibility complex MHC" located on another cell's surface. There are two classes of MHC complexes - class I and class II, and each class is made up of many different alleles. Different patients have different types of MHC complex alleles; they are said to have a 'different HLA type.'

[0130] Class I MHC complexes are found on virtually every cell and present peptides from proteins produced inside the cell. Thus, Class I MHC complexes are useful for killing cells which when infected by viruses or which have become cancerous and as the result of expression of an oncogene. T cells which have a protein called CD4 on their surface, bind to the MHC class I cells and secrete lymphokines. The lymphokines stimulate a response; cells arrive and kill the viral infected cell.

[0131] Class II MHC complexes are found only on antigen- presenting cells and are used to present peptides from circulating pathogens which have been endocytosed by the antigen- presenting cells. T cells which have a protein called CDS bind to the MHC class I cells and kill the cell by exocytosis of lytic granules.

[0132] Some guidelines in determining whether a protein contains epitopes of interest which will stimulate a T cell response, include: Peptide length - the peptide should be at least 8 or 9 amino acids long to fit into the MHC class-I complex and at least 13-25 amino acids long to fit into a class II MCH complex. This length is a minimum for the peptide to bind to the MHC complex. It is preferred for the peptides to be longer than these lengths because cells may cut the expressed peptides. The peptide should contain an appropriate anchor motif which will enable it to bind to the various class I or class II molecules with high enough specificity to generate an immune response-(See Bocchia, M. et al., Specific Binding of Leukemia Oncogene Fusion Protein Peptides to HLA Class I Molecules, Blood 85:2680-2684; Englehard, VH, structure of peptides associated with class I and class II MHC molecules Ann. Rev. Immunol. 12:181 (1994)). This can be done, without undue experimentation, by comparing the sequence of the protein of interest with published structures of peptides associated with the MHC molecules. Protein epitopes recognized by T cell receptors are peptides generated by enzymatic degradation of the protein molecule and are presented on the cell surface in association with class I or class II MHC molecules.

[0133] Further, the skilled artisan can ascertain an epitope of interest by comparing the protein sequence with sequences listed in the protein data base. Regions of the protein which share little or no homology are better choices for being an epitope of that protein and are therefore useful in a vaccine or immunological composition. Regions which share great homology with widely found sequences present in vital cells should be avoided.

[0134] Even further, another method is simply to generate or express portions of a protein of interest, generate monoclonal antibodies to those portions of the protein of interest, and then ascertain whether those antibodies inhibit growth in vitro of the pathogen from which the protein was derived. The skilled artisan can use the other guidelines set forth in this disclosure and in the art for generating or expressing portions of a protein of interest for analysis as to whether antibodies thereto inhibit growth in vitro.

[0135] For example, the skilled artisan can generate portions of a protein of interest by: selecting 8 to 9 or 13 to 25 amino acid length portions of the protein, selecting hydrophilic regions, selecting portions shown to bind from X-ray data of the antigen (full length)-antibody complex, selecting regions which differ in sequence from other proteins, selecting potential HLA anchor binding motifs, or any combination of these methods or other methods known in the art.

[0136] Epitopes recognized by antibodies are expressed on the surface of a protein. To determine the regions of a protein most likely to stimulate an antibody response one skilled in the art can preferably perform an epitope map, using the general methods described above, or other mapping methods known in the art.

[0137] As can be seen from the foregoing, without undue experimentation, from this disclosure and the knowledge in the art, the skilled artisan can ascertain the amino acid and corresponding DNA sequence of a lentivirus epitope of interest for obtaining a T cell, B cell and/or antibody response. In addition, reference is made to Gefter et al., U.S. Patent No. 5,019,384, issued May 28, 1991, and the documents it cites, (Note especially the "Relevant Literature" section of this patent, and column 13 of this patent which discloses that: "A large number of epitopes have been defined for a wide variety of organisms of interest. Of particular interest are those epitopes to which neutralizing antibodies are directed. Disclosures of such epitopes are in many of the references cited in the Relevant Literature section.")

[0138] The administration procedure for the inventive vector or recombinant or expression product thereof, compositions of the invention such as immunological, antigenic or vaccine compositions or therapeutic compositions can be via a parenteral route (intradermal, intramuscular or subcutaneous). Such an administration enables a systemic immune response. The administration can be via a mucosal route, e.g., oral, nasal, genital, etc. Such an administration enables a local immune response.

[0139] More generally, the inventive antigenic, immunological or vaccine compositions or therapeutic compositions (compositions containing the vectors or recombinants of the invention or expression products) can be prepared in accordance with standard techniques well known to those skilled in the pharmaceutical or veterinary arts. Such compositions can be administered in dosages and by techniques well known to those skilled in the medical and/or veterinary arts taking into consideration such factors as the breed or species, age, sex, weight, and condition of the particular patient, and the route of administration. The compositions can be administered alone, or can be co-administered or sequentially administered with other compositions of the invention or with other immunological, antigenic or vaccine or therapeutic compositions. Such other compositions can include purified native antigens or epitopes or antigens or epitopes from the expression by a poxvirus recombinant or another vector system; and are administered taking into account the aforementioned factors.

[0140] Examples of compositions of the invention include liquid preparations for orifice, e.g., oral, nasal, anal, genital, e.g., vaginal, etc., administration such as suspensions, syrups or elixirs; and, preparations for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable administration) such as sterile suspensions or emulsions. In such compositions the recombinant may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like.

[0141] Antigenic, immunological or vaccine compositions typically can contain an adjuvant and an amount of the recombinant or expression product to elicit the desired response. In human applications, alum (aluminum phosphate or aluminum hydroxide) is a typical adjuvant. Saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants are used in research and veterinary applications. Chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al., J. Immunol. 147:410-415 (1991) encapsulation of the protein within a proteoliposome as described by Miller et al., J. Exp. Med. 176:1739-1744 (1992), and encapsulation of the protein in lipid vesicles such as Novasome™ lipid vesicles (Micro Vesicular Systems, Inc., Nashua, NH) can also be used.

[0142] The compositions of the invention may be packaged in a single dosage form for immunization by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration or orifice administration, e.g., perlingual (i.e., oral), intragastric, mucosal including intraoral, intraanal, intravaginal, and the like administration. And again, the effective dosage and route of administration are determined by the nature of the composition, by the nature of the expression product, by expression level if the vector or recombinant is directly used, and by known factors, such as breed or species, age, sex, weight, condition and nature of host, as well as LD₅₀ and other screening procedures which are known and do not require undue experimentation.

[0143] Dosages of expressed product can range from a few to a few hundred micrograms, e.g., 5 to 500 µg. The inventive vector or recombinant can be administered in any suitable amount to achieve expression at these dosage levels. The inventive vector or recombinant can be administered to an animal or infected or transfected into cells in an amount of about at least 10^{3.5} pfu; thus, the inventive vector or recombinant is preferably administered to an animal or infected or transfected into cells in at least about 10⁴ pfu to about 10⁶ pfu; however, as shown by the Examples below, animals can be administered at least about 10⁸ pfu such that a more preferred amount for administration can be at least about 10⁷ pfu to about 10⁹ pfu. Other suitable carriers or diluents can be water or a buffered saline, with or without a preservative. The expression product or vector or recombinant may be lyophilized for resuspension at the time of administration or can be in solution.

[0144] The carrier may also be a polymeric delayed release system. Synthetic polymers are particularly useful in the formulation of a composition having controlled release. An early example of this was the polymerization of methyl methacrylate into spheres having diameters less than one micron to form so-called nano particles, reported by Kreuter, J., Microcapsules and Nanoparticles in Medicine and Pharmacology, (M. Donbrow, ed.) CRC Press, p. 125-148.

[0145] - Microencapsulation has been applied to the injection of microencapsulated pharmaceuticals to give a controlled release. A number of factors contribute to the selection of a particular polymer for microencapsulation. The reproducibility of polymer synthesis and the microencapsulation process, the cost of the microencapsulation materials and process, the toxicological profile, the requirements for variable release kinetics and the physicochemical compatibility of the polymer and the antigens are all factors that must be considered. Examples of useful polymers are polycarbonates, polyesters, polyurethanes, polyorthoesters and polyamides, particularly those that are biodegradable.

[0146] A frequent choice of a carrier for pharmaceuticals and more recently for antigens is poly (d, l-lactide-co-glycolide) (PLGA). This is a biodegradable polyester that has a long history of medical use in erodible sutures, bone plates and other temporary prostheses where it has not exhibited any toxicity. A wide variety of pharmaceuticals including peptides and antigens have been formulated into PLGA microcapsules. A body of data has accumulated on the adaption of PLGA for the controlled release of antigen, for example, as reviewed by Eldridge, J.H., et al., Current Topics in Microbiology and Immunology, 1989, 146:59-66. The entrapment of antigens in PLGA microspheres of 1 to 10 microns in diameter has been shown to have a remarkable adjuvant effect when administered orally. The PLGA microencapsulation process uses a phase separation of a water-in-oil emulsion. The compound of interest is prepared as an aqueous solution and the PLGA is dissolved in a suitable organic solvents such as methylene chloride and ethyl acetate. These two immiscible solutions are co-emulsified by high-speed stirring. A non-solvent for the polymer is then added, causing precipitation of the polymer around the aqueous droplets to form embryonic microcapsules. The microcapsules are collected, and stabilized with one of an assortment of agents (polyvinyl alcohol (PVA), gelatin, alginates, polyvinylpyrrolidone (PVP), methyl cellulose) and the solvent removed by either drying *in vacuo* or solvent extraction.

[0147] Thus, solid, including solid-containing-liquid, liquid, and gel (including "gel caps") compositions are envisioned. Additionally, the inventive vector or recombinant, and the expression products therefrom can stimulate an immune or antibody response in animals. From those antibodies, by techniques well-known in the art, monoclonal antibodies can be prepared and, those monoclonal antibodies, can be employed in well known antibody binding assays, diagnostic kits or tests to determine the presence or absence of antigen(s) and therefrom the presence or absence of the natural causative agent of the antigen or, to determine whether an immune response to that agent or to the antigen(s) has simply been stimulated.

[0148] Monoclonal antibodies are immunoglobulin produced by hybridoma cells. A monoclonal antibody reacts with a single antigenic determinant and provides greater specificity than a conventional, serum-derived antibody. Furthermore, screening a large number of monoclonal antibodies makes it possible to select an individual antibody with desired specificity, avidity and isotype. Hybridoma cell lines provide a constant, inexpensive source of chemically identical

antibodies and preparations of such antibodies can be easily standardized. Methods for producing monoclonal antibodies are well known to those of ordinary skill in the art, e.g., Koprowski, H. et al., U.S. Pat. No. 4,196,265, issued Apr. 1, 1989.

[0149] Uses of monoclonal antibodies are known. One such use is in diagnostic methods, e.g., David, G. and Greene, H., U.S. Pat. No. 4,376,110, issued Mar. 8, 1983.

[0150] Monoclonal antibodies have also been used to recover materials by immunoabsorption chromatography, e.g. Milstein, C., 1980, Scientific American 243:66, 70.

[0151] Furthermore, the inventive vector or recombinant or expression products therefrom can be used to stimulate a response in cells *in vitro* or *ex vivo* for subsequent reinfusion into a patient. If the patient is seronegative, the reinfusion is to stimulate an immune response, e.g., an immunological or antigenic response such as active immunization. In a seropositive patient, the reinfusion is to stimulate or boost the immune system against the lentivirus, retrovirus, or immunodeficiency virus, e.g., FIV.

[0152] - Accordingly, the inventive vector or recombinant has several utilities: In antigenic, immunological or vaccine compositions such as for administration to seronegative animals or humans (or patients, as veterinarians like to call animals, with "patients" including humans as well). In therapeutic compositions in seropositive animals or humans in need of therapy to stimulate or boost the immune system against the lentivirus, retrovirus, or immunodeficiency virus, e.g., feline immunodeficiency virus. *In vitro* to produce antigens or immunogens or epitopes of interest, which can be further used in antigenic, immunological or vaccine compositions or in therapeutic compositions. To generate antibodies (either by direct administration or by administration of an expression product of the inventive vectors or recombinants) which can be further used: in diagnosis, tests or kits to ascertain the presence or absence of antigens or epitopes in a sample such as sera, for instance, to ascertain the presence or absence of the lentivirus, retrovirus, or immunodeficiency virus, e.g., feline immunodeficiency virus, in a sample such as sera or, to determine whether an immune response has elicited to the lentivirus, retrovirus, or immunodeficiency virus, e.g., FIV, or, to particular antigen(s) or epitope(s); or, in immunoabsorption chromatography. To generate DNA for use as hybridization probes or to prepare PCR primers or for DNA immunization. And, the inventive vectors or recombinants, expression products therefrom, and immunogens, antigens, and epitopes from the inventive vectors or recombinants can be used to generate stimulated cells which can be further used (reinfused) to stimulate an immune response (antigenic, or immunological response; or active immunization) or, to boost or stimulate the immune system (for instance, of an immunocompromised or seropositive animal or human). Other utilities also exist for embodiments of the invention.

[0153] A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.

EXAMPLES

[0154] DNA Cloning and Synthesis. Plasmids were constructed, screened and grown by standard procedures (Maniatis et al., 1982; Perkus et al., 1985; Piccini et al., 1987). Restriction endonucleases were obtained from Bethesda Research Laboratories, Gaithersburg, MD, New England Biolabs, Beverly, MA; and Boehringer Mannheim Biochemicals, Indianapolis, IN. Klenow fragment of *E. coli* polymerase was obtained from Boehringer Mannheim Biochemicals. BAL-31 exonuclease and phage T4 DNA ligase were obtained from New England Biolabs. The reagents were used as specified by the various suppliers.

[0155] Synthetic oligodeoxyribonucleotides were prepared on a Biosearch 8750 or Applied Biosystems 380B DNA synthesizer as previously described (Perkus et al., 1989). DNA sequencing was performed by the dideoxy-chain termination method (Sanger et al., 1977) using Sequenase (Tabor et al., 1987) as previously described (Guo et al., 1989). DNA amplification by polymerase chain reaction (PCR) for sequence verification (Engelke et al., 1988) was performed using custom synthesized oligonucleotide primers and GeneAmp DNA amplification Reagent Kit (Perkin Elmer Cetus, Norwalk, CT) in an automated Perkin Elmer Cetus DNA Thermal Cycler. Excess DNA sequences were deleted from plasmids by restriction endonuclease digestion followed by limited digestion by BAL-31 exonuclease and mutagenesis (Mandecki, 1986) using synthetic oligonucleotides.

[0156] Cells, Virus, and Transfection. The origins and conditions of cultivation of the Copenhagen strain of vaccinia virus has been previously described (Guo et al., 1989). Generation of recombinant virus by recombination, *in situ* hybridization of nitrocellulose filters and screening for B-galactosidase activity are as previously described (Piccini et al., 1987).

[0157] The origins and conditions of cultivation of the Copenhagen strain of vaccinia virus and NYVAC and ALVAC has been previously described (Guo et al., 1989; Tartaglia et al., 1992, U.S. Patents Nos. 5,364,773 and 5,494,807). Generation of recombinant virus by recombination, *in situ* hybridization of nitrocellulose filters and screening for B-galactosidase activity are as previously described (Panicali et al., 1982; Perkus et al., 1989).

[0158] The parental canarypox virus (Rentschler strain) is a vaccinal strain for canaries. The ALVAC vaccine strain, as discussed above, was obtained from a wild type isolate and attenuated through more than 200 serial passages on chick embryo fibroblasts. A master viral seed was subjected to four successive plaque purifications under agar and one

plaque clone was amplified through five additional passages after which the stock virus was used as the parental virus in *in vitro* recombination tests. The plaque purified canarypox isolate is designated ALVAC.

[0159] The strain of fowlpox virus (FPV) designated FP-1 has been described previously (Taylor et al., 1988a). It is an attenuated vaccine strain useful in vaccination of day old chickens. The parental virus strain Duvette was obtained in France as a fowlpox scab from a chicken. The virus was attenuated by approximately 50 serial passages in chicken embryonated eggs followed by 25 passages on chicken embryo fibroblast cells. The virus was subjected to four successive plaque purifications. One plaque isolate was further amplified in primary CEF cells and a stock virus, designated as TROVAC, established.

[0160] NYVAC, ALVAC and TROVAC viral vectors and their derivatives were propagated as described previously (Piccini et al., 1987; Taylor et al., 1988a,b, U.S. Patents Nos. 5,364,773 and 5,494,807). Vero cells and chick embryo fibroblasts (CEF) were propagated as described previously (Taylor et al., 1988a,b).

EXAMPLE 1 - Construction of ALVAC-FIV env

[0161] The feline immunodeficiency virus (FIV) env coding sequence in plasmid ptg6184 and FIV nucleotide sequences were obtained from Rhone Merieux (Lyon, France). The cDNA clone was derived from the Villefranche strain of FIV. The FIV env nucleotide sequence is shown in Figure 2 (SEQ ID NO:1).

[0162] The FIV env coding sequence was placed under control of the modified early/late vaccinia virus H6 promoter (Perkus, et al., 1989). The FIV env coding sequence contains two T₅NT sequence motifs which may provide for premature early transcription termination (Yuen and Moss, 1987). The T₅NT sequences were modified, without altering the predicted amino acid coding sequence, by replacement with a PCR-derived fragment. TTTTAT between positions 2059 and 2065 in Figure 2 was changed to TTCTTAT; TTTTCT between positions 2110 and 2116 was changed to TTCTTCT.

[0163] Two overlapping PCR fragments were derived from the ptg6184 template, yielding a fragment with altered T₅NT sequences. A 585bp PCR fragment was generated using oligonucleotide primers MM040 (SEQ ID NO:9) (5'-AAATTCCTTATATACAGCTTTCGCTATGCAAGAATTAGGATGTAATCAAAATCAATTC TTCT GCAAAATCCCTCCTGGGT-3') and MM042 (SEQ ID NO:10) (5'-CCCATCGAGTGCGGCTAC-3'). MM040 primes toward the 3'-most sequences of the env coding sequence (from position 2056, Figure 2). MM042 primes from the env 3'-most sequences toward the 5'-most sequences. A second PCR primed with MM041 (SEQ ID NO:11)

(5'GCAGAAGAATTGATTTTGATTACATCCTAATTCTT GCATAGCGAAAGCTGTATATAAGAATTTTCCATAGCTTC-3') and MM043 (SEQ ID NO:12) (5'AAGTTCTGGCAACCCATC-3') generated a 187bp fragment. MM041 primes from position 2118 toward the 5'-most sequences of env and MM043 primes toward the 3'-most sequences of the env coding sequence from position 1931 (Figure 2). The two PCR products were pooled, primed with MM043 and MM042, and digested with ScaI at FIV coding sequence position 2020 in Figure 2 and EcoRI 3' of the env coding sequence. The resultant 564bp ScaI-EcoRI PCR fragment contains the 3'-most sequences of the FIV env coding sequence with the altered T₅NT motifs.

[0164] Plasmid ptg6184 was digested with EcoRI and partially digested with ScaI. This ptg6184 derived fragment with the 3' FIV env deleted from ScaI (Figure 2 position 2020) through EcoRI 3' of the env coding sequence was ligated to the 564bp ScaI-EcoRI PCR-derived fragment (above). The resultant plasmid pMM120 contains the FIV env with altered T₅NT motifs. The nucleotide sequence was confirmed using standard procedures (Goebel et al., 1990a). The 2.6kbp pMM120 PstI-EcoRI fragment, containing the FIV env coding sequence, was inserted between the pBS-SK (Stratagene, La Jolla, California) PstI and EcoRI sites generating pMM122.

[0165] The modified early/late vaccinia virus H6 promoter (Perkus et al., 1989) was added to pMM122 by overlapping the H6 translation initiation codon with the FIV env translation initiation codon. A fragment containing the H6 promoted 5'-most sequences of the env coding sequence was generated by PCR using primers MM037

(SEQ ID NO:13) (5' ATCATCCTGCAGAAGCTTCCCGGGTTCTTTATTCTATACTT-3'), MM038 (SEQ ID NO:14) (5'-CTGCAAATCCTTCTGCCATTACGATACAACTTAAC-3'), MM065 (SEQ ID NO:15) (5'-CGTTAAGTTTGTATCGTAATGGCAGAAGGATTTGCAGCC-3'), and MM036 (SEQ ID NO:16) (5'-CCTCTTGAATTCGTTCC-3'). pMM108, containing H6 promoter sequences, was used as template for PCR with MM037 and MM038 creating a 166bp fragment containing the H6 promoter and the 5'-most bp of the FIV env coding sequence. pMM122 was used as template for PCR with MM065 and MM036 to generate a 235bp fragment with the 3' H6 promoter and 5' env end. The two PCR products were pooled, primed with MM036 and MM037, and the resultant fragment, containing the H6 promoter fused to the 5' most bp of the FIV env coding sequence, was digested with PstI and KpnI generating a 266bp fragment. pMM122 was digested with PstI and partially digested with KpnI to remove the 5'-most

sequences of the FIV env coding region and the 266bp PstI-KpnI PCR-derived fragment described above was inserted. The resultant plasmid pMM125 contains the FIV env juxtaposed 3' to the vaccinia H6 promoter in pBS-SK (Stratagene, La Jolla, California).

[0166] Sequence analysis of pMM125 demonstrated correct PCR construction of the H6 promoted FIV env 5'-most

sequences, but frameshift mutations were observed 3' of the PCR insertion. The frameshifts were not observed in pMM122. All pMM125 clones contained frameshifts. These frameshifts were probably a result of the recently described instability of *env* sequences in high copy number plasmids (Wang and Mullins, 1995). Separate pMM125 clones had different frameshifts. An H6 promoted FIV *env*, without frameshifts, was constructed in the following manner.

[0167] Briefly, this is a summary of the following detailed description of the construction of an H6 promoted FIV *env* without frameshifts. The H6 promoted 5'-most sequences of the FIV *env* coding sequence, which did not contain frameshifts, from one pMM125 clone was ligated to the remaining unframeshifted 3'-most bp of FIV *env* end from another pMM125 clone. The first fragment was from the *Sma*I site 5' of the H6 promoter through the *Afl*III site in the FIV *env* coding sequence (Figure 1, position 1707). The second fragment was from the same *Afl*III site to the *Sma*I site 3' of the *env* coding sequence. The ligation product was digested with *Sma*I, liberating three fragments. One fragment contained two 5'-most sequences and another fragment contained two 3'-most sequences. The third *Sma*I digestion product containing the H6 promoted FIV *env* expression-cassette was isolated and inserted into a C6 vector, generating pRW945. To eliminate the possibility of frameshifts, pRW945 was not amplified in bacteria. Details of pRW945 construction follow.

[0168] One pMM125 clone, pMM125#11, had the correct sequence from *Sma*I 5' of the H6 promoter through the *Afl*III site at position 1707 (Figure 2); another pMM125 clone, pMM125#10, had the correct sequence from the *Afl*III site at position 1707 through *Sma*I 3' of the *env* coding sequence. The 1.8kbp pMM125#11 *Sma*I-*Afl*III fragment, containing the H6 promoted 5'-most *env* sequences, was ligated to the 0.9kbp pMM125#10 *Sma*I-partial *Afl*III fragment containing the 3' portion of *env*. The ligation product was *Sma*I digested and the 2.7kbp fragment was inserted into the C6 vector pMM117, yielding pRW945.

[0169] The C6 insertion plasmid, pMM117, was constructed in the following manner. A 3kbp ALVAC *Hind*III clone was sequenced and an open reading frame was defined. A PCR-derived fragment was used for replacement of the open reading frame with restriction sites for DNA insertions. The PCR-derived fragment was generated with primers C6A1 (SEQ ID NO:17) (5'-ATCATCGAGCTCGCCGCTATCAAAAGTCTTAATGAGTT-3'), C6B1 (SEQ ID NO:18) (5'-GAATTCCTCGAGCTGCAGCCCGGGTTTTATAGCTAATTAGTCAT TTTTCGTAAGTAAGTATTTTATTTAA-3'), C6C1 (SEQ ID NO:19) (5'-CCCGGGCTGCAGCTCGAGGAATTCCTTTTATTGATTAAGTCAAATGAGTATATA TAATTGA AAAAGTAA-3') and C6D1 (SEQ ID NO:20) (5'-GATGATGGTACCTTCATAAATACAAGTTTGATTAAACT-TAAGTTG-3'). ALVAC was used as template for PCR using oligonucleotides C6A1 and C6B1 generating a 380bp fragment. A second PCR reaction used ALVAC template and primers C6C1 and C6D1 to generate a 1155bp fragment. The PCR reaction products were pooled and primed for a final PCR with C6A1 and C6D1 yielding a 1613bp fragment. The final PCR product was digested with *Sac*I and *Kpn*I for insertion between the *Sac*I and *Kpn*I sites of pBS-SK (Stratagene, La Jolla, California). The resultant C6 insertion plasmid was designated pC6L. The C6 insertion plasmid pMM117 was constructed by adding the sequence GGGGGATCCTTAATTAATTAGTTATTAGACAAGGTGAAAAC-GAAACTATTTGTAGCT TAATTAATTAGCTGCAGGAATTC (SEQ ID NO:21) between the pC6L (Fig. 4; SEQ ID NO: 3) *Sma*I and *Eco*RI sites.

[0170] The above described plasmid pRW945 contains the H6 promoted FIV *env* coding sequence, with altered T₅NT motifs, in a C6 insertion plasmid. pRW945 was used in *in vitro* recombination experiments with ALVAC as the rescuing virus to derive recombinant vCP242. Figure 5 shows the predicted nucleotide sequence of the insertion in vCP242 (SEQ ID NO:4).

EXAMPLE 2 - Construction of Recombinant ALVAC Expressing FIV *gag*, and *pro*

[0171] The feline immunodeficiency virus (FIV) *gag* and *pol* coding sequences in plasmid ptg8133 and FIV *env* coding sequence in plasmid ptg6184 were obtained from Rhone Merieux (Lyon, France). The cDNA clones were derived from the Villefranche strain of FIV. Figure 3 (SEQ ID NO:2) contains the nucleotide sequence for the FIV *gag* and *pol* coding regions obtained from Rhone Merieux.

[0172] The FIV *gag* sequences encoding core antigens, followed by the *pol* sequences encoding a protease, reverse transcriptase and integrase, were placed under control of the early/intermediate vaccinia I3L promoter (Schmitt, J. and Stunnenberg, H., 1988; Vos, J. and Stunnenberg, H., 1988). The I3L promoter corresponds to positions 65073 through 64971 in Goebel et al., 1990 a,b. The *gag* and *pol* coding sequences were engineered in a single transcription unit. The *Gag* and *Pol* open reading frames (ORFs) differ and translation of the *Pol* ORF results via a ribosomal frameshift mechanism (Morikawa and Bishop, 1992) as it does normally in FIV-infected cells.

[0173] PCR-derived fragments were used for construction of the I3L promoted FIV *gag/pol* cassette. The PCR-derived fragments were also used to alter a T₅NT sequence motif which may provide for premature early transcription termination (Yuen and Moss, 1987). TTTTAT between positions 467 and 473 (Figure 3) was changed to TTTTCAT, without altering the predicted amino acid coding sequence. Manipulations to construct the I3L promoted FIV *gag/pol* expression cassette were performed in the following manner.

[0174] PCR was performed with ptg8133, containing the FIV *gag/pol* coding sequences, as template and MM027 (SEQ ID NO:22) (5'-CAAAAATGGTGTCCATTTTCATGGAAAAGGCAAGAGAAGGAC-3') and MM028 (SEQ ID NO:23)

(5'-CTGCTGCAGTAAATAGG-3') as primers to generate a 245bp fragment. MM027 primed from position 452 (Fig. 3) toward the 3'-most sequences containing a nucleotide change in the T₅NT sequence motif. MM028 primes from position 697 downstream of a HindIII site toward the gag 5'-most sequences. The 245bp PCR-derived fragment contains the FIV gag coding sequence from position 452 to position 697 with an altered T₅NT motif.

[0175] A second PCR using ptg8133 as template and primers MM029 (SEQ ID NO:24) (5'-CTTCTCTTGCCTTTTC-CATGAAAATGGACACCATTTT TGGGTC-3') and MM030 (SEQ ID NO:25) (5'-CAATTATTTAGGTTTAATCAT-GGGGAATGGACAGGGGC-3') generated a 508bp fragment. MM029 primes from position 490 (Fig. 3) toward the 5'-most sequences of the gag coding sequence and alters the T₅NT sequence motif. MM030 contains the 3'-most sequence of the I3L promoter and primes from the gag initiation codon toward the 3'-most sequences of the gag coding sequence. The 508bp PCR-derived fragment contains the 3'-most I3L promoter and the FIV gag coding sequence with an altered T₅NT motif through position 490.

[0176] Plasmid template pMM100, containing the I3L promoter sequences, was primed with MM031 (SEQ ID NO:26) (5'-CGCCCCTGTCCATTCCTCATGATTAACCTAAATAATTGTAC-3') and MM032 (SEQ ID NO:27) (5'-ATCATCGTC-GACATCGATACATCATGCAGTGGTTAAAC-3') to generate a 137bp PCR-derived fragment. The MM031 5'-most sequences contains the 5'-most bp of gag followed by a sequence which primes at the I3L promoter 3'-most sequences toward the I3L promoter 5'-most sequences. MM032 has SalI and ClaI sites followed by a sequence which primes from the I3L promoter 5'-most sequences toward the 3'-most sequences. The 137bp PCR-derived fragment contains the I3L promoted FIV gag 5'-most 20bp.

[0177] The three PCR products were pooled and primed for PCR with MM032 and MM028. The resultant 814bp fragment was digested with HindIII and SalI, generating a 726bp fragment containing the I3L promoted FIV gag 5'-most sequences with an altered T₅NT motif.

[0178] ptg8133 was digested with SacI and SalI, to remove the 7.2kbp plasmid sequences, and the 4.7kbp fragment was isolated and partially digested with HindIII. The 4kbp ptg8133 SacI-HindIII partial digestion product, containing the FIV gag coding sequence from position 615 through the FIV pol coding sequence, was isolated.

[0179] SacI-SalI digested pBS-SK (Stratagene, La Jolla, California) was ligated with the 726bp HindIII-SalI PCR-derived fragment (above) and the 4kbp ptg8133 SacI-HindIII fragment. The resultant plasmid pMM116 contains the I3L promoted FIV gag/pol expression cassette in pBS-SK.

[0180] The 4.7kbp pMM116 Asp718-Ecl136II fragment containing I3L promoted FIV gag/pol coding regions was treated with Klenow, in the presence of 20mM dNTPs, and inserted into SmaI digested pMM117 to produce pMM121. pMM117 is the C6 insertion plasmid described above.

[0181] The 1.4kbp pMM121 EcoRI fragment, containing the I3L promoted FIV gag/pol 5'-most region, was inserted into the pBS-SK (Stratagene, La Jolla, California) EcoRI site generating pMM123. A PCR-derived fragment was used to remove the coding sequences corresponding to the carboxy-end of Pol to achieve Gag-protease expression only. The PCR-derived fragment introduced a termination codon following the protease coding sequence at position 1709 (Fig. 3). Manipulations to construct the I3L promoted FIV gag and protease coding sequences were performed in the following manner.

[0182] Template pMM121, containing the I3L promoted FIV gag/pol coding sequences, was primed with MM063 (SEQ ID NO:28) (5'-CAGGACATCTAGCAAGAC-3') and MM064 (SEQ ID NO:29) (5'-GATGATCCCGGGATAAAAATTATT-GAGCCATTACTAACCT-3') to generate a 580bp PCR-derived fragment. MM063 primes from position 1148 (Fig. 3) toward the 3'-most sequences. MM064 primes from position 1709 toward the 5'-most sequences. The 580bp PCR-derived fragment, containing the FIV protease coding sequence with a stop codon at position 1709 (Fig. 3), was digested with EcoRI and SmaI yielding a 475bp fragment.

[0183] pMM123 was linearized at the SmaI site 3' of the FIV insertion, followed by partial EcoRI digestion. The 475bp SmaI-EcoRI PCR-derived fragment (above) was inserted into the pMM123 SmaI-EcoRI partial digestion product, with the EcoRI site digested at figure 3 position 1246. The resultant plasmid pMM127 contains the FIV gag and protease coding sequences, followed by a stop codon, in pBS-SK (Stratagene, La Jolla, California). The nucleotide sequence of the PCR-derived fragment in pMM127 was confirmed using standard procedures (Goebel et al., 1990a). A single bp deletion 3' of the FIV protease coding sequence was observed. MM064 was designed to add TTTTAT after the FIV protease stop-codon. One T in the TTTTAT sequence after the stop codon is missing from pMM127, resulting in the sequence TTTTAT.

[0184] The 1.8kbp pMM127 BamHI-SmaI fragment, containing the I3L promoted FIV gag and protease coding sequences, was inserted into SmaI-BamHI partially digested pMM117. The C6 insertion plasmid pMM117 is described above. The BamHI partial digestion was used to digest the BamHI site next to the SmaI site in pMM117. The resultant plasmid, containing the I3L promoted FIV gag and protease coding sequences in a C6 insertion plasmid, was designated pMM129. Plasmid pMM129 was used in *in vitro* recombination experiments with ALVAC as the rescuing virus to derive recombinant vCP253. Figure 6 (SEQ ID NO:5) shows the predicted nucleotide sequence of the I3L promoted FIV gag/protease expression cassette and flanking regions in vCP253.

EXAMPLE 3 - Construction of Recombinant ALVAC Expressing FIV env, gag, and pro

[0185] Plasmid pMM125, containing the H6 promoted FIV env with frameshift mutations, is described above. A deliberate insertion, containing a frameshift, into the FIV env coding sequence allowed stable maintenance of the remainder of the H6 promoted FIV env construct in bacteria. After bacterial amplification the insertion was removed. Manipulations to construct the H6 promoted FIV env coding sequence, with a deliberate frameshift insertion, were performed in the following manner.

[0186] pMM125#11 (described above) was modified by insertion of a PCR-derived fragment which repaired the spontaneous frameshift and introduced a deliberate frameshift flanked by BstEII sites. The BstEII insertion is at position 1920 (Fig. 2). The insertion introduces a stop codon followed by a frameshift, NotI and HindIII sites. There are no BstEII sites in pMM125. The PCR-derived fragment also changes the A at position 1920 in figure 2 to C. The A to C change does not alter the predicted amino acid coding sequence, but the change does introduce a BstEII site. pMM125#10 has a spontaneous frameshift at position 1604 (Figure 2). pMM125#10 was used as template for PCR with oligonucleotide primers RW542 (SEQ ID NO:30) (5'-TATGAATTGTAATTGTAC-3') and RW545 (SEQ ID NO:31) (5'-GTAGCATAAG-GTTACCGCGGCCGCTAAGCTTAGGTTACCATCCCTATAGCAGTA-3') to generate a 326bp fragment containing the BstEII insertion. RW542 primes from position 1632 toward the FIV env 3'-most sequences; RW545 primes from position 1919 toward the FIV env 5'-most sequences (Figure 2). pMM125#10 was used as template for PCR with RW544 (SEQ ID NO:32) (5'-GTAGCATAAGGTAACCTAAGCTTAGCGGCCGCGGTAACCCAATACCACCAAGTTCTG GC-3 ') and T3 (SEQ ID NO:33) (5'-ATTAACCCTCACTAAAG-3') generating a 791bp fragment containing the BstEII insertion and the FIV env coding sequence 3'-most sequences. RW544 primes from position 1914 toward the env 3'-most sequences. T3 primes in the pBS-SK plasmid, downstream of the FIV env stop codon, toward the FIV env 5'-most sequences. The two PCR products were pooled, primed with RW542 and T3, and the resultant 1.1Kbp product was digested with EcoRI and partially digested with AflII generating a 876bp fragment which was inserted into the following pMM125#11 vector. The PCR-derived fragment and pMM125#11 vector were digested with AflII at position 1709 (Fig. 2). pMM125#11 was digested with EcoRI and EcoRI to remove the FIV env coding sequence 3'-most sequences which contained a spontaneous frameshift. The 876bp EcoRI-AflII PCR-derived fragment was inserted into the pMM125#11 EcoRI-AflII vector. The resultant plasmid pMM134 contains the FIV env coding sequence juxtaposed 3' to the H6 promoter in pBS-SK (Stratagene, La Jolla, California). pMM134 also contains a deliberate frameshift mutation inserted between two BstEII sites. The entire H6 promoted FIV env sequence in pMM134, including the BstEII insertion, was confirmed. As - expected, the BstEII insertion allowed stable maintenance of the remainder of the H6 promoted FIV env construct.

[0187] Once the H6 promoted FIV env coding sequence from pMM134 is cloned into a poxvirus insertion plasmid, the BstEII insertion should be removed to allow expression of the full length FIV env coding sequence. The BstEII insertion is removed by BstEII digestion, followed by a dilute ligation reaction favoring intramolecular ligation. The intramolecular ligation product would contain the H6 promoted FIV env, without the BstEII insertion. After the BstEII insertion is removed, the H6 promoted FIV env coding sequence is not expected to be stably maintained in bacteria and the plasmid was not amplified in bacteria. After ligation, the plasmid was digested with NotI. Ligation products containing the BstEII insertion would be digested at the NotI site within the BstEII insertion. NotI digestion within the BstEII insertion would prevent the ability of the plasmid to generate a viable recombinant poxvirus. Full length FIV env, without the BstEII insertion, would not be cleaved by NotI digestion; FIV env coding sequences would remain intact.

EXAMPLE 4 - Construction of The H6 Promoted FIV env Coding Sequence In C6 With The I3L Promoted FIV gag And Protease Coding sequences

[0188] Construction of pMM134 containing the H6 promoted FIV env coding sequence with a BstEII insertion has been described above. The 2.7kbp H6 promoted FIV env SmaI fragment from pMM134, with the BstEII insertion, was cloned into the following pMM129 insertion plasmid.

[0189] pMM129, containing the I3L promoted FIV gag and protease coding sequences in C6, has been described above. The pMM129 Sall site 5' of the I3L promoter was blunt ended with Klenow in the presence of 20mM dNTPs. pMM138 was constructed by insertion of the 2.7kbp pMM134 SmaI fragment containing the H6 promoted FIV env coding sequence, with the BstEII insertion, into the pMM129 blunt ended Sall site. The H6 promoted FIV env coding sequence, in pMM138, is 5' of the I3L promoted FIV gag and protease coding sequences; the FIV coding sequences are transcribed in the same direction.

[0190] The two BstEII sites in pMM138 surround the insertion containing a frameshift. Digestion of pMM138 with BstEII, to remove the insertion, was followed by ligation. The resultant plasmid pMM146 was not amplified in bacteria. pMM146 was designed for NotI digestion before *in vitro* recombination experiments; NotI digestion served two purposes. First, any plasmid unintentionally containing the BstEII insertion would be digested with NotI within the insertion and the donor plasmid would be prevented from generating a viable ALVAC recombinant. Second, NotI linearizes pMM146 within the pBS-SK backbone for efficient generation of the intended ALVAC recombinant. pMM146 was digested with

Notl prior to use in in vitro recombination experiments with ALVAC as the rescuing virus to derive recombinant vCP255. Figure 7 (SEQ ID NO:6) shows the predicted nucleotide sequence of the H6 promoted FIV env/I3L promoted FIV gag/protease expression cassette and flanking regions in vCP255.

5 **EXAMPLE 5 - Construction of Recombinant ALVAC Expressing FIV 97TM, gag, and pro**

[0191] The FIV envelope glycoprotein is composed of two cleavage products, gp97 and gp40. The FIV env coding sequence was modified, by replacing gp40 with the transmembrane anchor domain from the FIV env coding sequences, in the following FIV 97TM construct. FIV 97TM, containing gp97 followed by the transmembrane anchor domain, was

10 constructed in the following manner.
[0192] A PCR-derived fragment PCR-FIV1 (242bp) was synthesized using pMM125#10 (containing the previously described FIV env with the correct sequence from AflIII site to 3'-most- sequences) as a template, and oligonucleotides MW196 (SEQ ID NO:34) (5'-ACTTGCCATCGTCATGGGGG-3') and MW195A (SEQ ID NO:35) (5'-GATACCTCCCAAT-AGTCCCCTTTTCTTCTAGGTTTATATTC-3') as primers. PCR-derived fragment PCR-FIV2 (193bp) was synthesized

15 using pMM125#10 as a template, and oligonucleotides MW194A (SEQ ID NO:36) (5'-GAATATAAACCTAGAAG-GAAAAGGGGACTATTGGGAGGTATC-3') and MW197 (SEQ ID NO:37) (5'-ATCATCGAATTCATAAAAATCATTCT-TCTCCTTCTACTTC-3') as primers. PCR-derived fragment PCR-FIV3 (393bp) was synthesized using PCR-derived fragments PCR-FIV1 and PCR-FIV2 as templates, and oligonucleotides MW196 and MW197 as primers. A complete AflIII/EcoRI digest of PCR-FIV3 was performed, and the 284bp fragment was isolated. This fragment was ligated into

20 the 4.8kb AflIII/EcoRI fragment of pMM125#11 (containing the previously described FIV env with the correct sequence from 5'-most sequences to the EcoRI site described above). The resultant plasmid, pMAW103, contains H6 promoted FIV 97TM.
[0193] A PstI site was added upstream of the H6 promoter in the following manner. PCR-derived fragment PCR-FIV4 (359bp) was synthesized using pMAW103 as a template, and oligonucleotides MW209 (SEQ ID NO:8) (5'-ATCAT-CAAGCTTCTGCAGTTCTTTATTCTA TACTTA-3') and MM036 (SEQ ID NO:16) (5'-CCTCTTGAATTCGTTCC-3') as

25 primers. A complete HindIII/NruI digest of PCR-FIV4 was performed, and the 110bp fragment was inserted into the 5.0kb HindIII/NruI fragment of pMAW103, yielding plasmid pMAW103A. The 2126bp pMAW103A PstI fragment containing the H6 promoted FIV 97TM was inserted into the PstI site of pMM117 (described above), yielding plasmid pMAW104.

30 **EXAMPLE 6 - ALVAC FIV Recombinant Expression Analysis**

[0195] Expression of the appropriate FIV-specific gene products encoded by the ALVAC recombinants vCP242, vCP253, vCP255, and vCP329 was demonstrated in various analyses. Expression analyses were performed using

40 either appropriate monoclonal antibodies or serum derived from FIV seropositive cats. Either reagent worked equally well in confirming expression in ALVAC-FIV-infected cells. Accordingly, without undue experimentation, from seropositive individuals, monoclonals can be derived for confirming expression.
[0196] vCP242 FIV Env expression was demonstrated by ELISA (described below). vCP242 was positive for surface expression in an immunofluorescence assay by FACS with an FIV Env specific monoclonal antibody (obtained from Rhone-Merieux, Lyon, France). vCP242 was positive by immunoprecipitation using polyclonal serum from FIV infected

45 cats and two different monoclonal antibodies (described below). Thus, without undue experimentation, monoclonals from seropositive individuals can be derived for confirming expression.
[0197] vCP253 was positive for internal expression of Gag by FACS. vCP253 was positive by immunoprecipitation for expression of the mature Gag p24. A dominant Gag precursor was detected at 37kDa; additional signals, representing

50 Gag cleavage products, were obtained at 49kDa, 40kDa, and 32kDa.
[0198] vCP255 surface expression for Env was positive by FACS with an Env-specific monoclonal antibody (described below). vCP255 internal expression of Gag was demonstrated with a Gag-specific monoclonal antibody by FACS. vCP255 was assayed by immunoprecipitation with monoclonal antibodies to each gene product: Gag was positive with signals at approximately 49kDa, 40kDa, 37kDa, and 24kDa; FIV Env expression was positive with signals at 130kDa

55 and 90kDa.
[0199] vCP329 expression of 97TM and gag were detected by immunoprecipitation with pooled serum from FIV infected cats.

[0200] FACS ANALYSIS: vCP255 contains the feline immunodeficiency virus (FIV) env, gag and protease coding

sequences in locus C6. pMM146 was used in in vitro recombination experiments with ALVAC as the rescuing virus to derive recombinant vCP255. vCP255 FIV-specific gene product expression was assayed on a fluorescence activated cell sorter (FACS). The FIV Env protein product was assayed on the surface of vCP255 infected cells. The FIV p24 product was assayed for using internal expression analyses. The antisera used for FACS analysis were:

- 1) monoclonal anti-FIV env: 128F10 EP110592 from Rhone Merieux (1:200 dilution)
- 2) monoclonal anti-FIV p24: pool 125A3, 314B5 EP072092 from Rhone Merieux (1:100 dilution)
- 3) monoclonal anti-rabies G: 24-3F-10 021387 from C. Trimarchi, Griffin Laboratories, New York State Health Department (1:200 dilution)
- 4) polyclonal goat anti-mouse IgG coupled to fluorescein isothiocyanate (FITC) from Boehringer Mannheim, catalogue number 605240, lot number 24064 (1:100 dilution)

[0201] FACS ANALYSIS OF EXPRESSION ON CELL SURFACE: 1×10^7 HeLa-S3 cells (ATCC #CCL2.2) were infected with 5×10^7 PFU of vCP255 in minimum essential medium (S-MEM: Gibco #380-2380AJ) supplemented with 10% fetal bovine sera, 20mM Glutamine and 0.5% penicillin-streptomycin. The infected cells were incubated at 37°C for 30 minutes with occasional agitation. The cells were washed with 10mls S-MEM. After each wash the cells were pelleted at 1000 RPM for 5 minutes in a Beckman GPKR centrifuge. The infected cell pellet was resuspended in 1ml S-MEM, transferred to a 5ml Sarstadt tube and slowly rotated at 37°C overnight.

[0202] After overnight incubation, 100µl aliquots of the infected cells were added to 5ml polypropylene tubes. The cells were washed with 3mls of PBS-CMF (137mM NaCl, 2.7mM KCl, 1.5mM KH_2PO_4 , and 8mM Na_2HPO_4 ; pH 7.4) which included 0.2% NaN_3 and 0.2 % bovine serum albumen (BSA). The cells were pelleted and the supernatant was discarded. Specific antibody was added to one tube and nonspecific antibody (anti-rabies G) was added to a second tube in the following manner.

[0203] 100µl of antibody (previously preadsorbed with HeLa Cells) diluted in PBS-CMF supplemented with 0.2% NaN_3 and 0.2% BSA was added to each cell pellet, and incubated at 4°C for 30 minutes. The cells were washed and pelleted twice in 3mls of PBS-CMF containing 0.2% NaN_3 and 0.2% BSA. 100µl of secondary FITC coupled antibody (previously preadsorbed with HeLa Cells) diluted 1:50 in PBS-CMF containing 0.2% NaN_3 and 0.2% BSA was added and incubated at 4°C, in the dark, for 30 minutes. The cells were washed and pelleted twice in 3mls of PBS-CMF containing 0.2% NaN_3 and 0.2% BSA. The cell pellets were resuspended in 1ml PBS-CMF, containing 0.2% NaN_3 and 0.2% BSA, transferred to 5ml polystyrene tubes and assayed on the FACS.

[0204] FACSCAN ANALYSIS OF INTERNAL EXPRESSION: 1×10^7 HeLa-S3 cells (ATCC# CCL2.2) were infected with 5×10^7 PFU of vCP255 in minimum essential medium (S-MEM: Gibco #380-2380AJ) supplemented with 10% fetal bovine serum, 20mM Glutamine and 0.5% penicillin-streptomycin. The infected cells were incubated at 37°C for 30 minutes with occasional agitation. The cells were washed with 10mls S-MEM. After each wash the cells were pelleted at 1000 RPM for 5 minutes in a Beckman GPKR centrifuge. The infected cell pellet was resuspended in 1ml S-MEM, transferred to a 5ml Sarstadt tube and slowly rotated at 37°C overnight.

[0205] After overnight incubation, 100µl aliquots of the injected cells were added to 5ml polypropylene tubes. The cells were washed with 3mls PBS-CMF which contained 0.2% NaN_3 . 100µl of 4% paraformaldehyde (Polysciences Inc. #00380) pH 7.4 in PBS-CMF containing 0.2% NaN_3 was added to the cell pellet and incubated on ice for 10 minutes. Specific antibody was added to one tube and nonspecific antibody (anti-rabies G) was added to a second tube in the following manner.

[0206] The paraformaldehyde treated cells were washed with 3mls PBS-CMF containing 0.2% NaN_3 . Following the wash, 100µl PBS-CMF containing 0.2% NaN_3 , 1% saponin (SIGMA S-7900) and 20% heat inactivated newborn calf serum (Gibco #200-6010AJ) was added. The cells were incubated on ice for 30 minutes and washed with 3mls PBS-CMF which contained 0.2% NaN_3 .

[0207] 100µl of antibody (previously preadsorbed with HeLa Cells) diluted in PBS-CMF supplemented with 0.1% saponin and 20% heat inactivated newborn calf serum was added to each cell pellet, and incubated at 4°C for 30 minutes. The cells were washed and pelleted twice in 3mls of PBS-CMF containing 0.2% NaN_3 and 0.1% saponin.

[0208] 100µl of secondary antibody coupled to FITC (previously preadsorbed with HeLa Cells) diluted 1:50 in PBS-CMF containing 0.2% NaN_3 and 0.1% saponin and 20% heat inactivated newborn calf serum was added and incubated at 4°C, in the dark, for 30 minutes. The cells were washed and pelleted twice in 3mls of PBS-CMF containing 0.2% NaN_3 and 0.1% saponin. The cell pellets were resuspended in 1ml PBS-CMF containing 0.2% NaN_3 , transferred to 5ml polystyrene tubes and assayed on the FACS.

[0209] vCP255 FACS ANALYSIS: Antisera/HeLa suspensions were assayed on a Becton Dickinson model FC FAC-Scan flow cytometer. Data was analyzed on Lysis II Software (Becton Dickinson, UK). The antisera/HeLa suspensions were excited with a 488 nm argon laser, and FITC emission spectra was identified using FL-1 channel detectors. Ungated data was collected on 10,000 cells.

[0210] Fluorescence emission spectra, obtained by FACS analysis of ALVAC infected HeLa cells, demonstrated

background levels of rabies G and FIV-specific gene products. Background levels of the rabies G glycoprotein were obtained by FACS analysis of vCP255 infected HeLa cells.

[0211] The fluorescence emission spectra of vCP255 infected HeLa cells, probed with FIV specific monoclonal antibodies, demonstrated expression of the FIV-specific gene products. The FIV p24 coding sequence product was detected internally from vCP255 infected HeLa cells. The FIV Env product was detected on the surface of vCP255 infected HeLa cells.

[0212] IMMUNOPRECIPITATION ANALYSIS: CEF or VERO cells were infected at an m.o.i. of 10 pfu/cell with ALVAC (the parental virus), vCP242, vCP253, vCP255 or vCP329. Following an hour adsorption period, the inoculum was removed and the cells were overlaid with 2mls of modified Eagle's medium (minus cysteine and methionine) containing 2% dialyzed fetal bovine serum and [³⁵S]-TRANSLabel (New England Nuclear, Boston, MA; 30uCi/ml). The lysates were harvested 18-24 hrs post-infection by addition of 1ml 3X buffer A (450mM NaCl, 3% NP-40, 30mM Tris (pH7.4), 3mMEDTA, 0.03% Na-azide, and 0.6 mg/ml PMSF) and analyzed for expression of FIV env and gag gene products. The above described polyclonal cat antisera or FIV-specific monoclonal antibodies were used for immunoprecipitation analysis in the following manner.

[0213] Lysates were incubated overnight at 4°C with FIV-specific antisera-protein A-sepharose complexes. The samples were washed 4X with 1X buffer A and 2X with a LiCl₂/urea buffer (200mM LiCl, 2M urea, and 10mM Tris pH8.0). Precipitated proteins were dissociated from the immune complexes by addition of 2X Laemmli buffer (124mM Tris (pH6.8), 4% SDS, 20% glycerol, 10% 2-mercaptoethanol) and boiling for 5 minutes. Proteins were fractionated on 10% SDS-polyacrylamide gels, fixed in methanol, and treated with 1M Na-salicylate for fluorography. Proteins of the appropriate size were precipitated from the lysates derived from cells infected with the ALVAC-FIV recombinants, but were not precipitated from uninfected or ALVAC infected cells. The results indicated appropriate expression of the FIV gene products by the ALVAC-FIV recombinants.

[0214] ELISA ANALYSIS: Primary chick embryo fibroblast (CEF) cells were infected with vCP219, vCP242, or ALVAC. The infected cells were analyzed with the following FIV-specific monoclonal antibodies (Rhone Merieux, Lyon, France).

FIV gag: 0126B4 (anti-P15)
314B5 (anti-P24)
125A3 (anti-p24)

FIV env: 128F10
117E5
115G8

SERUM SAMPLES TESTED BY ELISA:

[0215]

1. Serum from FIV-infected cats:

Received from Rhone Merieux.
Cats #34 and #103

2. Normal cat serum: Cat #1229 (Select Labs, Athens, GA).

3. Rabbit serum obtained from immunization with vCP65 (ALVAC-RG):

Rabbit A039: prebleed week 14

[0216] Infected cell lysates were prepared in the following manner. Roller bottles of CEF cells were infected with ALVAC, vCP219, or vCP242 at an MOI of 5 PFU per cell in serum-free medium. Each roller bottle was harvested at 20 hours post infection, when the cells were completely round but not detached. Harvest consisted of pouring off the medium, washing once with PBS, and scraping the cells in 3 ml of PBS supplemented with aprotinin (3.6 T.I.U; Sigma #A-6279). The harvested cells were sonicated for four minutes on ice, and then centrifuged for 10 min at 1000xg. Supernates were recovered and the protein concentration was approximately 7 mg/ml for each preparation.

[0217] A kinetic ELISA was performed in the following manner. Serum samples (above) were assayed by a sandwich kinetic ELISA for the detection of FIV env and gag gene products. Microtiter plates were coated with the pooled monoclonal antibodies, listed above, specific for either FIV env or FIV gag, at 2 or 5 µg/well. Infected cell lysates were applied at 0.2, 1, or 5 µg/well, for capture by the monoclonals. Each serum sample was assayed in triplicate at a dilution of 1:100. Antibody was detected with a 1:200 dilution of horse radish peroxidase(HRP)-conjugated anti-cat serum (Jackson Immuno Research cat# 102-035-003) or HRP-conjugated anti-rabbit serum (DAKO, cat# P217), followed by HRP substrate,

o-phenylenediamine dihydrochloride (OPD). The optical densities at A_{450} were read for 15 min and rates for each sample were calculated as mOD per minute.

[0218] Results from these ELISAs clearly demonstrated that FIV Env and Gag expression were detected with serum from FIV infected cats, but not normal cat serum (data not shown). Env was demonstrated with plates prepared using Env-specific MAb and lysates derived from cells infected with vCP242, and not with lysates from ALVAC or vCP219 infected cells. Similarly, Gag was demonstrated with plates prepared using Gag-specific MAb and lysates from cells infected with vCP219, and not ALVAC or vCP242 infected cells.

TABLE 1. DETECTION OF FIV ENV EXPRESSION BY KINETIC ELISA

CAT SERUM: ^b lysate conc (μg/well)	ALVAC lysate ^a		env lysate		gag lysate	
	NCS	FIV	NCS	FIV	NCS	FIV
KELISA (mOD/min)						
0.2	1.3	5.2	1.2	5.1	1.2	3.5
1	1.7	5.0	1.4	11.3	1.7	4.9
5	2.2	5.4	1.6	22.0	2.0	5.0
RABBIT SERUM: ^c	PB	Wk.14 -	PB	Wk 14	PB	Wk 14
0.2	1.3	4.8	0.9	2.3	0.9	2.8
1	1.0	5.0	0.7	4.1	0.8	3.0
5	1.1	6.4	0.9	3.0	1.0	4.6

^a Cell lysates from CEF cells infected with ALVAC, ALVAC-FIV env, or ALVAC-FIV gag were applied at U.Z. 1, or 3 μg/well to wells previously coated with 2 μg/well of pooled FIV env-specific MAb.

^b Cat-serum: normal cat (NCS), FIV-infected cats (FIV).

^c Rabbit sera: prebleed (PB) and week 14 serum from rabbits inoculated with vCP-65 (NYVAC-RG).

TABLE 2 DETECTION OF FIV GAG-SPECIFIC ANTIBODIES BY KINETIC ELISA

CAT SERUM ^b lysate conc (μg/ml)	ALVAC lysate ^a		env lysate		gag lysate	
	NCS	FIV	NCS	FIV	NCS	FIV
KELISA (mOD/min)						
0.2	2.7	6.7	1.5	3.9	1.4	10.4
1	2.3	6.2	1.8	3.6	1.3	30.7
5	2.7	6.5	1.9	4.3	1.7	32.2
RABBIT SERUM ^c	PB	wk 14	PB	wk 14	PB	wk 14
0.2	1.3	5.1	1.0	4.0	1.3	4.4
1	1.1	6.0	1.2	4.0	1.2	4.1
5	1.2	6.6	1.0	4.3	1.0	4.4

^a Cell lysates from CEI² cells infected with ALVAC, ALVAC-FIV env, or ALVAC-FIV gag were applied at 0.2, 1, or 5 μg/well to wells previously coated with 2 μg/well of pooled FIV gag-specific MAb.

^b Cat sera: normal cat (NCS), FIV-infected cats (FIV).

^c Rabbit sera: prebleed (PB) and week 14 serum from rabbits inoculated with vCP-65 (NYVAC-RG).

EXAMPLE 7 - Efficacy of ALVAC-FIV Recombinants In Cats

[0219] Grouping And Immunization: A total of 36 SPF animals purchased from Liberty (Waverly, NY), age 12 weeks, were divided into seven groups as follows:

GroupsA	GroupB	GroupC	GroupD	GroupE	GroupF	GroupG
QH4F	QH5F	QQ1F	QQ2M	QH2M	QH3M	QC5F

Table continued

GroupsA	GroupB	GroupC	GroupD	GroupE	GroupF	GroupG
PY1M	PY3M	QA5F	PY5F	PY2M	PY4M	QG4F
OO1F	QS4F	QU2F	QO2F	QA4F	QA6F	QE4M
QC1M	QC3M	QX3M	QX4M	QC4M		
QU1M	QG3F	QI1M	QI2M	QG5F		
QL2F	QE2M	QL3F	QL4M	QE3F		

[0220] Immunizations were administered as follows:

<u>Group A (6 cats)</u>	Immunization
(Days)	
Primary immunization: ALVAC- <i>env</i> (VCP242)	Day 0
Secondary immunization: ALVAC- <i>env</i>	Day 28
Tertiary immunization: ALVAC- <i>env</i>	Day 56
<u>Group B (6 cats)</u>	
Primary immunization: ALVAC- <i>env</i> , <i>gag/pro</i> (vCP255)	Day 0
Secondary immunization: ALVAC- <i>env</i> , <i>gag/pro</i>	Day 28
Tertiary immunization: ALVAC- <i>env</i> , <i>gag/pro</i>	Day 56
<u>Group C (6 cats)</u>	
Primary immunization: ALVAC- <i>gag/pro</i> (vCP253)	Day 0
Secondary immunization: ALVAC- <i>gag/pro</i>	Day 28
Tertiary immunization: ALVAC- <i>gag/pro</i>	Day 56
<u>Group D (6 cats)</u>	
Primary immunization: ALVAC-97TM <i>gag/pro</i> (vCP329)	Day 0
Secondary immunization: AZVAC-97TM <i>gag/pro</i>	Day 28
Tertiary immunization: ALVAC-97TM <i>gag/pro</i>	Day 56
<u>Group E (6 cats/control)</u>	
Primary immunization: ALVAC (CPpp)	Day 0
Secondary immunization: ALVAC	Day 28
Tertiary immunization: ALVAC	Day 56
<u>Group F (3 cats/boost)</u>	
Primary immunization: ALVAC- <i>env</i> , <i>gag/pro</i> (vCP255) -	Day 0
Secondary immunization: ALVAC- <i>env</i> , <i>gag/pro</i>	Day 28
Boost: Inactivated FIV cell vaccine (ICV)	Day 56
<u>Group G (3 cats/control)</u>	
Primary immunization: ALVAC	Day 0
Secondary immunization: ALVAC	Day 28
Boost: Inactivated FIV cell vaccine	Day 56

[0221] All cats received 1×10^8 PFU of the respective ALVAC recombinant in 1 ml sterile PBS via the intramuscular route. The ICV boost consisted of 2.5×10^7 fixed allogenic FIV-Petaluma infected feline T-cells (FI-4 cell line), mixed with 250 μ g muramyl dipeptide (Hosie et al., 1995). The ICV boost was given subcutaneously.

[0222] Challenge: All cats were challenged via an -intra-peritoneal (IP) administration 4 weeks following final immunization with 50 CI_{50} of FIV-Petaluma (cell free supernatant derived from PBMC cultures infected with FIV Petaloma strain).

[0223] The following assays were performed to determine the FIV-specific virological status of the challenged animals. This provided a direct measurement of the protective efficacy of the ALVAC-based FIV vaccine candidates.

1) Virus Isolation: Detection of Infectious FIV by RT Assay. Peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, and lymph node (LN) cells were collected upon challenge for virus isolation (Yamamoto et al., 1991, 1993; Okada et al., 1994). Virus isolation was performed by monitoring reverse transcriptase (RT) activity of

culture supernatants. Isolated cells were cultured in the presence of IL-2 for 4 weeks. One-ml aliquots by standard procedures for Mg⁺⁺-dependent RT activity (specific for lentiviruses).

2) FIV-specific PCR. Proviral sequence detection was Performed on DNA extracted from PBMC, BM, and LN cells. As a means of increasing the sensitivity, four consensus primer sets were used to amplify either env-or gag-specific coding regions, respectively (Yamamoto et al., 1991; Okada et al., 1994).

[0224] Following the initial PCR amplification, 1/25th of the product was re-amplified with the nested primer pair.

[0225] The results of the virological assays for samples pre- and post-challenge are presented in Tables 3 and 4. None of the cats demonstrated FIV viremia prior to challenge assessed either by RT determination or by the FIV-specific PCR analysis (Table 3). By 8 weeks post-challenge 4 of the 6 cats immunized with three doses of the ALVAC parental virus developed a persistent FIV-specific viremia (Table 3). Infection of these cats was also demonstrable by virus isolation and PCR in tissue samples taken post-challenge and by apparent FIV-specific seroconversion post-challenge (Table 4 and 5). No clear indications of infection were observed in the other two cats (QA4 and QE3) in the control group. Further, in comparison to this control group, no significant differences in efficacy were observed in groups of cats receiving three inoculations (10⁸ pfu/dose) of ALVAC-FIV env (vCP242), ALVAC-FIV env/gag-pr (vCP255), or ALVAC-FIV 97TMG (vCP329).

[0226] Significantly, three administrations of ALVAC-FIV gag-pr(vCP253) afforded complete protection against FIV challenge exposure. Protection from infection was clearly evident in six of six cats throughout the 29 week post-challenge observation period by virus isolation and FIV-specific PCR in the periphery and lymphoid tissue (Table 3 and 4). Further, these cats also did not seroconvert relative to FIV seroreactivity by Western blot or ELISA (Table 4 and 5). To further substantiate the efficacy of vCP253, cells (PBMCs, lymph node, and bone marrow) from two animals in this group were transferred to SPF kittens. These cats have thus far tested negative by virus isolation (RT and PCR) and FIV-specific Western blot, whereas an SPF cats receiving similar cells from an infected control cat (Py2) clearly was positive for infection by these criteria.

[0227] Collectively, these results show that the Gag-pr is sufficient to protect against a lentivirus challenge exposure. As shown in Table 6, these results are indeed statistically significant. The results also show that the presence of Env may actually interfere with the establishment of a protective immune response. Further, the data for the experimental arm where cats received vCP255 (2x) followed by ICV immunogen illustrated that any impairment of Env can be overcome by such a prime/boost regimen (Table 3 and 4). Clearly the priming activity contributed by vCP255 was useful for protection, since the cats in the group receiving 2 administrations of ALVAC parental virus followed by ICV were readily infected upon challenge exposure (Table 3 and 4).

[0228] In short, this data provides for the first time protection against FIV infection in cats using a subunit immunogen, including only the FIV Gag-pr. In fact, the presence of Env may have reduced efficacy.

[0229] The importance of such data is also apparent in general for lentivirus vaccine development. Protection using solely the Gag-pr provides several important elements to vaccine and diagnostic design. First, one can readily employ existing Env-based assays to discriminate vaccinated versus infected individuals. Secondly, the Gag-pr appears less variable than the Env species between lentivirus isolates and thus may serve for provision of cross-protective responses.

TABLE 3

Virus isolation (Reverse Transcriptase assay and PCR on PBMC)

Vaccine	Cat no.	Pre		Post challenge							
				4 weeks		8 week		12 weeks		17 weeks	
				RT	PCR	RT	PCT	RT	PCT	RT	PCT
ALVAC- Env	QH4	-	-	-	-	-	-	-	-	-	-
	PY1	-	-	+	+	+	+	+	+	+	+
	QO1	-	-	+	+	+	+	T	T	+	+
	QC1	-	-	-	-	-	-	-	-	-	-
	QU1	-	-	-	-	-	-	-	-	-	-
ALVAC- Eng, gag/prot	QL2	-	-	+	+	+	+	+	+	+	+
	QH5	-	-	-	-	-	-	-	-	-	-
	PY3	-	-	-	-	-	-	-	-	-	-
	QS4	-	-	+	+	+	+	+	+	+	+
	QC3	-	-	-	-	-	-	-	-	-	-
ALVAC- gag/prot	QE2	-	-	-	-	-	-	+	+	-	+
	QO1	-	-	-	-	-	-	-	-	-	-
	QA5	-	-	-	-	-	-	-	-	-	-
	QU2	-	-	-	-	-	-	-	-	-	-
	QX3	-	-	-	-	-	-	-	-	-	-
ALVAC- 97TH OF gag/prot	QI1	-	-	-	-	-	-	-	-	-	-
	QL3	-	-	-	-	-	-	-	-	-	-
	QO2	-	-	-	-	-	-	-	-	-	-
	PY5	-	-	-	-	-	-	-	-	-	-
	QO2	-	-	+	+	+	+	T*	T*	-	-
ALVAC- control	QX4	-	-	+	+	+	+	+	+	+	+
	QI2	-	-	-	-	-	-	-	-	-	-
	QL4	-	-	-	-	-	-	-	-	-	-
	QH2	-	-	+	+	+	+	T*	+	+	+
	PY2	-	-	-	-	+	+	+	+	-	-
ALVAC- env, gag, prot & ICV	QA4	-	-	-	-	-	-	-	-	-	-
	QC4	-	-	-	-	+	+	-	+	+	+
	QG5	-	-	+	+	+	+	T*	-	-	-
	QE3	-	-	-	-	-	-	-	-	-	-
	QH3	-	-	-	-	-	-	-	-	-	-
ALVAC- control & ICV	PY4	-	-	-	-	-	-	-	-	-	-
	QA6	-	-	-	-	-	-	-	-	-	-
	QC5	-	-	+	+	+	+	+	+	T*	-
	QG4	-	-	+	+	+	+	+	+	T*	-
	QE4	-	-	-	-	+	+	+	+	+	+

*T: Animal was euthanized.

ND: Not Determined

TABLE 4

FINAL VIRUS ISOLATION ON PBMC and TISSUE SAMPLES

Vaccine	Cat no.	TISSUE SAMPLE										
		PBL RT	PCR	LN RT	PCR	BH RT	PCR	THY RT	PCR	WB	Elisa	Tissues taken at x weeks post-chall.
ALVAC-Env	Q114	-	"+"	-	"+"	-	"+"	-	-	-	-	27
	PY1	-	-	-	-	-	-	-	-	-	-	24
	QC1	-	+	+	+	+	+	+	+	+	+	10
	QU1	-	-	-	-	-	-	ND	ND	-	-	28
	QL2	-	-	+	+	+	+	ND	ND	-	-	28
ALVAC-Env, gag/prot	Q115	-	-	-	-	-	-	-	-	-	-	28
	PY3	-	-	-	-	-	-	ND	ND	ND	-	27
	QS4	-	-	+	+	-	+	-	-	+	+	24
	QC3	-	-	-	-	-	-	-	-	-	-	28
	QG3	-	-	-	-	-	-	-	-	-	-	28
ALVAC-gag/prot	QE2	-	"+"	-	+	-	+	-	"+"	+	+	28
	QO1	-	-	-	-	-	-	ND	ND	-	-	29
	QA5	-	-	-	-	-	-	ND	ND	-	-	29
	QU2	-	-	-	-	-	-	ND	ND	-	-	29
	QX3	-	-	-	-	-	-	ND	ND	-	-	29
ALVAC-97TH OF gag/prot	Q11	-	-	-	-	-	-	ND	ND	-	-	29
	QL3	-	-	-	-	-	-	ND	ND	-	-	29
	QO2	-	-	-	+	-	-	-	-	-	-	27
	PY5	-	-	-	-	-	-	-	-	-	-	28
	QO2	+	+	+	+	+	+	ND	ND	+	+	10
ALVAC control	QX4	-	-	-	-	-	-	-	-	+	-	25
	Q12	-	-	-	-	-	-	-	-	+	-	25
	QL4	-	-	-	-	-	-	-	-	ND	-	27
	Q112	+	+	+	+	+	+	ND	ND	+	-/+	10
	PY2	+	+	-	-	-	+	ND	ND	+	-	39
ALVAC-Env/gag/prot & ICV	QA4	-	-	-	-	-	-	-	-	-	-	28
	QC4	+	+	+	+	+	+	+	+	+	+	26
	QG5	-	+	+	+	+	+	+	+	+	+	10
	QE3	-	-	-	-	-	-	ND	ND	+	+	28
	Q113	-	-	-	-	-	-	ND	ND	+	-	36
ALVAC-control & ICV	PY4	-	-	-	-	-	-	ND	ND	+	-	36
	QA6	-	-	-	-	-	-	ND	ND	+	-	36
	QC5	+	+	+	+	-	-	ND	ND	+	+	10
	QG4	-	+	+	+	-	+	ND	ND	+	+	10
	QE4	+	+	ND	ND	+	+	ND	ND	+	+	39

*T: Animal was euthanized.

ND: Not Determined

"++": Show only very faintly positive by PCR.

NOTE Westernblot: serum dilution 1:100

ELISA: serum dilution 1:200, Transmembrane peptide used: QELGCNQNGFFCK1

EXAMPLE 8 - ALVAC-FIV Recombinants induce protective Immunity

Against Multiple Subtype FIV Challenge In Cats

MATERIALS AND METHODS

[0230] Animals: Specific pathogen free (SPF), were purchased from Liberty Research, Inc.

[0231] Vaccine preparation: Canaripoxvirus (ALVAC)-FIV recombinants were generated as described above (vCP255). The ALVAC vCP255 vaccine was prepared from a serum free lysate of infected CEF. ALVAC vCP255 immunizations were given at 1×10^8 PFU intramuscularly. The inactivated cell vaccine (ICV) consisted of 2×10^8 paraformaldehyde inactivated FI-4 cells (a feline lymphoid cell line chronically infected with FIV Petaluma) mixed with 250µg

SAF/MDP adjuvant (Hoise et al., 1995) and was given subcutaneously.

[0232] *Grouping and immunization protocol:* The challenge study involved 6 cats; the ALVAC-*env,gag/pro/ICV* immunized group (#PY4, #QH3, #QA6) which received the FIV Petaluma challenge described in Example 7 and a control group of three age matched SPF cats (#EJ2, #DH3, #GU5) which had received no immunizations prior to the FIV Bangston challenge. (See Tables 5).

[0233] *Challenge:* The second challenge inoculum consisted of 75 ID₅₀ cell free FIV Bangston (subtype B) and was given 8 months after the initial FIV Petaluma challenge (See Example 7).

[0234] *Immunogenicity monitoring:* The induction of FIV specific antibody responses were determined by Western blotting (immunoblot). Viral neutralizing antibody responses (VNA) were determined using previously described assays (Yamamoto et al., 1991).

[0235] *Viral infectivity monitoring:* Viral infection was monitored by several methods. This included assessment of viral reverse transcriptase activity in PBMC, bone marrow and lymph node cells taken at various times post-challenge by previously described methods (Yamamoto et al., 1991). In addition, pro-viral DNA (latent infection) was monitored by polymerase chain reaction (PCR) using FIV-*env* primers on DNA extracted from PBMC, bone marrow and lymph node cells upon culturing for RT activity (Yamamoto et al., 1991; Okada et al, 1994). Further, FIV infection was determined by monitoring and comparing the character of FIV-specific humoral responses and viral neutralizing (VN) antibody responses in serum taken before and after challenge.

RESULTS AND DISCUSSION

[0236] The immunogenicity and the protective efficacy of ALVAC prime/boost protocols was evaluated against experimental challenge with a distinctly heterologous FIV isolate (Bangston strain). First, the protective efficacy of immunizing with ALVAC-*env,gag/pol* alone was compared to priming with ALVAC-*env,gag/pol* followed by boosting with inactivated FIV-infected cell vaccine (ICV). All cats received a total of three immunizations and were challenged 4 weeks after the final immunization with cell free 50 ID₅₀ of FIV Petaluma (See Example 7). The FIV Petaluma isolate, like the FIV Villefranche isolate used to generate the ALVAC-FIV recombinant vaccine, is classified as a subtype A virus and differs from FIV Villefranche 3% in the Env and 1% in the Gag amino-acid coding region.

[0237] It was then evaluated whether the ALVAC-*env,gag/pro/ICV* immunized cats (#QA6, #QH3, #PY4) which resisted the FIV Petaluma challenge described in Example 7, could be protected from a second challenge with a distinctly heterologous FIV isolate of another subtype. The second challenge consisted of 75 ID₅₀ cell free FIV Bangston (PBMC derived) and was given at eight months after the initial challenge without any intervening booster. FIV Bangston is a subtype B isolate and differs from FIV Petaluma (subtype A) by 21% in the envelope glycoprotein amino acid coding region. Three age matched SPF cats (#EJ2, #GU5, #DH3) served as control cats for the FIV Bangston challenge. As presented in Table 7, all control cats became readily infected upon challenge. In contrast, ALVAC-*env,gag/pro/ICV* immunized cats #QH3 and #QA6 remained virus negative as determined by virus isolation (RT) and PCR of peripheral blood up to three months post-challenge. Cat #PY4 remained virus negative as determined by virus isolation (RT) of peripheral blood but tested positive by PCR at three months post-challenge. Nucleotide sequence analysis of the PCR product revealed FIV Bangston specific sequences. Thus ALVAC-*env,gag/pro/ICV* immunized cats were partially protected from a heterologous subtype FIV challenge. It is clear that these cats demonstrated, at least, a delay in infection as all control cats became viremic by 6 weeks post-challenge and only one of three ALVAC-*env,gag/pro/ICV* immunized cats became positive based on PCR analysis at 12 weeks post-challenge. This shows a potential utility for recombinants expressing Env.

[0238] In summary, prime/boost protocols involving priming with ALVAC recombinants followed by boosting with inactivated FIV-infected cell vaccines can elicit protective immunity against experimental challenge with heterologous FIV strains. This immunity is long lasting and also provides partial protection against distinctly heterologous FIV-strains of other subtypes. The data supports a role for cell mediated rather than viral neutralizing antibody responses and FIV-specific antibody responses. These findings are relevant not only to the development of multiple subtype FIV-vaccines but also to the development of effective multiple subtype HIV vaccines (as well as multiple subtype vaccines for other lentiviruses and other retroviruses) as new subtypes continue to arise and existing subtypes increasingly spread to new geographical areas.

[0239] A Fisher's exact test was performed. This is a modification of the Chi square test. This test should be used when comparing two sets of discontinuous, quantal (all or none) data. The analysis was set up as follows:

	Vaccinated	Unvaccinated
Infected	A	B
Uninfected	C	D

[0240] For a single tailed probability the P value is calculated as:

$$P(\text{probability}) = (A+B)!(C+D)!(A+C)!(B+D)!/N!A!B!C!D!$$

[0241] Each group was compared to the ALVAC-control group (n=6) and to the ALVAC-control group +ALVAC-control&ICV group (n=9). A P value equal or less than 0.05 was considered significant.

Table 5: Viral neutralizing antibody titers upon immunization.

	VN titer				
Vaccine	Cat ID#	pre-	post-immunizations	post-challenge	
				3 mo.	12 mo.
Alvac-env	QU1	<5	<5	<5	
	PY1	<5	<5	>100	
Alvac-gag/prot	QX3	<5	<5	<5	<5
	QQ1	<5	<5	<5	<5
	QI1	<5	<5	<5	<5
	QL3	<5	<5	<5	<5
Alvac-env,gag/prot	QS4	<5	<5	>100	
	PY3	<5	<5	<5	
Alvac-env,gag/prot &ICV	QH3	<5	<5	5-20	<5
	QA3	<5	<5	5-20	<5
	PY4	<5	<5	5-20	5-20
ALVAC-control	QC4	<5	<5	>100	ND ^a
	PY4	<5	<5	>100	
	QA4	in prep			
	QE3	in prep			
ALVAC-control &ICV	QG4	<5	<5	>100	ND
	QC5	<5	<5	>100	
	QE4	<5	<5	>100	
^a ND - Not Determined					

Table 6 Statistical significance of efficacy-data.

vaccine	viral status			
	vaccine group +/-	control group +/- (control)	P value (Single-tailed)	significant
Alvac-env	3/3	4/2 7/2	0.5 0.28	no no
Alvac-gag/prot	0/6	4/2 7/2	0.0303 0.00914	yes yes
Alvac-env, gag/prot	2/4	4/2 7/2	0.28 0.118	no no
Alvac-97 TMG	3/3	4/2 7/2	0.5 0.28	no no
Alvac-env,gag/prot IWC	0/3 0/3	3/0 7/2	0.05 0.00914	yes yes
All groups combined	8/19	7/2	0.0158	yes

Table 7 Parameters pre- and post-secondary challenge (FIV Bangston)

pre 2nd challenge WB titer		VN pre 2nd challenge ^a FIVpet titer FIVbang titer		VN post 2nd challenge ^b FIVpet titer FIVbang titer		post 2nd challenge ^b WB titer virus status RT/PCR		Protection Rate
QA6	+(4-5)	<5	ND	>5	ND	+(3-4)	-/-	
QH3	+(4)	<5	ND	>5	ND	+(3)	-/-	2/3
PY4	+(4-5)	5-20	ND	>5	ND	+(3-4)	-/+	
GU5	0(<2)	<5	<5	ND	ND	+(4-5)	+/+	
DH3	0(<2)	<5	<5	ND	ND	+(5)	+/+	0/3
EJ2	0(<2)	<5	<5	ND	ND	+(4)	+/+	
^a Serum sample taken 8 months post challenge, at the day of 2nd challenge.								
^b Serum taken 4 months post 2nd-challenge.								
^c ND-NotDetermined.								

EXAMPLE 9 - Generation of Additional NYVAC & TROVAC Recombinants

[0242] Using the strategies outlined above for generating FIV coding DNA linked to a promoter, flanking DNA for NYVAC and TROVAC for insertion into regions of these vectors, analogous to embodiments in U.S. Patent No. 5,494,807 and USSN 08/417,210, are employed to generate NYVAC and TROVAC FIV recombinants. Analysis demonstrates incorporation into the vectors of the exogenous DNA and of expression thereof. Such additional recombinants are useful in the same manner as the above-described ALVAC embodiments.

EXAMPLE 10 - Generation of Additional Lentivirus and Additional Vector System Recombinants

[0243] Using the strategies analogous to those outlined above for generating FIV coding DNA linked to a promoter and the strategies for generating alternative poxvirus, baculovirus, adenovirus, herpesvirus, alphavirus, poliovirus, Epstein-Barr, bacterial, and DNA-based systems in the documents cited herein and the knowledge of coding DNA from lentiviruses, retroviruses or immunodeficiency viruses, e.g., EIAV, FIV, BIV, HIV, or SIV, from the documents cited herein, alternative poxvirus, baculovirus, adenovirus, herpesvirus, alphavirus, poliovirus, Epstein-Barr, bacterial, and DNA-based recombinants containing and expressing DNA from lentiviruses, retroviruses or immunodeficiency viruses, e.g., EIAV, FIV, BIV, HIV, or SIV, such as Env, Gag and protease and Gag and protease, recombinants are generated. Analysis demonstrates incorporation into the vectors of the exogenous DNA and of expression thereof. Such additional recombinants are useful in the same manner as the above-described ALVAC embodiments.

REFERENCES

[0244]

1. Abimiku, A., Franchini, G., Tartaglia, J., Aldrich, K., Myagkikh, M., Markham, P.D., Chong, P., Klein, M., Kieny, M.P., Paoletti, E., Gallo, R.C., and Guroff, M.R., *Nature Medicine* **1**, 321-329 (1995).
2. Altenburger, W., C-P. Suter and J. Altenburger, *Archives Virol.* **105**, 15-27 (1989). Beatty, J et al., *Journal of Virology* **70**, 6199-6206 (1996).
3. Behbehani, A.M., *Microbiological Reviews* **47**, 455-509 (1983).
4. Bergoin, M., and Dales, S., In *Comparative Virology*, eds. K. Maramorosch and E. Kurstak, (Academic Press, NY) pp. 169-205 (1971).
5. Berman, P., Gregory, T., Riddle, L., Nakamura, G., Champe, M., Porter, J., Wurm, F., Hershberg, R., Cobb, E. and Eichberg, J., *Nature* **345**, 622-625 (1990).

6. Bocchia, M. et al., *Blood* **85**, 2680-2684.

7. Buller, R.M.L., G.L. Smith, Cremer, K., Notkins, A.L., and Moss, B., *Nature* **317**, 813-815 (1985).

8. Cadoz, M., A. Strady, B. Meignier, J. Taylor, J. Tartaglia, E. Paoletti and S. Plotkin, *The Lancet*, **339**, 1429-1432 (1992).

9. Child, S.J., Palumbo, G.J., Buller, R.M.L., and Hruby, D.E. *Virology* **174**, 625-629 (1990).

10. Clements, M.L., Weinhold, K., Siliciano, R., Schwartz, D., Matthews, T., Graham, B., Keefer, M., McElrath, J., Gorse, G., Hsieh, R., Duliege, A.M., Excler, J., Meignier, B., Tartaglia, J., and Paoletti, E., HIV immunity induced by canarypox (ALVAC)-MN g1160, -SF-2, rgp120 or both. XI International Conference on AIDS/Vancouver 1996/Mo.A.281 (1996).

11. Clewell, D.B. and D.R. Helinski, *Proc. Natl. Acad. Sci. USA* **62**, 1159-1166 (1969).

12. Clewell, D.B., *J. Bacteriol* **110**, 667-676 (1972).

13. Cox, W.I., Tartaglia, J., and E. Paoletti. *Virology* **195**, 845-850 (1993).

14. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K., and Descssers, R., *Science* **258**, 1938-1941 (1992).

15. Drillien et al., *Virology* **111**, 488-499 (1981)

16. Edbauer, C., R. Weinberg, J. Taylor, A. Rey-Senelongue, J.F. Bouquet, P. Desmettre, and E. Paoletti, *Virology* **179**, 901-904 (1990).

17. Eldridge, J.H., et al., *Current Topics in Microbiology and Immunology*, **146**:59-66 (1989).

18. Emini, E., Schleif, W., Nunberg, J., Conley, A., Eda, Y., Tokiyoshi, S., Putney, S., Matsushita, S., Cobb, K., Jett, C., Eichberg, J., and K. Murthy, *Nature* **355**, 728-730 (1992).

19. Engelke, D.R., Hoener, P.A., and Collins, F.S., *Proc. Natl. Acad. Sci. USA* **85**, 544-548 (1988).

20. Englehard, V.H., *Ann. Rev. Immunol.* **12**:181 (1994).

21. Franchini, G., Tartaglia, J., Markham, P., Benson, J., Fullen, J., Wills, M., Arp, J., Dekaban, G., Paoletti, E., and Gallo, R.C., *AIDS Res. Hum. Retroviruses* **11**, 307-313 (1995).

22. Francini, G., Guroff, M.R., Tartaglia, J., Aggarwal, A., Abimiku, A., Benson, J., Markham, P., Limbach, K., Hurteau, G., Fullen, J., Aldrich, K., Miller, N., Sadoff, J., Paoletti, E., and Gallo, R.C., *AIDS Res. Hum. Retroviruses* **11**, 909-920 (1995).

23. Fries et al., 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA (October 1992).

24. Fries, L.F., Tartaglia, J., Taylor, J., Kauffman, E. K., Meignier, B., Paoletti, E., and Plotkin, S., *Vaccine* **14**, 428-434 (1996).

25. Fultz, P., Nara, P., Barre-Sinoussi, F., Chaput, A., Greenberg, M., Muchmore, E., Kieny, M.-P. and Girard, M. *Science* **256**, 1687-1689 (1992).

26. Funahashi, S., T. Sato and H. Shida, *J. Gen. Virol.* **69**, 35-47 (1988).

27. Gillard, S., Spehner, D., Drillien, R., and Kim, A., *Proc. Natl. Acad. Sci. USA* **83**, 5573-5577 (1986).

28. Girard, M., Kieny, M.-P., Pinter, A., Barre-Sinoussi, F., Nara, P., Kolbe, H., Kusui, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kaczorek, M., Gomard, E., Gluckman, J.-C. and Fultz, P., *Proc. Natl. Acad. Sci. USA* **88**,

542-546 (1991).

29. Goebel, S.J., G.P. Johnson, M.E. Perkus, S.W. Davis, J.P. Winslow and E. Paoletti, *Virology* **179**, 517-563 (1990b).

30. Goebel, S.J., Johnson, G.P., Perkus, M.E., Davis, S.W., Winslow, J.P., Paoletti, E., *Virology* **179**, 247-266 (1990a).

31. Goldstein, D.J. and S.K. Weller, *Virology* **166**, 41-51 (1988). Gouin, P et al., *Veterinary Microbiology* **45**, 393-401, (1995.)

32. Goodman-Snitkoff et al., *J. Immunol.* **147**:410-415 (1991).

33. Guo, P., Goebel, S., Davis, S., Perkus, M.E., Languet, B., Desmettre, P., Allen, G., and Paoletti, E., *J. Virol.* **63**, 4189-4198 (1989).

34. Guo et al., *J. Virol.* **64**, 2399-2406 (1990).

35. Hardy, Jr., W.D. in *Retrovirus Biology and Human Disease*, Gallo, R.C. and Wong-Staal, eds., Marcel Dekker, New York, pp. 33-86, 1990.

36. Heeney, J.L., Holterman, L., ten Hooff, P., et al., *AIDS Res. Human. Retrovir.* **10 suppl. 2**, S117-S121 (1994).

37. Hoise, M.J., Osborne, R. Yamamoto, J.K., Neil, J.C., and Jarrett, O. *J. Virol.* **69**, 1253-1255 (1995).

38. Hruby, D.E. and L.A. Ball, *J. Virol.* **43**, 403-409 (1982).

39. Hruby, D.E., R.A. Maki, D.B. Miller and L.A. Ball, *Proc. Natl. Acad. Sci. USA* **80**, 3411-3415 (1983).

40. Hu, S.-L., Polacino, P., Klaniecki, J., Travis, B., Wrey, T., Pennathur, S., Stallard, V., Kornas, H., Langlois, A.J., and Benveniste, R.E. (1995) *AIDS Research and Human Retroviruses* **11**:5136.

41. Hu, S.-L., Polacino, P., Stallard, V., Klaniecki, J., Pennathur, S., Travis, B.M., Misher, L., Kornas, H., Langlois, A.J., Morton, W.R., and Benveniste, R. *Retroviruses of Human AIDS and Related Animal Diseases* Nuvième Colloque des Cent Gardes; pg. 275-281, (1994).

42. Hu, S.-L., Abrams, K., Barber, G., Morn, P., Zarling, J., Langlois, A., Kuller, L., Morton, W. and Benveniste, R., *Science* **255**, 456-459 (1992).

43. Ichihashi, Y. and Dales, S., *Virology* **46**, 533-543 (1971).

44. Issel, C.J., Horohov, D.W., Lea, D.F. et al., *J. Virology* **66**, 3398-3408 (1992).

45. Itamura, S., H. Iinuma, H. Shida, Y. Morikawa, K. Nerome and A. Oya, *J. Gen. Virol.* **71**, 2859-2865 (1990).

46. Jacobson, J.G., D.A. Leib, D.J. Goldstein, C.L. Bogard, P.A. Schaffer, S.K. Weller and D.M. Coen, *Virology* **173**, 276-283 (1989).

47. Jamieson, A.T., G.A. Gentry and J.H. Subak-Sharpe, *J. Gen. Virol.* **24**, 465-480 (1974).

48. Johnson, C.A., Torres, B.A., Koyama, H., and Yamamoto, J.K. *AIDS Res. and Human. Retrovir.* **10**, 225-228 (1994).

49. Kato, S., M. Takahashi, S. Kameyama and J. Kamahora, *Biken's* **2**, 353-363 (1959).

50. Kendrew, In *The Encyclopedia of Molecular Biology* (Blackwell Science Ltd.) (1995).

51. Konishi et al., *Virology* **190**, 454-458 (1992).

52. Kotwal, G.J. and B. Moss, *Virology* **167**, 524-537 (1988b).

53. Kotwal, G.J. and Moss, B., *Nature (Lond.)* **335**, 176-178 (1988a).

54. Kotwal, G.J., S.N. Isaacs, R. McKenzie, M.M. Frank and B. Moss, *Science* **250**, 827-830 (1990).

55. Kotwal, G.J., A.W. Hugin and B. Moss, *Virology* **171**, 579-587 (1989a).

56. Kotwal, G.J. and B. Moss, *J. Virol.* **63**, 600-606 (1989b).

57. Kreuter, J., *In* *Microcapsules and Nanoparticles in Medicine and Pharmacology*, M. Donbrow, ed. (CRC Press) p. 125-148.

58. Kuby, Janis, *Immunology*, pp. 79-81 (1992).

59. Lai et al., *Virus Res.* **12**, 239-250 (1989)

60. Lawrence, C., Weinhold, K., McElrath, J., Excler, J.L. Duliege, A.M., Clements, M.L., Belche, R., Dolin, R., and Graham, B., AVUE 022: safety and immunogenicity of live recombinant canarypox vector containing the envelope, gag and protease genes of HIV-1 in seronegative adult volunteers. XI International Conference on AIDS/Vancouver 1996/Mo.A.282 (1996).

61. Mandecki, W., *Proc. Natl. Acad. Sci. USA* **83**, 7177-7182 (1986).

62. Maniatis, T., Fritsch, E.F., and Sambrook, J. *In* *Molecular cloning: a laboratory manual*, (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) (1982).

63. Matthews, R.E.F., *Intervirology* **17**, 42-44 (1982).

64. Miller et al., *J. Exp. Med.* **176**, 1739-1744 (1992).

65. Milstein, C., *scientific American* **243**, 66, 70 (1980).

66. Morgan, A.J., M. Mackett, S. Finerty, J.R. Arrand, F.T. Scullion and M.A. Epstein, *J. Med. Virol.* **25**, 189-195 (1988).

67. Morikawa, S. and Bishop, D., *Virol.* **186**, 389-397 (1992).

68. Moss, B., E. Winters and J. A. Cooper, *J. Virol.* **40**, 387-395 (1981).

69. Nabel et al., *Tibtech*, May, **11**, 211-215 (1993).

70. Okada, S. Ruiyu, P., Young, E., Stoffs, W.V., and Yamamoto, J.K., *AIDS Res. and Human Retrovir.* **10**, 1739-1746 (1994).

71. Paez et al., *PNAS USA* **82**, 3365-3369 (1985); see also Paez et al., *Virology* **169**, 418-426 (1985).

72. Palumbo, G.J., Pickup, D.J., Fredrickson, T.N., McIntyre, L.J., and Buller, R.M.L., *Virology* **172**, 262-273 (1989).

73. Panicali, D., Davis, S.W., Mercer, S.R., and Paoletti, E., *J. Virol.* **37**, 1000-1010 (1981).

74. Panicali, D. and E. Paoletti, *Proc. Natl. Acad. Sci. USA* **79**, 4927-4931 (1982).

75. Patel, D.D. and Pickup, D.J., *EMBO* **6**, 3787-3794 (1987).

76. Patel, D.D., Ray, C.A., Drucker, R.P., and Pickup, D.J., *Proc. Natl. Acad. Sci. USA* **85**, 9431-9435 (1988).

77. Pedersen, N.C., Ho, E.W., Brown, M.L., and Yamamoto, J.K., *Science* **235**, 790-793 (1987).

78. Perkus, M.E., S.J. Goebel, S.W. Davis, G.P. Johnson, E.K. Norton and E. Paoletti, *Virology* **180**, 406-410 (1991).
79. Perkus, M.E., Goebel, S.J., Davis, S.W., Johnson, G.P., Limbach, K., Norton, E.K., and Paoletti, E., *Virology* **179**, 276-286 (1990).
80. Perkus, M.E., A. Piccini, B.R. Lipinskas and E. Paoletti, *Science* **229**, 981-984 (1985).
81. Perkus, M.E., Limbach, K., and Paoletti, E., *J. Virol.* **63**, 3829-3836 (1989).
82. Perkus, M. E., D. Panicali, S. Mercer and E. Paoletti, *Virology* **152**, 285-297 (1986).
83. Pialoux et al., *Aids Research and Human Retroviruses*, **11(3)**:373-81 (1995).
84. Piccini, A., M.E. Perkus, and E. Paoletti, *Methods in Enzymology* **153**, 545-563 (1987).
85. Pickup, D.J., B.S. Ink, B.L. Parsons, W. Hu and W.K. Joklik, *Proc. Natl. Acad. Sci. USA* **81**, 6817-6821 (1984).
86. Pickup, D.J., B.S. Ink, W. Hu, C.A. Ray and W.K. Joklik, *Proc. Natl. Acad. Sci. USA* **83**, 7698-7702 (1986).
Pincus et al., *Biologicals* **23**, 159-164 (1995)
87. Sadora, D.L., Shapaer, E.G., Kitchell, B.E., Dow, S.W., Hoover, E.A., and Mullins, J.I., *J. Virol.* **68** (1994).
88. Sanger, F., Nickel, S. Coulson, A.R., *Proc. Natl. Acad. Sci.* **74**, 5463-5467 (1977).
89. Schmidt, J.F.C. and H.G. Stunnenberg, *J. Virol.* **62**, 1889-1897 (1988).
90. Shida, H., *Virology* **150**, 451-462 (1986).
91. Shida, H., T. Tochikura, T. Sato, T. Konno, K. Hirayoshi, M. Seki, Y. Ito, M. Hatanaka, Y. Hinuma, M. Sugimoto, F. Takahashi-Nishimaki, T. Maruyama, K. Miki, K. Suzuki, M. Morita, H. Sashiyama and M. Rayami, *EMBO* **6**, 3379-3384 (1987).
92. Shida, H., Hinuma, Y., Hatanaka, M., Morita, M., Kidokoro, M., Suzuki, K., Maruyama, T., Takahashi-Nishimaki, F., Sugimoto, M., Kitamura, R., Miyazawa, T., and Hayami, M., *J. Virol.* **62**, 4474-4480 (1988).
93. Slabaugh, M., N. Roseman, R. Davis and C. Mathews, *J. Virol.* **62**, 519-527 (1988).
94. Song, W., Collison, E.W., Bilingsley, P., and Brown, W.C. *J. Virol.* **66**, 5409-5417 (1992).
95. Stanberry, L. R., S. Kit and M. G. Myers, *J. Virol.* **55**, 322-328 (1985).
96. Tabor, S. and C. C. Richardson, *Proc. Natl. Acad. Sci. USA* **84**, 4767-4771 (1987).
97. Tartaglia, J., Jarrett, O., Desmetre, P., Paoletti, E., *J. Virol.* **67**, 2370-2375 (1993b).
98. Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J.-C., Cox, W.I., Davis, S.W., Van Der Hoeven, J., Meignier, B., Riviere, M., Languet, B., Paoletti, E., *Virology* **188**, 217-232 (1992).
99. Tartaglia, J., Pincus, S., Paoletti, E., *Critical Reviews in Immunology* **10**, 13-30 (1990a).
100. Tartaglia, J., J. Taylor, W.I. Cox, J.-C. Audonnet, M.E. Perkus, A. Radaelli, C. de Giuli Morghen, B.-Meignier, M. Riviere, K. Weinhold & E. Paoletti, In - *AIDS Research Reviews*, W. Koff, F. Wong-Staal & R.C. Kenedy, Eds., Vol. 3, Marcel Dekker, NY, pp. 361-378 (1993a).
101. Tartaglia, J. & E. Paoletti, In *Immunochemistry of Viruses, II. The Basis for Serodiagnosis and Vaccines*. M.H.V. van Regenmortel & A.R. Neurath, Eds. 125-151. Elsevier Science Publishers, Amsterdam (1990b).
102. Taylor, J., R. Weinberg, J. Tartaglia, C. Richardson, G. Alkhatib, D. Briedis, M. Appel, E. Norton & E. Paoletti,

Virology **187**, 321-328 (1992).

103. Taylor, J., Edbauer, C., Rey-Senelongue, A., Bouquet, J.-F., Norton, E., Goebel, S., Desmettre, P., Paoletti, E., J. Virol. **64**, 1441-1450 (1990).

104. Taylor, J., Weinberg, R., Kawaoka, Y., Webster, R.G., and Paoletti, E., Vaccine **6**, 504-508 (1988a).

105. Taylor, J., R. Weinberg, B. Lanquet, P. Desmettre, and E. Paoletti, Vaccine **6**, 497-503 (1988b).

106. Taylor, G., E. J. Stott, G. Wertz and A. Ball, J. Gen. Virol. **72**, 125-130 (1991a).

107. Taylor, J., C. Trimarchi, R. Weinberg, B. Languet, F. Guillemin, P. Desmettre and E. Paoletti, Vaccine **9**, 190-193 (1991b).

108. Van der Ryst, E., Fultz, P.N., Tartaglia, J., Barre-Sinuousi, F., Paoletti, E., Nara, P., Meignier, B., Blondeau, C., Muchmore, E., and Girard, M., Protection from HIV-1 challenge in chimpanzees by immunization with a canarypox virus recombinant. XI International conference on AIDS/Vancouver/1996, We.A.280 (1996).

109. Verschoor, E.J., Willemse, M.J., Stam, J.G., van Vliet, A.L. W., Pouwels, H., Chalmers, S.K., Horzinek, M.C., Sandermeijer, P.J.A., Hesselink, W., and de Ronde, A., Vaccine **14**, 285-289 (1996).

110. Vos, J. and Stunnenberg, H., EMBO J. **7**, 3487-3492 (1988).

111. Wang, R-F and Mullins, J.I., Gene **153**, 197-202 (1995). Wardley et al., J. Gen. Virol **73**, 1811-1818 (1992)

112. Webster et al., Vaccine, **12(16)**, 1495-1498 (1994).

113. Weir, J.P. and B. Moss, J. Virol. **46**, 530-537 (1983).

114. Yamamoto, J.K., Hohdatsu, T., Olmstead, R.A., Pu, R., Lowe, H. Zochlinski, H., Acevedo, V., Johnson, H.M., Soulds, G.A., and Gardner, M.B., J. Virol. **67**, 601-605 (1993).

115. Yamamoto, J.K., Okuda, T., Ackley, C.D., Lowe, H. Zochlinski, H., Pembroke, E., and Gardner, M.B., AIDS Res. Human Retrovir. **7**, 911-922 (1991).

116. Yuen, L., and Moss, B., Proc. Natl. Acad. Sci. USA **84**, 6417-6421 (1987).

117. Zhou, J., L. Crawford, L. McLean, X. Sun, M. Stanley, N. Almond and G.L. Smith, J. Gen. Virol. **71**, 2185-2190 (1990).

SEQUENCE LISTING

[0245]

<110> Virogenetics Corp.

<120> Poxvirus-Based Expression Vectors Containing
Heterologous Inserts Derived From Lentiviruses

<130> 150-65

<140> 97 94 6609.1

<141> 1999-06-14

<150> PCT/US97/20430

<151> 1997-11-07

<160> 37

<170> PatentIn Ver. 2.0

<210> 1

<211> 2571

<212> DNA

<213> Feline immunodeficiency virus

<400> 1

```

10  atggcagaag gatttgcagc caatagacaa tggataggac cagaagaagc tgaagagtta 60
    ttagatTTTTg atatagcaac acaaTgagT gaagaaggac cactaaatcc aggagTaaac 120
    ccatttaggg tacctggaat aacagaaaaa gaaaagcaaa actactgtaa catattacaa 180
    cctaagttac aagatctaag gaacgaaatt caagaggTaa aactggaaga aggaaatgca 240
15  ggtaagttta gaagagcaag atttttaagg tattctgatg aacaagtatt gtccctgggt 300
    catgcgttca taggatattg tatatatTTa ggtaatcgaa ataagTtagg atctttaaga 360
    catgacattg atatagaagc accccaagaa gagTgttata ataatagaga gaagggTaca 420
    actgacaata taaaatatgg tagacgatgt Tgcctaggaa cggTgacttt gtacctgatt 480
    ttattttatag gattaataat atattcacag acaaccaacg ctCaggtagt atgggagactt 540
20  ccaccattag tagtcccagT agaagaatca gaaataattt tttgggactg ttgggcacca 600
    gaagaacccg cctgtcagga ctttcttggg gcaatgatac atctaaaagc taagacaaat 660
    ataagtatac gagagggacc taccttgggg aattggacta gagaaatatg ggcaacatta 720
    ttcaaaaagg ctactagaca atgtagaaga ggcagaatat ggaaaagatg gaatgagact 780
25  ataacaggac catcaggatg tgctaataac acatgttata atgtttcagT aatagtacct 840
    gattatcagT gttattttaga tagagtagat acttggttac aagggaaaat aaatatatca 900
    ttatgtctaa caggaggaaa aatgttgtac aataaagTta caaaacaatt aagctattgt 960
    acagacccat tacaaatccc actgatcaat tatacatttg gacctaatca aacatgtatg 1020
30  tggaataactt cacaaattca ggaccctgaa ataccaaaat gtggatggTg gaatcaaatg 1080
    gcctattata acagttgtaa atgggaagag gcaaaggTaa agtttcattg tcaaagaaca 1140
    cagagtcagc ctggatcatg gcgtagagca atctcgTcat ggaaacaaag aaatagatgg 1200
    gagTggagac cagatttttg aagTaaaaag gtgaaaatat ctctacagTg caatagcaca 1260
35  aaaaacctaT cctttgcaat gagaagttca ggagattatg gagaagTaaC gggagcttgg 1320
    atagagtttg gatgtcatag aaataaatca aaacatcatt ctgaagcaag gtttagaatt 1380

```

40

45

50

55


```

agatgtagat ggaatgtagg atccgatacc tcgctcattg atacatgtgg aaacactcga 1440
gatgtttcag gtgcgaatcc tgtagattgt accatgtatt caaataaaaat gtacaattgt 1500
tctttacaaa atgggtttac tatgaaggta gatgacctta ttgtgcattt caatatgaca 1560
5 aaagctgtag aaatgtataa tattgctgga aattggctct gtacatctga cttgccatcg 1620
tcatgggggt atatgaattg taattgtaca aatagtagta gtagttatag tggactaaaa 1680
atggcatgtc ctagcaatcg aggcattcta aggaattggg ataaccagat agcaggatta 1740
cgacaatcct tagaacagta tcaagttgta aaacaaccag attacttagt ggtcccagag 1800
10 gaagtcatgg aatataaacc tagaaggaaa agggcagcta ttcattgtat gttggctctt 1860
gcaacagtat tatctattgt cgggtgcaggg acgggggcta ctgctatagg gatggtaaca 1920
caataccacc aagttctggc aacccatcaa gaagctatag aaaagggtgac tgaagcctta 1980
aagataaaca acttaagatt agttacatta gagcatcaag tactagtaat aggattaaaa 2040
gtagaagcta tggaaaaaatt tttatataca gctttcgcta tgcaagaatt aggatgtaat 2100
15 caaaatcaat ttttctgcaa aatccctcct ggggtgtgga caaggataaa tatgactata 2160
aatcaaaca tatggaatca tggaaatata actttggggg catgggtataa ccaaacaaaa 2220
gatttacaac aaaagtctta tgaaataata atggacatag aacaaaataa tgtacaaggg 2280
aaaacaggga tacaacaatt acaaaagtgg gaagattggg taggatggat gggaaatatt 2340
20 ccacaatatt taaagggact attgggaggt atcttgggaa taggattagg agtggtatta 2400
ttgattttat gtttacctac attggttgat tgtataagaa attgtatcca caagatacta 2460
ggatacacag taattgcaat gcctgaagta gaaggagaag aaatacaacc acaaattggaa 2520
ttgaggagaa atggtaggca atgtggcatg tctgaaaaag aggaggaatg a 2571

```

<210> 2

<211> 4616

<212> DNA

<213> Feline immunodeficiency virus

<400> 2

```

atggggaatg gacaggggag agattggaaa atggccatta agagatgtag taatgttgct 60
35 gtaggagtag gggggaagag taaaaaattt ggagaaggga atttcagatg ggccattaga 120
atggctaata tatctacagg acgagaacct ggtgatatac cagagacttt agatcaacta 180
aggttgggta tttgcgattt acaagaaaga agagaaaaat ttggatctag caaagaaatt 240
gatatggcaa ttgtgacatt aaaagtcttt gcggtagcag gacttttgaa tatgacggtg 300
tctactgctg ctgcagctga aaatatgtat tctcaaatgg gattagacac taggccatct 360
40 atgaaagaag cagggtggaaa agaggaaggc cctccacagg catatcctat tcaaacagta 420
aatggagtag cacaatatgt agcacttgac caaaaaatgg tgtccatttt tatggaaaag 480
gcaagagaag gactaggagg ggaggaagtt caactatggt ttactgcctt ctctgcaaat 540
ttaacaccta ctgacatggc cacattaata atggcccagc caggtgagcg tgcagataaa 600
45 gaaatattgg atgaaagctt aaagcaactg acagcagaat atgatcgac acatccccct 660
gatgctccca gaccattacc ctattttact gcagcagaaa ttatgggtat aggattaaact 720
caagaacaac aagcagaagc aagatttgca ccagctagga tgcagtgtag agcatgggat 780
ctcagggcat taggaaaatt ggctgccata aaagctaagt ctctcgagc tgtgcagtta 840
agacaaggag ctaaggaaga ttattcatcc tttatagaca gattgtttgc ccaaatagat 900
50 caagaacaaa atacagctga agttaagtta tatttaaaac agtcattaag catagctaat 960
gctaatagcag actgtaaaaa ggcaatgagc caccttaagc cagaaagtac cctagaagaa 1020
aagttgagag cttgtcaaga aataggctca ccaggatata aaatgcaact cttggcagaa 1080
gctcttacia aagttcaagt agtgcaatca aaaggatcag gaccagtgtg ttttaattgt 1140
55 aaaaaaccag gacatctagc aagacaatgt agagaagtga aaaaatgtaa taaatgtgga 1200
aaacctggtc atctagctgc caaatgttgg caaggaaata gaaagaattc gggaaactgg 1260

```

aaggcggggc gagctgcagc cccagtgaat caaatgcagc aagcagtaāt gccatctgca 1320
 cctccaatgg aggagaaact attggattta taaattataa taaagtaggt acgactacaa 1380
 cattagaaaa gagggcagaa atacttatat ttgtaaatgg atatcctata aaatttttat 1440
 5 tagatacagg agcagatata acaattttta ataggagaga ttttcaagta aaaaattcta 1500
 tagaaaaatgg aaggcaaaat atgattggag taggaggagg aaagagagga acaaattata 1560
 ttaatgtaca tttagagatt agagatgaaa attataagac acaatgtata tttggtaatg 1620
 tttgtgtcctt agaagataac tcattaatac aaccattatt ggggagagat aatatgatta 1680
 10 aattcaatat taggttagta atggctcaaa tttctgataa gattccagta gtaaaaagtaa 1740
 aaatgaagga tcctaataaa ggacctcaaa taaaacaatg gccattaaca aatgaaaaaa 1800
 ttgaagcctt aacagaaata gtagaaagac tagaaagaga agggaaagta aaaagagcag 1860
 atccaaataa tccatggaat acaccagtat ttgctataaa aaagaaaagt ggaaaatgga 1920
 gaatgctcat agattttaga gaattaaaca aactaactga gaaaggagca gaggtccagt 1980
 15 tgggactacc tcatcctgct gggttacaaa taaaaaaaca agtaacagta ttagatatag 2040
 gggatgcata tttcaccatt cctcttgatc cagattatgc tccttataca gcatttactt 2100
 tacctaggaa aaataatgag ggaccaggaa ggagatttgt gtggtgtagt ctaccacaag 2160
 gctggatttt aagtccattg atatatcaaa gtacattaga taatataata caacctttta 2220
 20 ttagacaaaa tcctcaatta gatatttacc aatatatgga tgacatttat ataggatcaa 2280
 atttaagtaa aaaggagcat aaagaaaagg tagaagaatt aagaaaatta ctattatggt 2340
 ggggatttga aactccagaa gataaattac aggaagaacc cccatataca tggatgggtt 2400
 atgaattaca tccattaaca tggacaatac aacagaaaca gtagacatt ccagaacagc 2460
 25 cactctaaa tgagttgcaa aaattagcag gaaaaattaa ttgggctagc caagctattc 2520
 cagacttgag tataaaagca ttaactaaca tgatgagagg aaatcaaaac ctaaattcaa 2580
 caagacaatg gactaaagaa gctcagctgg aagtacaaaa ggcaaaaaag gctatagaag 2640
 aacaagtaca actaggatac tatgacccca gtaaggagtt atatgctaaa ttaagtttgg 2700
 tgggaccaca tcaataaagt tatcgagtat atcagaagga tcaagaaaag atactatggt 2760
 30 atggaaaaat gagtagacaa aagaaaaagg cagaaaatac atgtgatata gccttaagag 2820
 catgctataa gataagagaa gagtctatta taagaatagg aaaagaacca agatatgaaa 2880
 tacctacttc tagagaagcc tgggaatcaa atctaattaa ttcaccatat cttaaggccc 2940
 cacctcctga ggtagaatat atccatgctg ctttgaatat aaagagagcg ttaagtatga 3000
 35 taaaagatgc tccaatacca ggagcagaaa catgggtatat agatggagggt agaaaactag 3060
 gaaaagcagc aaaagcagcc tattggacag atacaggaaa gtggaaagtg atggaaattag 3120
 aaggcagtaa tcagaaggca gaaatacaag cattattatt ggcattaaaa gcaggatcag 3180
 aggagatgaa tattataaca gattcacaat atgctataaa tattattctt caacaaccag 3240
 40 atatgatgga gggaatctgg caagaagttt tagaagaatt ggagaagaaa acagcaatat 3300
 ttatagattg ggtcccagga cataaaggta ttccaggaaa tgaggaagta gataagcttt 3360
 gtcaacaat gatgataata gaaggggatg ggatattaga caaaagggtca gaagatgcag 3420
 gatatgattt attagctgca aaagaaatac atttattgcc aggagaggta aaagtaatac 3480
 caacaggggt aaagctaatt ctgcctaaag gacattgggg attaataatc ggaaaaagct 3540
 45 cgatggggag taaaggattg gatgtattag gaggagtaat agatgaagga tatcgagggtg 3600
 aaattggagt aataatgatt aatgtatcaa gaaaatcaat caccttaatg gaacgacaaa 3660
 agatagcaca attaataata ctgccttgta aacatgaagt attagaacaa ggaaaagtag 3720
 taagggattc agagagagga ggcaatggtt atgggtcaac aggagtattc tcctcttggg 3780
 50 ttgacagaat tgaggaagca gaaataaatc atgaaaaatt tcaactcagat ccacagtact 3840
 taaggactga atttaattta cctaaaatgg tagcagaaga gataagacga aaatgccag 3900
 tatgcagaat cagaggagaa caagtgggag gacaattgaa aatagggcct ggtatctggc 3960
 aaatggattg cacacacttt gatggcaaaa taattcttgt ggggtatacat gtggaatcag 4020
 gatatatatg ggcacaaata atttctcaag aaactgctga ctgtacagtt aaagctgttt 4080
 55 tacaattgtt gagtgtcat aatgttactg aattacaaac agataatgga ccaaatttta 4140

aaaatcaaaa gatggaagga gtactcaatt acatgggtgt gaaacataag tttggtatcc 4200
 cagggaaacc acagtcacaa gcattagtgtg aaaatgtaaa tcatacatta aaagtttggg 4260
 5 ttcggaaatt tttgcctgaa acaacctcct tggataatgc cttatctctc gctgtacata 4320
 gtctcaattt taaaagaaga ggtaggatag gagggatggc cccttatgaa ttattagcac 4380
 aacaagaatc cttaagaata caagattatt tttctgcaat accacaaaaa ttgcaagcac 4440
 agtggattta ttataaagat caaaaagata agaaatggaa aggaccaatg agagtagaat 4500
 actggggaca gggatcagta ttattaaagg atgaagagaa gggatatttt cttataccta 4560
 10 ggagacacat aaggagagtt ccagaaccct gcgctcttcc tgaaggggat gagtga 4616

<210> 3

<211> 1615

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

ALVAC-nucleotide sequence comprised in the C6 donor plasmid pC6L.

<400> 3

gagctcgcgg ccgcctatca aaagtcttaa tgagttaggt gtagatagta tagatattac 60
 tacaaaggta ttcataatttc ctatcaattc taaagtagat gatattaata actcaaagat 120
 gatgatagta gataatagat acgctcatat aatgactgca aatttggacg gttcacattt 180
 30 taatcatcac gcgttcataa gtttcaactg catagatcaa aatctcacta aaaagatagc 240
 cgatgtattt gagagagatt ggacatctaa ctacgctaaa gaaattacag ttataaataa 300
 tacataatgg atttttggtat catcagttat atttaacata agtacaataa aaagtattaa 360
 ataaaaatac ttacttacga aaaaatgact aattagctat aaaaaccggy gctgcagctc 420
 gaggaattct ttttattgat taactagtca aatgagtata tataattgaa aaagtaaaat 480
 35 ataaatcata taataatgaa acgaaatatc agtaatagac aggaactggc agattcttct 540
 tctaataag taagtactgc taaatctcca aaattagata aaaatgatac agcaaataca 600
 gcttcattca acgaattacc ttttaatttt ttcagacaca ccttattaca aactaactaa 660
 gtcagatgat gagaaagtaa atataaattt aacttatggg tataatataa taaagattca 720
 40 tgatattaat aatttactta acgatgttaa tagacttatt ccatcaacc cttcaaacc 780
 ttctggatat tataaaatac cagttaatga tattaaaata gattgtttta gagatgtaa 840
 taattatttg gaggtaaagg atataaaatt agtctatctt tcacatggaa atgaattacc 900
 taatattaat aattatgata ggaatttttt aggatttaca gctgttatat gtatcaacaa 960
 tacaggcaga tctatgggta tggtaaaaca ctgtaacggg aagcagcatt ctatggtaac 1020
 45 tggcctatgt ttaatagcca gatcatttta ctctataaac attttaccac aaataatagg 1080
 atcctctaga tatttaatat tatatctaac aacaacaaaa aaatttaacg atgtatggcc 1140
 agaagtattt tctactaata aagataaaga tagtctatct tatctacaag atatgaaaga 1200
 agataatcat ttagtagtag ctactaatat ggaaagaaat gtatacaaaa acgtggaagc 1260
 50 ttttatatta aatagcatat tactagaaga tttaaaatct agacttagta taacaaaaca 1320
 gttaaagtcc aatatcgatt ctatatttca tcataacagt agtacattaa tcagtgatat 1380
 actgaaacga tctacagact caactatgca aggaataagc aatatgcaa ttatgtctaa 1440
 tattttaact ttagaactaa aacgttctac caatactaaa aataggatac gtgataggct 1500
 55 gttaaaagct gcaataaata gtaaggatgt agaagaaata ctttgttcta taccttcgga 1560
 ggaaagaact ttagaacaac ttaagttaa tcaaacttgt atttatgaag gtacc 1615

<210> 4
 <211> 2879
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: predicted nucleotide sequence of vaccinia virus H6 promoter and FIV env in an expression cassette.

<400> 4

```

ttaaataaaa atacttactt acgaaaaatg actaattagc tataaaaaacc cggggttcttt 60
attctatact taaaaagtga aaataaatat aaagggttctt gaggggttggtg ttaaattgaa 120
agcgagaaat aatcataaat tatttcatta tcgcgatatc cgттаagtтт gtatcgtaat 180
ggcagaagga tttgcagcca atagacaatg gataggacca gaagaagctg aagagttatt 240
agatттtgat atagcaacac aaatgagtga agaaggacca ctaaatccag gagtaaacc 300
atттtagggtta cctggaataa cagaaaaaga aaagcaaac tactgtaaca tattacaacc 360
taagttacaa gatctaagga acgaaattca agaggtaaaa ctggaagaag gaaatgcagg 420
taagттtaga agagcaagat ттттаaggta ttctgatgaa caagtattgt ccctggttca 480
tgcgttcata ggatattgta tatatттtagg taatcgaaat aagttaggat cтттаagaca 540
tgacattgat atagaagcac cccaagaaga gtgttataat aatagagaga agggtaacaac 600
tgacaatata aaatatggta gacgatgttg cctaggaacg gtgactттgt acctgattтт 660
atттtatagga ттаатаatat атсacagac aaccaacgct caggtagtat ggagacttcc 720
accattagta gtcccagtag aagaatcaga aataаттттт tgggactgtt gggcaccaga 780
agaaccgcgc tgtcaggact ttcttggggc aatgatacat ctaaaagcta agacaaatat 840
aagtatacga gagggaccta ccттgggggaa ttggactaga gaaatatggg caacattatt 900
caaaaaggct actagacaat gtagaagagg cagaatatgg aaaagatgga atgagactat 960
aacaggacca tcaggatgtg ctaataacac atgtttataat gtttcagtaa tagtacctga 1020
ttatcagtgt татттtagata gagtagatac ttggттacaa gggaaaataa atatatcatt 1080
atgtctaaca ggaggaaaaa tgттgtacaa тaaagттaca aaacaattaa gctattgtac 1140
agacccatta caaatcccac tgatcaatta tacatттgga cctaатcaaa catgtatgtg 1200
gaatacttca caaatccagg accctgaaat accaaaatgt ggatgggtgga atcaaatggc 1260
ctattataac agттgtaaat gggaaagaggc aaaggтаaaг ttтcattgtc aaagaacaca 1320
gagtcagcct ggatcatggc gtagagcaat ctctgcatgg aaacaaagaa atagatggga 1380
gtggagacca gatttgгaaa gтаaaaaggт gaaaatatct ctacagtgca atagcacaaa 1440
aaacctaacc тттgcaatga gaagттcagg agattatgga gaagtaacgg gagcttggtat 1500
agagттtgga tgтcatagaa ataaатcaaa acatcattct gaagcaaggт ttagaattag 1560
atgtagatgg aatgtaggat ccgatacctc gtcattgat acatgtggaa aactcgaga 1620
tgттtcaggт gcgaatcctg tagattgtac catgtattca aataaaatgt acaattgttc 1680
ттtacaaaat gggттtacta tgaaggtaga tgacctatt gtgcatttca atatgacaaa 1740
agctgtagaa atgtataata ttgctggaaa ttggtcttgt acatctgact tgccatcgtc 1800
atgggggtat atgaattgta attgtacaaa tagtagtagt agттtatagt gtactaaaat 1860
ggcatgtcct agcaatcgag gcatcttaag gaattggtat aaccagtag caggattacg 1920
acaatcctta gaacagtatc aagттgтаaa аcaaccagat tacttagtgг tcccagagga 1980
agtcatggaa татаaaccta gaaggaaaag ggcagctatt catgttatgt tggctcttgc 2040
aacagtatta tctattgtcg gtgcaggгac gggggctact gctataggga tggтаacca 2100
ataccaccaa gттctggcaa cccatcaaga agctatagaa aaggтgactg aagccttaaa 2160
gataaacaac ттаagattag ttacattaga gcatcaagta ctagтаatag gattaaaagt 2220

```

agaagctatg gaaaaattct tatatacagc ttctgctatg caagaattag gatgtaatca 2280
 aaatcaattc ttctgcaaaa tccctcctgg gttgtggaca aggtataata tgactataaa 2340
 tcaacaata tgggaatcatg gaaatataac tttgggggaa tggataaacc aaacaaaaga 2400
 5 tttacaacaa aagttttatg aaataataat ggacatagaa caaaataatg tacaagggaa 2460
 aacagggata caacaattac aaaagtggga agattgggta ggatggatgg gaaatattcc 2520
 acaatattta aagggactat tgggaggtat cttgggaata ggattaggag tgttattatt 2580
 gattttatgt ttacctacat tggttgattg tataagaaat tgtatccaca agatactagg 2640
 10 atacacagta attgcaatgc ctgaagtaga aggagaagaa atacaaccac aaatggaatt 2700
 gaggagaaat ggtaggcaat gtggcatgtc tgaaaaagag gaggaatgat gaagtatctc 2760
 agaattcctg cagcccgggg gatccttaat taattagtta ttagacaagg tgaaaacgaa 2820
 actatttgta gcttaattaa ttagctgcag gaattctttt tattgattaa ctagtcaaa 2879

<210> 5

<211> 2032

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: predicted nucleotide sequence of vaccinia virus I3L promoter and FIV gag/protease in an expression cassette.

<400> 5

ttaatcaata aaaagaattc ctgcagccct gcagctaatt aattaagcta caaatagttt 60
 cgttttcacc ttgtctaata actaattaat taaggatccc ccgtaccggg cccccctcg 120
 30 aggtcgacat cgatacatca tgcagtgggt aaacaaaaac atttttattc tcaaatgaga 180
 taaagtgaat atatatatca ttatattaca aagtacaatt atttaggttt aatcatgggg 240
 aatggacagg ggcgagattg gaaaatggcc attaagagat gtagtaatgt tgctgtagga 300
 gtagggggga agagtataaa atttggagaa ggggaatttc gatgggcat tagaatggct 360
 aatgtatcta caggacgaga acctggtgat ataccagaga ctttagatca actaagggtg 420
 35 gttatttgcg atttacaaga aagaagagaa aaatttggat ctagcaaaga aattgatatg 480
 gcaattgtga cattaaaagt ctttgcggtg gcaggacttt tgaatatgac ggtgtctact 540
 gctgctgcag ctgaaaatat gtattctcaa atgggattag acactaggcc atctatgaaa 600
 gaagcagggt gaaaagagga aggcctcca caggcatatc ctattcaaac agtaaatgga 660
 40 gtaccacaat atgtagcact tgacccaaaa atgggtgtcca ttttcatgga aaaggcaaga 720
 gaaggactag gaggggagga agttcaacta tggtttactg ctttctctgc aaatttaaca 780
 cctactgaca tggccacatt aataatggcc gcaccagggt gcgctgcaga taaagaaata 840
 ttggatgaaa gcttaaagca actgacagca gaatatgatc gcacacatcc cctgatgct 900
 45 cccagaccat taccctatct tactgcagca gaaattatgg gtataggatt aactcaagaa 960
 caacaagcag aagcaagatt tgcaccagct aggatgcagt gtagagcatg gtatctcgag 1020
 gcattaggaa aattggctgc cataaaagct aagtctcctc gagctgtgca gtttaagacaa 1080
 ggagctaagg aagattattc atcctttata gacagattgt ttgcccacaa agatcaagaa 1140
 caaaatacag ctgaagttaa gttatatatta aaacagtcac taagcatagc taatgctaata 1200
 50 gcagactgta aaaaggcaat gagccacctt aagccagaaa gtaccctaga agaaaagtgt 1260
 agagcttgct aagaaatagg ctaccagga tataaaatgc aactcttggc agaagctctt 1320
 acaaaagtgc aagtagtgca atcaaaagga tcaggaccag tgtgttttaa ttgtaaaaaa 1380
 ccaggacatc tagcaagaca atgtagagaa gtgaaaaaat gtaataaatg tggaaaacct 1440
 55 ggtcatctag ctgccaaatg ttggcaagga aatagaaaga attcgggaaa ctggaaggcg 1500

gggcgagctg cagccccagt gaatcaaagt cagcaagcag taatgccatc tgcacctcca 1560
 atggaggaga aactattgga ttataaatt ataataaagt aggtacgact acaacattag 1620
 aaaagaggcc agaaatactt atatttgtaa atggatatcc tataaaattt ttattagata 1680
 5 caggagcaga tataacaatt ttaaatagga gagattttca agtaaaaaat tctatagaaa 1740
 atggaaggca aaatatgatt ggagtaggag gaggaagag aggaacaaat tatattaatg 1800
 tacatttaga gattagagat gaaaattata agacacaatg tatatttggt aatgtttgtg 1860
 tcttagaaga taactcatta atacaacatc tattggggag agataatatg attaaattca 1920
 10 atattagggt agtaatggct caataatttt atcccgggt ttatagcta attagtcatt 1980
 tttcgtaagt aagtattttt atttaatact ttttattgta cttatgttaa at 2032

<210> 6

<211> 4727

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: predicted nucleotide sequence of vaccinia virus H6 promoter and FIV env, and vaccinia virus I3L promoter and FIV gag/protease in an expression cassette.

<400> 6

ttaatcaata aaaagaattc ctgcagccct gcagctaatt aattaagcta caaatagttt 60
 cgttttcacc ttgtctaata actaattaat taaggatccc cegtaccggg cccccctcg 120
 aggtcgactt ctttattcta tacttaaaaa gtgaaaaata atacaaagggt tcttgagggt 180
 30 tgtgttaaat tgaaagcgag aaataatcat aaattatttc attatcgga tatccgttaa 240
 gtttgtatcg taatggcaga aggatttgca gccaatagac aatggatagg accagaagaa 300
 gctgaagagt tattagattt tgatatagca acacaaatga gtgaagaagg accactaaat 360
 ccaggagtaa acccatttag ggtacctgga ataacagaaa aagaaaagca aaactactgt 420
 aacatattac aacctaaagt acaagatcta aggaacgaaa ttcaagagggt aaaactggaa 480
 35 gaaggaaatg caggtaagt tagaagagca agatttttaa ggtattctga tgaacaagta 540
 ttgtccctgg ttcatgcgtt cataggatat tgtatatatt taggtaatcg aaataagtta 600
 ggatctttta gacatgacat tgatatagaa gcacccaag aagagtgtta taataataga 660
 gagaagggtg caactgacaa tataaaatat ggtagacgat gttgcctagg aacggtgact 720
 ttgtacctga ttttatttat aggattaata atatattcac agacaaccaa cgctcaggta 780
 40 gtatggagac ttccaccatt agtagtccc gtagaagaat cagaaataat tttttgggac 840
 tgttgggcac cagaagaacc cgctgtcag gactttcttg gggcaatgat acatctaaaa 900
 gctaagacaa atataagtat acgagagggg cctaccttg ggaattggac tagagaaata 960
 tgggcaacat tattcaaaaa ggctactaga caatgtagaa gaggcagaat atggaaaaga 1020
 45 tggaatgaga ctataacagg accatcagga tgtgctaata acacatgtta taatgtttca 1080
 gtaatagtac ctgattatca gtgttattta gatagagtag atacttggtt acaagggaaa 1140
 ataaatatat cattatgtct aacaggagga aaaatgttgt acaataaagt tacaaaacaa 1200
 ttaagctatt gtacagaccc attacaaatc ccactgatca attatacatt tggacctaat 1260
 50 caaacatgta tgtggaatac ttcacaaatt caggaccctg aaataccaaa atgtggatgg 1320
 tggaatcaaa tggcctatta taacagttgt aaatgggaag aggcaagggt aaagtttcat 1380
 tgtcaaagaa cacagagtca gcctggatca tggcgtagag caatctcgtc atggaaacaa 1440
 agaaatagat gggagtggag accagatttg gaaagtaaaa aggtgaaaat atctctacag 1500
 55 tgcaatagca caaaaaacct aacctttgca atgagaagtt caggagatta tggagaagta 1560

acgggagctt ggatagagtt tggatgtcat agaaataaat caaaacatca ttctgaagca 1620
 aggttttagaa ttagatgtag atggaatgta ggatccgata cctcgctcat tgatacatgt 1680
 ggaaacactc gagatgtttc aggtgcgaat cctgtagatt gtacatgta ttcaaataaa 1740
 5 atgtacaatt gttctttaca aaatgggttt actatgaagg tagatgacct tattgtgcat 1800
 ttcaatatga caaaagctgt agaaatgtat aatattgctg gaaattgggtc ttgtacatct 1860
 gacttgccat cgtcatgggg gtatatgaat tgtaattgta caaatagtag tagtagttat 1920
 agtgggtacta aaatggcatg tcctagcaat cgaggcatct taagggaattg gtataaccca 1980
 10 gtagcaggat tacgacaatc cttagaacag tatcaagttg taaaacaacc agattactta 2040
 gtgggtcccag aggaagtcac ggaatataaa cctagaaggga aaagggcagc tattcatgtt 2100
 atgttggtctc ttgcaacagt attatctatt gtcggtgcag ggacgggggc tactgctata 2160
 gggatggtaa cccaatacca ccaagttctg gcaaccatc aagaagctat agaaaagggtg 2220
 actgaagcct taaagataaa caacttaaga ttagttacat tagagcatca agtactagta 2280
 15 ataggattaa aagtagaagc tatggaaaaa ttcttatata cagctttcgc tatgcaagaa 2340
 ttaggatgta atcaaaatca attcttctgc aaaatccctc ctgggttggtg gacaagggtat 2400
 aatatgacta taaatcaaac aatatggaat catggaaata taactttggg ggaatgggtat 2460
 aaccaaacaa aagatttaca acaaaagttt tatgaaataa taatggacat agaacaaaat 2520
 20 aatgtacaag ggaaaacagg gatacaacaa ttacaaaagt gggaagattg ggtaggatgg 2580
 atgggaaata ttccacaata tttaaaggga ctattgggag gtatcttggg aataggatta 2640
 ggagtgttat tattgatatt atgtttacct acattgggtg attgtataag aaattgtatc 2700
 cacaagatac taggatacac agtaattgca atgcctgaag tagaaggaga agaaatacaa 2760
 ccacaaatgg aattgaggag aaatggtagg caatgtggca tgtctgaaaa agaggaggaa 2820
 25 tgaatcgata catcatgcag tgggttaaaca aaaacatttt tattctcaa tgagataaaag 2880
 tgaaaatata tatcattata ttacaaagta caattattta ggtttaatca tggggaatgg 2940
 acaggggcga gattggaaaa tggccattaa gagatgtagt aatgttgctg taggagtagg 3000
 ggggaagagt aaaaaatttg gagaagggaa tttcagatgg gccattagaa tggctaattgt 3060
 30 atctacagga cgagaacctg gtgatatacc agagacttta gatcaactaa ggttggttat 3120
 ttgcgattta caagaaagaa gagaaaaatt tggatctagc aaagaaattg atatggcaat 3180
 tgtgacatta aaagtctttg cggtagcagg acttttgaat atgacggtgt ctactgctgc 3240
 tgcagctgaa aatatgtatt ctcaaaggg attagacact aggccatcta tgaaagaagc 3300
 aggtggaaaa gaggaaggcc ctccacaggc atatcctatt caaacagtaa atggagtacc 3360
 35 acaatatgta gcacttgacc caaaaatgggt gtccattttc atggaaaagg caagagaagg 3420
 actaggaggg gaggaagttc aactatggtt tactgccttc tctgcaaatt taacacctac 3480
 tgacatggcc acattataaa tggccgcacc aggggtgcgt gcagataaag aaatattgga 3540
 tgaaagctta aagcaactga cagcagaata tgatcgaca catccccctg atgctcccag 3600
 accattacce tattttactg cagcagaaat tatgggtata ggattaactc aagaacaaca 3660
 40 agcagaagca agatttgcac cagctaggat gcagtgtaga gcatgggtatc tcgaggcatt 3720
 aggaaaattg gctgcataa aagctaagtc tcctcgagct gtgcagttaa gacaaggagc 3780
 taagggaagat tattcatcct ttatagacag attgtttgcc caaatagatc aagaacaaaa 3840
 tacagctgaa gttaagttat atttaaaaca gtcattaaagc atagctaattg ctaatgcaga 3900
 45 ctgtaaaaag gcaatgagcc accttaagcc agaaagtacc ctagaagaaa agttgagagc 3960
 ttgtcaagaa ataggctcac caggatataa aatgcaactc ttggcagaag ctcttacaaa 4020
 agttcaagta gtgcaatcaa aaggatcagg accagtgtgt tttaattgta aaaaaccagg 4080
 acatctagca agacaatgta gagaagtga aaaaatgtaaat aaatgtggaa aacctgggtca 4140
 50 tctagctgcc aaatgttggc aaggaaatag aaagaattcg ggaaactgga aggcggggcg 4200
 agctgcagcc ccagtgaatc aaatgcagca agcagtaattg ccactctgcac ctccaatgga 4260
 ggagaaacta ttggatttat aaattataat aaagtaggta cgactacaac attagaaaag 4320
 aggccagaaa tacttatatt tgtaaatgga tatcctataa aatttttatt agatacagga 4380
 gcagatataa caatttttaa taggagagat tttcaagtaa aaaattctat agaaaatgga 4440

```

aggcaaaata tgattggagt aggaggagga aagagaggaa caaattatat taatgtacat 4500
ttagagatta gagatgaaaa ttataagaca caatgtatat ttggtaatgt ttgtgtctta 4560
gaagataact cattaatata accattattg gggagagata atatgattaa attcaatatt 4620
5 aggttagtaa tggctcaata attttatccc gggtttttat agctaattag tcatttttcg 4680
taagtaagta tttttattta atacttttta ttgtacttat gttaaat 4727

```

<210> 7

<211> 4150

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: predicted nucleotide sequence of vaccinia virus H6 promoter and altered FIV env, and vaccinia virus I3L promoter and FIV gag/pol in an expression cassette.

<400> 7

```

20 ttaatcaata aaaagaattc ctgcaggaat tcataaaaat cattcttctc cttctacttc 60
aggcattgca attactgtgt atcctagtat cttgtggata caatttctta tacaatcaac 120
caatgtagggt aaacataaaa tcaataataa cactccta atcctattcca agatacctcc 180
caatagtccc cttttccttc taggtttata ttccatgact tcctctggga ccactaagta 240
25 atctgggtgt tttacaactt gatactgttc taaggattgt cgtaatcctg ctactgggtt 300
ataccaattc cttaagatgc ctcgattgct aggacatgcc attttagtac cactataact 360
actactacta tttgtacaat tacaattcat ataccccat gacgatggca agtcagatgt 420
acaagaccaa tttccagcaa tattatacat ttctacagct tttgtcatat tgaaatgcac 480
aataagggtca tctaccttca tagtaaacc attttgtaaa gaacaattgt acattttatt 540
30 tgaatacatg gtacaatcta caggattcgc acctgaaaca tctcgagtgt ttccacatgt 600
atcaatgagc gaggtatcgg atcctacatt ccatctacat ctaattctaa accttgcttc 660
agaatgatgt tttgatttat ttctatgaca tccaaactct atccaagctc ccgttacttc 720
tccataatct cctgaacttc tcattgcaaa ggttaggttt tttgtgctat tgcactgtag 780
35 agatattttc acctttttac tttccaaatc tgggtctccac tcccatctat ttctttggtt 840
ccatgacgag attgctctac gccatgatcc aggctgactc tgtgttcttt gacaatgaaa 900
ctttaccttt gcctcttccc atttacaact gttataatag gccatttgat tccaccatcc 960
acattttgggt atttcagggt cctgaatttg tgaagtattc cacatacatg tttgattagg 1020
tccaaatgta taattgatca gtgggatttg taatgggtct gtacaatagc ttaattgttt 1080
40 tgtaacttta ttgtacaaca ttttccctcc tgtagacat aatgatatat ttattttccc 1140
ttgtaaccaa gtatctactc tatctaaata aacttgataa tcaggtaacta ttactgaaac 1200
attataacat gtgttattag cacatcctga tggctcctgt atagtctcat tccatctttt 1260
ccatattctg cctcttctac attgtctagt agcctttttg aataatgttg cccatatttc 1320
45 tctagtccaa tttcccaagg taggtccctc tcgtatactt atatttgtct tagcttttag 1380
atgtatcatt gcccgaagaa agtcctgaca ggcgggttct tctggtgccc aacagtccca 1440
aaaaattatt tctgattctt ctactgggac tactaatggg ggaagtctcc atactacctg 1500
agcgttggtt gtctgtgaat atattattaa tcctataaat aaaatcagggt acaaagtcac 1560
cgttcctagg caacatcgtc taccatattt tatattgtca gttgtaccct tctctctatt 1620
50 attataacac tcttcttggg gtgcttctat atcaatgtca tgtcttaaag atcctaactt 1680
atttcgatta cctaaatata tacaatatcc tatgaacgca tgaaccaggg acaatacttg 1740

```



```

ttcatcagaa taccttaaaa atcttgctct tctaaactta cctgcatttc cttcttccag 1800
ttttacctct tgaatttcgt tccttagatc ttgtaactta ggttgtaata tgttacagta 1860
gttttgcttt tctttttctg ttattccagg taccctaaat gggtttactc ctggatttag 1920
5  tggtccttct tcactcattt gtgttgctat atcaaaatct aataactctt cagcttcttc 1980
tggtcctatc cattgtctat tggctgcaaa tccttctgcc attacgatac aaacttaacg 2040
gatatcgcga taatgaaata atttatgatt atttctcgct ttcaatttaa cacaaccctc 2100
aagaaccttt gtatttattt tcacttttta agtatagaat aaagaactgc agctaattaa 2160
10 ttaagctaca aatagtttcg ttttcacctt gtctaataac taattaatta aggatccccc 2220
gtaccggggc cccctcgag gtctgacatcg atacatcatg cagtgggttaa acaaaaacat 2280
ttttattctc aaatgagata aagtgaanaa atatatcatt atattacaaa gtacaattat 2340
ttaggtttta tcatggggaa tggacagggg cgagattgga aaatggccat taagagatgt 2400
agtaatgttg ctgtaggagt aggggggaag agtaaaaaat ttggagaagg gaatttcaga 2460
15 tgggccatta gaatggctaa tgtatctaca ggacgagaac ctggtgatat accagagact 2520
ttagatcaac taaggttggt tatttgcat ttacaagaaa gaagagaaaa atttggatct 2580
agcaaagaaa ttgatatggc aattgtgaca ttaaaagtct ttgcggtagc aggacttttg 2640
aatatgacgg tgtctactgc tgctgcagct gaaaatatgt attctcaaat gggattagac 2700
20 actaggccat ctatgaaaga agcaggtgga aaagaggaa ggcctccaca ggcatacct 2760
attcaaacag taaatggagt accacaatat gtagcacttg acccaaaaat ggtgtccatt 2820
ttcatggaaa aggcaagaga aggactagga ggggaggaag ttcaactatg gtttactgcc 2880
ttctctgcaa atttaacacc tactgacatg gccacattaa taatggccgc accaggtgc 2940
25 gctgcagata aagaaatatt ggatgaaagc ttaaagcaac tgacagcaga atatgatcgc 3000
acacatcccc ctgatgctcc cagaccatta ccctatttta ctgcagcaga aattatgggt 3060
ataggattaa ctcaagaaca acaagcagaa gcaagatttg caccagctag gatgcagtgt 3120
agagcatggt atctcgaggc attaggaaaa ttggctgcca taaaagctaa gtctcctcga 3180
gctgtgcagt taagacaagg agctaaggaa gattattcat cctttataga cagattgttt 3240
30 gcccaaatag atcaagaaca aaatacagct gaagttaagt tatattttaa acagtcatta 3300
agcatagcta atgctaatagc agactgtaaa aaggcaatga gccaccttaa gccagaaagt 3360
accctagaag aaaagttgag agcttgtcaa gaaataggct caccaggata taaaatgcaa 3420
ctcttggcag aagctcttac aaaagttcaa gtagtgcaat caaaaggatc aggaccagt 3480
35 tgttttaatt gtaaaaaacc aggacatcta gcaagacaat gtagagaagt gaaaaaatgt 3540
aataaatgtg gaaaacctgg tcatctagct gccaaatgtt ggcaaggaaa tagaaagaat 3600
tcgggaaaact ggaaggcggg gcgagctgca gcccagtgat atcaaatgca gcaagcagta 3660
atgccatctg cacctccaat ggaggagaaa ctattggatt tataaattat aataaagtag 3720
40 gtacgactac aacattagaa aagaggccag aaatacttat atttgtaaat ggatatccta 3780
taaaattttt attagataca ggagcagata taacaatttt aaataggaga gattttcaag 3840
taaaaaatc tatagaaaat ggaaggcaaa atatgattgg agtaggagga ggaaagagag 3900
gaacaaatta tattaatgta catttagaga ttagagatga aaattataag acacaatgta 3960
tatttggtaa tgtttgtgtc ttagaagata actcattaat acaaccatta ttggggagag 4020
45 ataatatgat taaattcaat attaggttag taatggctca ataattttat cccgggtttt 4080
tatagcta at tagtcatttt tcgtaagtaa gtatttttat ttaatacttt ttattgtact 4140
tatgttaaat 4150

```

50 <210> 8
 <211> 36
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <223> sequence not described in specification

<220>

EP 0 956 360 B1

<223> Description of Artificial Sequence: PCR primer used in a reaction with pMAW103 template, for construction of FIV expression plasmid pMAW103A.

<400> 8

atcatcaagc ttctgcagtt ctttattcta tactta 36

<210> 9

<211> 79

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of FIV env in a reaction with ptg6184 template.

<400> 9

aaattcttat atacagcttt cgctatgcaa gaattaggat gtaatcaaaa tcaattcttc 60 tgcaaaatcc ctctgggt 79

<210> 10

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of FIV env in a reaction with ptg6184 template.

<400> 10

cccatcgagt gcggctac 18

<210> 11

<211> 75

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of FIV env.

<400> 11

gcagaagaat tgattttgat tacatcctaa ttctgcata gcgaaagctg tatataagaa 60
ttttccata gcttc 75

<210> 12

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of FIV env.

<400> 12

aagtctctggc aacctatc 18

<210> 13

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used to amplify the vaccinia virus H6 promoter and the 5' part of FIV env in a reaction with pMM108 template.

5 <400> 13
atcatcctgc agaagcttcc cgggttcttt attctatact t 41

<210> 14

<211> 36

10 <212> DNA

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: PCR primer used to amplify the vaccinia virus H6 promoter and the 5' part of FIV env in a reaction with pMM108 template.

<400> 14
ctgcaaatcc ttctgccatt acgatacaaa cttaac 36

20 <210> 15

<211> 39

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence: PCR primer used to amplify the 3' part of the vaccinia virus H6 promoter and the 5' part of FIV env in a reaction with pMM122 template.

30 <400> 15
cgtaagttt gtatcgtaat ggcagaagga ttgcagcc 39

<210> 16

<211> 18

35 <212> DNA

<213> Artificial Sequence

<220>

40 <223> Description of Artificial Sequence: PCR primer used to amplify the 3' part of the vaccinia virus H6 promoter and the 5' part of FIV env in a reaction with pMM122 template.

<400> 16
cctcttgaat ttcgttcc 18

45 <210> 17

<211> 42

<212> DNA

<213> Artificial Sequence

50 <220>

<223> Description of Artificial Sequence: PCR primer used in a reaction with ALVAC template, for construction of insertion plasmid pC6L.

55 <400> 17
atcatcgagc tcgcgccgc ctatcaaaag tcttaatgag tt 42

<210> 18

<211> 73

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer used in a reaction with ALVAC template, for construction of insertion plasmid pC6L.

<400> 18
gaattcctcg agctgcagcc cgggtttta tagctaatta gtcattttt cgtaagtaag 60
tattttatt taa 73

<210> 19
<211> 72
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer used in a reaction with ALVAC template, for construction of insertion plasmid pC6L.

<400> 19
cccgggctgc agctcgagga attctttta ttgattaact agtcaaatga gtatatataa 60 ttgaaaaagt aa 72

<210> 20
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer used in a reaction with ALVAC template, for construction of insertion plasmid pC6L.

<400> 20
gatgatgga ccttcataaa tacaagttg attaaactta agttg 45

<210> 21
<211> 80
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sequence added to insertion plasmid pC6L in construction of pMM117.

<400> 21
gggggatcct taattaatta gtattagac aagggtgaaaa cgaaactatt ttagcttaa 60 ttaattagct gcaggaattc 80

<210> 22
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 5' PCR primer used to amplify the central part of FIV gag in a reaction with ptg8133 template.

<400> 22
caaaaatggt gtccatttc atggaaaagg caagagaagg ac 42

<210> 23
 <211> 18
 <212> DNA
 <213> Artificial Sequence

5

<220>
 <223> Description of Artificial Sequence: 3' PCR primer used to amplify the central part of FIV gag in a reaction with ptg8133 template.

10

<400> 23
 ctgctgcagt aaaatagg 18

15

<210> 24
 <211> 43
 <212> DNA
 <213> Artificial Sequence

20

<220>
 <223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of the vaccinia virus I3L promoter and the 5' part of FIV gag in a reaction with ptg8133 template.

<400> 24
 cttctctgc ctttccatg aaaatggaca ccattttgg gtc 43

25

<210> 25
 <211> 38
 <212> DNA
 <213> Artificial Sequence

30

<220>
 <223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of the vaccinia virus I3L promoter and the 5' part of FIV gag in a reaction with ptg8133 template.

35

<400> 25
 caattattta ggtttaatca tggggaatgg acaggggc 38

40

<210> 26
 <211> 42
 <212> DNA
 <213> Artificial Sequence

45

<220>
 <223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of the vaccinia virus I3L promoter and the 5' part of FIV gag in a reaction with pMM100 template.

<400> 26
 cgcccctgtc cattcccat gattaaacct aaataattgt ac 42

50

<210> 27
 <211> 38
 <212> DNA
 <213> Artificial Sequence

55

<220>
 <223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of the vaccinia virus I3L promoter and the 5' part of FIV gag in a reaction with pMM100 template.

<400> 27

EP 0 956 360 B1

atcatcgctcg acatcgatac atcatgcagt ggtaaac 38

<210> 28

<211> 18

5 <212> DNA

<213> Artificial Sequence

<220>

10 <223> Description of Artificial Sequence: 5' PCR primer used to amplify FIV protease in a reaction with pMM121 template.

<400> 28

caggacatct agcaagac 18

15 <210> 29

<211> 40

<212> DNA

<213> Artificial Sequence

20 <220>

<223> Description of Artificial Sequence: 3' PCR primer used to amplify FIV protease in a reaction with pMM121 template.

<400> 29

25 gatgatcccg ggataaaaat tattgagcca ttactaacct 40

<210> 30

<211> 18

<212> DNA

30 <213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of FIV env in a reaction with pMM125#10 template.

<400> 30

tatgaattgt aattgtac 18

<210> 31

40 <211> 54

<212> DNA

<213> Artificial Sequence

<220>

45 <223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of FIV env in a reaction with pMM125#10 template.

<400> 31

50 gtagcataag gttaccgcgg ccgctaagct taggttacca tccctatagc agta 54

<210> 32

<211> 59

<212> DNA

55 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of FIV env in a reaction with pMM125#10 template.

<400> 32
gtagcataag gtaacctaaag cttagcggcc gcggtaaccc aataccacca agttctggc 59

<210> 33
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of FIV env in a reaction with pMM125#10 template.

<400> 33
attaaccctc actaaag 17

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer used in a reaction with pMM125#10 template, for construction of FIV expression plasmid pMAW103.

<400> 34
acttgccatc gtcattggggg 20

<210> 35
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer used in a reaction with pMM125#10 template, for construction of FIV expression plasmid pMAW103.

<400> 35
gataacctccc aatagtccttct tttccttct aggtttatat tc 42

<210> 36
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer used in a reaction with pMM125#10 template, for construction of FIV expression plasmid pMAW103.

<400> 36
gaatataaac ctagaaggaa aaggggacta ttgggagga tc 42

<210> 37
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer used in a reaction with pMM125#10 template, for construction

of FIV expression plasmid pMAW103.

<400> 37
atcatcgaat tcataaaaaat cattcttctc cttctacttc 40

SEQUENCE LISTING

[0246]

<110> Virogenetics Corp.

<120> Poxvirus-Based Expression Vectors Containing
Heterologous Inserts Derived From Lentiviruses

<130> 150-65

<140> 97 94 6609.1

<141> 1999-06-14

<150> PCT/US97/20430

<151> 1997-11-07

<160> 37

<170> PatentIn Ver. 2.0

<210> 1

<211> 2571

<212> DNA

<213> Feline immunodeficiency virus

<400> 1

EP 0 956 360 B1

atggcagaag gatttgcagc caatagacaa tggataggac cagaagaagc tgaagagtta 60
 ttagattttg atatagcaac acaaatgagt gaagaaggac cactaaatcc aggagtaaac 120
 ccatntaggg tacctggaat aacagaaaaa gaaaagcaaa actactgtaa catattacaa 180
 5 cctaagttac aagatctaag gaacgaaatt caagaggtaa aactggaaga aggaaatgca 240
 ggtaagttta gaagagcaag atttttaagg tattctgatg aacaagtatt gtccctgggt 300
 catgcgttca taggatattg tatatatatta ggtaatcgaa ataagttagg atctttaaga 360
 catgacattg atatagaagc accccaagaa gagtgttata ataatagaga gaagggtaca 420
 10 actgacaata taaaatatgg tagacgatgt tgcctaggaa cgggtgacttt gtacctgatt 480
 ttatttatag gattaataat atattcacag acaaccaacg ctcaggtagt atggagactt 540
 ccaccattag tagtcccagt agaagaatca gaaataattt tttgggactg ttgggcacca 600
 gaagaacccg cctgtcagga ctttcttggg gcaatgatac atctaaaagc taagacaaat 660
 ataagtatac gagagggacc taccttgggg aattggacta gagaaatatg ggcaacatta 720
 15 ttcaaaaagg ctactagaca atgtagaaga ggcagaatat ggaaaagatg gaatgagact 780
 ataacaggac catcaggatg tgctaataac acatgttata atgtttcagt aatagtacct 840
 gattatcagt gttatttaga tagagtagat acttgggttac aagggaaaat aaatatatca 900
 ttatgtctaa caggaggaaa aatgttgtac aataaagtta caaaacaatt aagctattgt 960
 20 acagacccat tacaatccc actgatcaat tatacatctg gacctaatac aacatgtatg 1020
 tggaatactt cacaaattca ggaccctgaa ataccaaaat gtggatggtg gaatcaaatg 1080
 gcctattata acagttgtta atgggaagag gcaaaggtaa agtttcattg tcaaagaaca 1140
 cagagtcagc ctggatcatg gcgtagagca atctcgtcat ggaaacaaag aaatagatgg 1200
 25 gagtggagac cagatttttg aagtaaaaag gtgaaaatat ctctacagtg caatagcaca 1260
 aaaaacctaa cctttgcaat gagaagttca ggagattatg gagaagtaac gggagcttgg 1320
 atagagtttg gatgtcatag aaataaatca aaacatcatt ctgaagcaag gtttagaatt 1380
 30
 agatgtagat ggaatgtagg atccgatacc tcgctcattg atacatgtgg aaacactcga 1440
 gatgtttcag gtgcgaatcc thtagattgt accatgtatt caaataaaat gtacaattgt 1500
 tctttacaaa atgggtttac tatgaaggta gatgacctta ttgtgcattt caatatgaca 1560
 aaagctgtag aaatgtataa tattgctgga aattgggtctt gtacatctga cttgccatcg 1620
 35 tcatgggggt atatgaattg taattgtaca aatagtagta gtagttatag tggactaaa 1680
 atggcatgtc ctagcaatcg aggcattcta aggaattggt ataaccagc agcaggatta 1740
 cgacaatcct tagaacagta tcaagttgta aaacaaccag attacttagt ggtcccagag 1800
 gaagtcatgg aatataaacc tagaaggaaa agggcagcta ttcattgttat gttggctctt 1860
 40 gcaacagtat tatctattgt cgggtgcaggg acgggggcta ctgctatagg gatggtaaca 1920
 caataccacc aagttctggc aacccatcaa gaagctatag aaaagggtgac tgaagcctta 1980
 aagataaaca acttaagatt agttacatta gagcatcaag tactagtaat aggattaaaa 2040
 gtagaagcta tggaaaaatt tttatataca gctttcgcta tgcaagaatt aggatgtaat 2100
 caaaatcaat ttttctgcaa aatccctcct ggggtgtgga caaggataa tatgactata 2160
 45 aatcaaaca tatggaatca tggaaatata actttggggg catggtataa ccaaacaaaa 2220
 gatttacaac aaaagtttta tgaaataata atggacatag aacaaaataa tgtacaaggg 2280
 aaaacaggga tacaacaatt acaaaaagtgg gaagattggg taggatggat gggaaatatt 2340
 ccacaatatt taaagggact attgggaggt atcttgggaa taggattagg agtggtatta 2400
 50 ttgattttat gtttacctac attggttgat tgtataagaa attgtatcca caagatacta 2460
 ggatacacag taattgcaat gcctgaagta gaaggagaag aaatacaacc acaaatggaa 2520
 ttgaggagaa atggtaggca atgtggcatg tctgaaaaag aggaggaatg a 2571

55

<210> 2
 <211> 4616
 <212> DNA

<213> Feline immunodeficiency virus

<400> 2

```

5      atggggaatg gacaggggcg agattggaaa atggccatta agagatgtag taatgttgct 60
      gtaggagtag gggggaagag taaaaaatTT ggagaaggga atttcagatg ggccattaga 120
      atggctaata tatctacagg acgagaacct ggtgatatac cagagacttt agatcaacta 180
      aggttggtta tttgCGattt acaagaaaga agagaaaaat ttggatctag caaagaaatt 240
10     gatatggcaa ttgtgacatt aaaagtcttt gCGgtagcag gacttttgaa tatgacggtg 300
      tctactgctg ctgcagctga aaatatgtat tctcaaattg gattagacac taggccatct 360
      atgaaagaag caggtggaaa agaggaaggc cctccacagg catatcctat tcaaacagta 420
      aatggagtag cacaaatatgt agcacttgac ccaaaaatgg tgtccatttt tatggaaaag 480
15     gcaagagaag gactaggagg ggaggaagtt caactatggt ttactgcctt ctctgcaaat 540
      ttaacaccta ctgacatggc cacattaata atggcccgac cagggtgCGc tgcagataaa 600
      gaaatattgg atgaaagctt aaagcaactg acagcagaat atgatCGcac acatccccct 660
      gatgctccca gaccattacc ctatTTtact gcagcagaaa ttatgggtat aggattaact 720
20     caagaacaac aagcagaagc aagatttgca ccagctagga tgcagtgtag agcatggtat 780
      ctCGaggcat taggaaaatt ggctgCCata aaagctaagt ctCctCGagc tgtgCagtta 840
      agacaaggag ctaaggaaga ttattcatcc tttatagaca gattgTTtgc ccaaatagat 900
      caagaacaaa atacagctga agttaagtta tatttaaaac agtcattaag catagctaata 960
      gctaatagcag actgtaaaaa ggcaatgagc caccttaagc cagaaagtac cctagaagaa 1020
25     aagttgagag cttgtcaaga aataggctca ccaggatata aaatgcaact cttggcagaa 1080
      gctcttacia aagttcaagt agtgcaatca aaaggatcag gaccagtgtg ttttaattgt 1140
      aaaaaaccag gacatctagc aagacaatgt agagaagtga aaaaatgtaa taaatgtgga 1200
      aaacctgggtc atctagctgc caaatgttgg caaggaaata gaaagaattc gggaaactgg 1260

```

30

35

40

45

50

55

aaggcggggc gagctgcagc cccagtgaat caaatgcagc aagcagtaat gccatctgca 1320
cctccaatgg aggagaaact attggattta taaattataa taaagtaggt acgactacaa 1380
cattagaaaa gaggccagaa atacttatat ttgtaaatgg atatcctata aaatTTTTat 1440
5 tagatacagg agcagatata acaattttta ataggagaga ttttcaagta aaaaattcta 1500
tagaaaatgg aaggcaaaat atgattggag tagggaggagg aaagagagga acaaattata 1560
ttaatgtaca tttagagatt agagatgaaa attataagac acaatgtata tttggtaatg 1620
tttgtgtctt agaagataac tcattaatac aaccattatt ggggagagat aatatgatta 1680
10 aattcaatat taggttagta atggctcaaa tttctgataa gattccagta gtaaaagtaa 1740
aaatgaagga tcctaataaa ggacctcaaa taaaacaatg gccattaaca aatgaaaaaa 1800
ttgaagcctt aacagaaata gtagaaagac tagaaagaga agggaaagta aaaagagcag 1860
atccaaataa tccatggaat acaccagtat ttgctataaa aaagaaaagt ggaaaatgga 1920
gaatgctcat agatttttaga gaattaaaca aactaactga gaaaggagca gaggtccagt 1980
15 tgggactacc tcctcctgct gggttacaaa taaaaaaaca agtaacagta ttagatatag 2040
gggatgcata tttcaccatt cctcttgatc cagattatgc tccttatata gcatttactt 2100
tacctaggaa aaataatgcg ggaccaggaa ggagatttgt gtggtgtagt ctaccacaag 2160
gctggatttt aagtcctattg atatatcaaa gtacattaga taatataata caacctttta 2220
20 ttagacaaaa tcctcaatta gatatttacc aatatatgga tgacatttat ataggatcaa 2280
atttaagtaa aaaggagcat aaagaaaagg tagaagaatt aagaaaatta ctattatggt 2340
ggggatttga aactccagaa gataaattac aggaagaacc cccatatata tggatgggtt 2400
atgaattaca tccattaaca tggacaatac aacagaaaca gttagacatt ccagaacagc 2460
ccactctaaa tgagttgcaa aaattagcag gaaaaattaa ttgggctagc caagctattc 2520
25 cagacttgag tataaaagca ttaactaaca tgatgagagg aaatcaaaac ctaaattcaa 2580
caagacaatg gactaaagaa gctcgactgg aagtacaaaa ggcaaaaaag gctatagaag 2640
aacaagtaca actaggatac tatgacccca gtaaggagtt atatgctaaa ttaagtttgg 2700
tgggaccaca tcaaataagt tatcgagtat atcagaagga tcaagaaaag atactatggt 2760
30 atggaaaaat gagtagacaa aagaaaaagg cagaaaatac atgtgatata gccttaagag 2820
catgctataa gataagagaa gagtctatta taagaatagg aaaagaacca agatatgaaa 2880
tacctacttc tagagaagcc tgggaatcaa atctaattaa ttcaccatat cttaaggccc 2940
cacctcctga ggtagaatat atccatgctg ctttgaatat aaagagagcg ttaagtatga 3000
35 taaaagatgc tccaatacca ggagcagaaa catggtatat agatggagggt agaaaactag 3060
gaaaagcagc aaaagcagcc tattggacag atacaggaaa gtggaaagtg atggaattag 3120
aaggcagtaa tcagaaggca gaaatacaag cattattatt ggcattaaaa gcaggatcag 3180
aggagatgaa tattataaca gattcacaat atgctataaa tattattctt caacaaccag 3240
atatgatgga gggaaatctgg caagaagttt tagaagaatt ggagaagaaa acagcaatat 3300
40 ttatagattg ggtcccagga cataaaggta ttccaggaaa tgaggaagta gataagcttt 3360
gtcaaacaat gatgataata gaaggggatg ggatattaga caaaagggtca gaagatgcag 3420
gatatgattt attagctgca aaagaaatac atttattgcc aggagaggta aaagtaatac 3480
caacaggggt aaagctaatt ctgcctaaag gacattgggg attaataatc ggaaaaagct 3540
45 cgatggggag taaaggattg gatgtattag gaggagtaat agatgaagga tatcgagggtg 3600
aaattggagt aataatgatt aatgtatcaa gaaaatcaat caccttaatg gaacgacaaa 3660
agatagcaca attaataata ctgccttgta aacatgaagt attagaacaa ggaaaagtag 3720
taagggattc agagagagga ggcaatgggt atgggtcaac aggagtattc tcctcttggg 3780
ttgacagaat tgaggaagca gaaataaatc atgaaaaatt tcaactcagat ccacagtact 3840
50 taaggactga atttaattta cctaaaatgg tagcagaaga gataagacga aaatgcccg 3900
tatgcagaat cagaggagaa caagtgggag gacaattgaa aatagggcct ggtatctggc 3960
aaatggattg cacacacttt gatggcaaaa taattcttgt gggatatacat gtggaatcag 4020
gatatatatg ggcacaaaata atttctcaag aaactgctga ctgtacagtt aaagctgttt 4080
55 tacaattggt gagtgctcat aatgttactg aattacaaac agataatgga ccaaatttta 4140

EP 0 956 360 B1

```

aaaatcaaaa gatggaagga gtactcaatt acatgggtgt gaaacataag tttgggtatcc 4200
caggggaaccc acagtcacaa gcattagttg aaaatgtaaa tcatacatta aaagtttggg 4260
ttcggaaatt tttgcctgaa acaacctcct tggataatgc cttatctctc gctgtacata 4320
5 gtctcaattt taaaagaaga ggtaggatag gagggatggc cccttatgaa ttattagcac 4380
aacaagaatc cttaagaata caagattatt tttctgcaat accacaaaaa ttgcaagcac 4440
agtggattta ttataaagat caaaaagata agaaatggaa aggaccaatg agagtagaat 4500
actggggaca gggatcagta ttattaaagg atgaagagaa gggatatttt cttataccta 4560
10 ggagacacat aaggagagtt ccagaaccct gcgctcttcc tgaaggggat gagtga 4616

```

<210> 3

<211> 1615

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ALVAC-nucleotide sequence comprised in the C6 donor plasmid pC6L.

<400> 3

```

gagctcgcgg ccgcctatca aaagtcttaa tgagttaggt gtagatagta tagatattac 60
tacaaaggta ttcataatttc ctatcaattc taaagtagat gatattaata actcaaagat 120
25 gatgatagta gataatagat acgctcatat aatgactgca aatttggacg gttcacattt 180
taatcatcac gcgttcataa gtttcaactg catagatcaa aatctcacta aaaagatagc 240
cgatgtattt gagagagatt ggacatctaa ctacgctaaa gaaattacag ttataaataa 300
tacataatgg attttgttat catcagttat atttaacata agtacaataa aaagtattaa 360
30 ataaaaatac ttacttacga aaaaatgact aattagctat aaaaaccggg gctgcagctc 420
gaggaattct ttttattgat taactagtca aatgagtata tataattgaa aaagtaaaat 480
ataaatcata taataatgaa acgaaatata agtaatagac aggaactggc agattcttct 540
tctaataaag taagtactgc taaatctcca aaattagata aaaatgatac agcaaataca 600
gcttcattca acgaattacc ttttaatttt ttcagacaca cttattaca aactaactaa 660
35 gtcagatgat gagaaagtaa atataaattt aacttatggg tataatataa taaagattca 720
tgatattaat aatttactta acgatgttaa tagacttatt ccatcaaccc cttcaaacct 780
ttctggatat tataaaatac cagttaatga tattaaaata gattgtttta gagatgtaaa 840
taattatttg gaggtaaagg atataaaatt agtctatctt tcacatggaa atgaattacc 900
40 taatattaat aattatgata ggaatttttt aggattttaca gctgttatat gtatcaacaa 960
tacaggcaga tctatggtta tggtaaaaca ctgtaacggg aagcagcatt ctatggtaac 1020
tggcctatgt ttaatagcca gatcatttta ctctataaac attttaccac aaataatagg 1080
atcctctaga tatttaatat tatatctaac aacaacaaaa aaatttaacg atgtatggcc 1140
45 agaagtattt tctactaata aagataaaga tagtctatct tatctacaag atatgaaaga 1200
agataatcat ttagtagtag ctactaatat ggaaagaaat gtatacaaaa acgtggaagc 1260
ttttatatta aatagcatat tactagaaga tttaaaatct agacttagta taacaaaaca 1320
gttaaatgcc aatatcgatt ctatatttca tcataacagt agtacattaa tcagtgatat 1380
actgaaacga tctacagact caactatgca aggaataagc aatatgccaa ttatgtctaa 1440
50 tattttaact ttagaactaa aacgttctac caatactaaa aataggatac gtgataggct 1500
gttaaaagct gcaataaata gtaaggatgt agaagaaata ctttgttcta taccttcgga 1560
ggaaagaact ttagaacaac ttaagtttaa tcaaacttgt atttatgaag gtacc 1615

```

<210> 4

<211> 2879

<212> DNA
 <213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence: predicted nucleotide sequence of vaccinia virus H6 promoter and FIV env in an expression cassette.

<400> 4

```

10 ttaaataaaa atacttactt acgaaaaatg actaattagc tataaaaaacc cgggttcttt 60
   attctatact taaaaagtga aaataaatac aaaggttctt gagggttgtg ttaaattgaa 120
   agcgagaaat aatcataaat tatttcatta tcgcgatatc cgттаagtтт gtatcgtaat 180
   ggcagaagga tttgcagcca atagacaatg gataggacca gaagaagctg aagagttatt 240
15 agattttgat atagcaacac aaatgagtga agaaggacca ctaaатccag gagtaaaccс 300
   atttagggta cctggaataa cagaaaaaga aaagcaaaac tactgtaaca tattacaacc 360
   taagtтacaa gatctaagga acgaaattca agaggtaaaa ctggaagaag gaaatgcagg 420
   taagtttaga agagcaagat ttttaaggta ttctgatgaa caagtattgt ccctggttca 480
20 tgcgttcata ggatattgta tatatttagg таатсгааат ааgttaggat ctтtaagaca 540
   tgacattgat atagaagcac cccaagaaga gtgttataat аatagagaga aggttacaac 600
   tgacaatata aaatatggta gacgatgttg cctaggaacg gtgactttgt acctgatttt 660
   atttatagga ttaataatat attcacagac aaccaacgct caggtagtat ggagacttcc 720
   accattagta gtcccagtag aagaatcaga aataattttt tgggactgtt gggcaccaga 780
25 agaаcccgcc tgtcaggact ttcttggggc аatgatacat ctaaaagcta agacaaatat 840
   aagtatacga gagggaccta ccttggggaa ttggactaga gaaatatggg caacattatt 900
   caaaaaggct actagacaat gtagaagagg cagaatatgg aaaagatgga atgagactat 960
   aacaggacca tcaggatgtg ctaataacac atgttataat gtttcagtaa tagtacctga 1020
30 ttatcagtgt tatttagata gagtagatac ttggttacaa gggaaaataa atatatcatt 1080
   atgtctaaca ggaggaaaaa tgttgtacaa taaagttaca aaacaattaa gctattgtac 1140
   agaccatta caaatccac tgatcaatta tacatttggg cctaатcaaa catgtatgtg 1200
   gaatacttca caaattcagg accctgaaat accaaaatgt ggatggтgga atcaaatggc 1260
   ctattataac agttgtaaat gggaaagggc aaaggtaaag ttтcattgtc aaagaacaca 1320
35 gagtcagcct ggatcatggc gtagagcaat ctcgтcatgg aaacaaagaa atagatggga 1380
   gtggagacca gatttggaaa gtaaaaaggт gaaaатatct ctacagtgca atagcacaaa 1440
   aaacctaacc tttgcaatga gaagttcagg agattatgga gaagtaacgg gagcttggat 1500
   agagtttгga tgtcatagaa ataaатcaaa acatcattct gaagcaaggт ttagaattag 1560
40 atgtagatgg аatgtaggat ccgatacctc gtcattgat acatgtggaa аactcgaga 1620
   tgtttcaggт gcgaatcctg tagattgtac catgtattca aataaaatgt аcaattgttc 1680
   tttaaaaaat gggtttacta tgaaggtaga tgaccttatt gtgcatttca atatgacaaa 1740
   agctgtagaa atgtataata ttgctggaaa ttggтcttgt acatctgact tgccatcgtc 1800
45 atgggggtat atgaattgta attgtacaaa tagtagtagt agttatagtг gtactaaaat 1860
   ggcатgtcct agcaatcgag gcатcttaag gaattggтat aaccцagtag caggattacg 1920
   аcaатcctta gaacagtatc aagttgtaaa аcaaccagat tacttagtgg тccцagagga 1980
   agтcatggaa tataaaccta gaaggaaaag ggcagctatt catgttatgt tggctcttgc 2040
50 aacagtatta tctattgtcg gtgcaggгac gggggctact gctataggga tggtaaacca 2100
   ataccaccaа gttctggcaa cccatcaaga agctatagaa aaggтgactg aagccttaaa 2160
   gataaacaac ttaagattag ttacattaga gcатcaagta ctagtaatag gattaaaagt 2220

```

EP 0 956 360 B1

```

agaagctatg gaaaaattct tatatacagc tttcgctatg caagaattag gatgtaatca 2280
aatcaattc ttctgcaaaa tccctcctgg gttgtggaca aggtataata tgactataaa 2340
tcaaacaata tggatcatg gaaatataac tttgggggaa tggataaacc aaacaaaaga 2400
5 tttacaacaa aagttttatg aaataataat ggacatagaa caaataatg tacaagggaa 2460
aacagggata caacaattac aaaagtggga agattgggta ggatggatgg gaaatattcc 2520
acaatattta aagggactat tgggaggtat cttgggaata ggattaggag tgttattatt 2580
gattttatgt ttacctacat tggttgattg tataagaaat tgtatccaca agatactagg 2640
10 atacacagta attgcaatgc ctgaagtaga aggagaagaa atacaaccac aaatggaatt 2700
gaggagaaat ggtaggcaat gtggcatgtc tgaaaaagag gaggaatgat gaagtatctc 2760
agaattcctg cagcccgggg gatccttaat taattagtta ttagacaagg tgaaacgaa 2820
actatttgta gcttaattaa ttagctgcag gaattctttt tattgattaa ctagtcaaa 2879

```

<210> 5

<211> 2032

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: predicted nucleotide sequence of vaccinia virus I3L promoter and FIV gag/protease in an expression cassette.

<400> 5

```

ttaatcaata aaaagaattc ctgcagccct gcagctaatt aattaagcta caaatagttt 60
cgttttcacc ttgtctaata actaattaat taaggatccc ccgtaccggg cccccctcg 120
30 aggtcgacat cgatacatca tgcagtgggt aaacaaaaac atttttattc tcaaatgaga 180
taaagtgaat atatatatca ttatattaca aagtacaatt atttaggttt aatcatgggg 240
aatggacagg ggcgagattg gaaaatggcc attaagagat gtagtaatgt tgctgtagga 300
gtagggggga agagtaaaaa atttgagaga ggggaatttc gatgggcat tagaatggct 360
aatgtatcta caggacgaga acctggtgat ataccagaga ctttagatca actaagggtg 420
35 gttatttgcg atttacaaga aagaagagaa aaatttggat ctagcaaaga aattgatatg 480
gcaattgtga cattaaaagt ctttgcggtg gcaggacttt tgaatatgac ggtgtctact 540
gctgctgcag ctgaaaatat gtattctcaa atgggattag acactaggcc atctatgaaa 600
gaagcaggtg gaaaagagga aggcctcca caggcatatc ctattcaaac agtaaagga 660
40 gtaccacaat atgtagcact tgacccaaaa atgggtgtcca ttttcatgga aaaggcaaga 720
gaaggactag gaggggagga agttcaacta tggtttactg ctttctctgc aaatttaaca 780
cctactgaca tggccacatt aataatggcc gcaccagggt gcgctgcaga taaagaaata 840
ttggatgaaa gcttaaagca actgacagca gaatatgatc gcacacatcc ccctgatgct 900
45 cccagaccat taccctatct tactgcagca gaaattatgg gtataggatt aactcaagaa 960
caacaagcag aagcaagatt tgcaccagct aggatgcagt gtagagcatg gtatctcgag 1020
gcattaggaa aattggctgc cataaaagct aagtctcttc gagctgtgca gttaagacaa 1080
ggagctaagg aagattattc atcctttata gacagattgt ttgcccaaat agatcaagaa 1140
caaaatacag ctgaagttaa gttatattta aaacagtcac taagcatagc taatgctaata 1200
50 gcagactgta aaaaggcaat gagccacctt aagccagaaa gtaccctaga agaaaagttg 1260
agagcttgct aagaaatagg ctaccagga tataaaatgc aactcttgge agaagctctt 1320
acaaaagttc aagtagtgca atcaaaagga tcaggaccag tgtgttttaa ttgtaaaaaa 1380
ccaggacatc tagcaagaca atgtagagaa gtgaaaaaat gtaataaatg tggaaaacct 1440
55 ggtcatctag ctgccaaatg ttggcaagga aatagaaaga attcgggaaa ctggaaggcg 1500

```

```

    gggcgagctg cagccccagt gaatcaaagt cagcaagcag taatgccatc tgcacctcca 1560
    atggaggaga aactattgga ttataaatt ataataaagt aggtacgact acaacattag 1620
    aaaagaggcc agaaatactt atatttgtaa atggatatcc tataaaattt ttattagata 1680
5   caggagcaga tataacaatt ttaaatagga gagattttca agtaaaaaat tctatagaaa 1740
    atggaaggca aaatatgatt ggagtaggag gaggaagag aggaacaaat tatattaatg 1800
    tacatttaga gattagagat gaaaattata agacacaatg tatatttggt aatgtttgtg 1860
    tcttagaaga taactcatta atacaacat tattggggag agataaatg attaaattca 1920
10  atattagggt agtaatggct caataatttt atcccgggt tttatagcta attagtcatt 1980
    tttcgtaagt aagtattttt atttaatact ttttattgta cttatgttaa at 2032

```

<210> 6

15 <211> 4727

<212> DNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: predicted nucleotide sequence of vaccinia virus H6 promoter and FIV env, and vaccinia virus I3L promoter and FIV gag/protease in an expression cassette.

<400> 6

```

25  ttaatcaata aaaagaattc ctgcagccct gcagctaatt aattaagcta caaatagttt 60
    cgttttcacc ttgtctaata actaattaat taaggatccc ccgtaccggg cccccctcg 120
    aggtcgactt ctttattcta tacttaaaaa gtgaaaataa atacaaagggt tcttgagggt 180
30  tgtgttaaat tgaaagcgag aaataatcat aaattatttc attatcgga tatccgttaa 240
    gtttgtatcg taatggcaga aggatttgca gccaatagac aatggatagg accagaagaa 300
    gctgaagagt tattagattt tgatatagca acacaaatga gtgaagaagg accactaaat 360
    ccaggagtaa acccathtag ggtacctgga ataacagaaa aagaaaagca aaactactgt 420
    aacatattac aacctaaagt acaagatcta aggaacgaaa ttcaagagggt aaaactggaa 480
35  gaaggaaatg caggtaagtt tagaagagca agatttttaa ggtattctga tgaacaagta 540
    ttgtccctgg ttcatgcgtt cataggatat tgtatatatt taggtaatcg aaataagtta 600
    ggatctttta gacatgacat tgatatagaa gcacccaag aagagtgtta taataataga 660
    gagaagggta caactgacaa tataaaatat ggtagacgat gttgcctagg aacggtgact 720
    ttgtacctga ttttatttat aggattaata atatattcac agacaacca cgctcaggta 780
40  gtatggagac ttccaccatt agtagtcca gtagaagaat cagaaataat tttttgggac 840
    tgttgggcac cagaagaacc cgcctgtcag gactttcttg gggcaatgat acatctaaaa 900
    gctaagacaa atataagtat acgagaggga cctaccttgg ggaattggac tagagaaata 960
    tgggcaacat tattcaaaaa ggctactaga caatgtagaa gaggcagaat atggaaaaga 1020
45  tggaatgaga ctataacagg accatcagga tgtgctaata acacatgtta taatgtttca 1080
    gtaatagtac ctgattatca gtgttattta gatagagtag atacttggtt acaagggaaa 1140
    ataaatatat cattatgtct aacaggagga aaaatgttgt acaataaagt taaaaacaa 1200
    ttaagctatt gtacagaccc attacaaatc ccactgatca attatacatt tggacctaat 1260
50  caaacatgta tgtggaatac ttcacaaatt caggacctg aaataccaaa atgtggatgg 1320
    tggaatcaaa tggcctatta taacagttgt aaatgggaag aggcaaagggt aaagtttcat 1380
    tgtcaaagaa cacagagtca gcctggatca tggcgtagag caatctcgtc atggaaacaa 1440
    agaaatagat gggagtggag accagatttg gaaagtaaaa aggtgaaaat atctctacag 1500
    tgcaatagca caaaaaacct aacctttgca atgagaagtt caggagatta tggagaagta 1560

```

55

acgggagctt ggatagagtt tggatgtcat agaaataaat caaaacatca ttctgaagca 1620
 aggttttagaa ttagatgtag atggaatgta ggatccgata cctcgctcat tgatacatgt 1680
 ggaaacactc gagatgtttc aggtgccaat cctgtagatt gtaccatgta ttcaaataaa 1740
 5 atgtacaatt gttctttaca aaatgggttt actatgaagg tagatgacct tattgtgcat 1800
 ttcaatatga caaaagctgt agaaatgtat aatattgctg gaaattgggtc ttgtacatct 1860
 gacttgccat cgtcatgggg gtatatgaat tgtaattgta caaatagtag tagtagttat 1920
 agtggacta aaatggcatg tcctagcaat cgaggcatct taaggaattg gtataaccca 1980
 10 gtagcaggat tacgacaatc cttagaacag tatcaagttg taaaacaacc agattactta 2040
 gtggtcccag aggaagtcac ggaatataaa cctagaagga aaagggcagc tattcatgtt 2100
 atgttggtc ttgcaacagt attatctatt gtcggtgcag ggacgggggc tactgctata 2160
 gggatggtaa cccaatacca ccaagttctg gcaaccatc aagaagctat agaaaagggtg 2220
 actgaagcct taaagataaa caacttaaga ttagttacat tagagcatca agtactagta 2280
 15 ataggattaa aagtagaagc tatggaaaaa ttcttatata cagctttcgc tatgcaagaa 2340
 ttaggatgta atcaaaatca attcttctgc aaaatccctc ctgggttggtg gacaagggtat 2400
 aatatgacta taaatcaaac aatatggaat catggaaata taactttggg ggaatgggtat 2460
 aaccaaacaa aagattttaca acaaaagttt tatgaaataa taatggacat agaacaaaat 2520
 20 aatgtacaag ggaaaacagg gatacaacaa ttacaaaagt gggaagattg ggtaggatgg 2580
 atgggaaata ttccacaata tttaaaggga ctattgggag gtatcttggg aataggatta 2640
 ggagtgttat tattgatttt atgtttacct acattgggtg attgtataag aaattgtatc 2700
 cacaagatac taggatacac agtaattgca atgcctgaag tagaaggaga agaaatacaa 2760
 25 ccacaaatgg aattgaggag aaatggtagg caatgtggca tgtctgaaaa agaggaggaa 2820
 tgaatcgata catcatgcag tggttaaaca aaaacatttt tattctcaaa tgagataaag 2880
 tgaaaatata tatcattata ttacaaagta caattattta ggtttaatca tggggaatgg 2940
 acaggggcga gattggaaaa tggccattaa gagatgtagt aatgttgctg taggagtagg 3000
 ggggaagagt aaaaaatttg gagaaggga tttcagatgg gccattagaa tggctaattg 3060
 30 atctacagga cgagaacctg gtgatatacc agagacttta gatcaactaa ggttggttat 3120
 ttgcgattta caagaaagaa gagaaaaatt tggatctagc aaagaaattg atatggcaat 3180
 tgtgacatta aaagtctttg cggtagcagg acttttgaat atgacggtgt ctactgctgc 3240
 tgcagctgaa aatatgtatt ctcaaattggg attagacact aggccatcta tgaaagaagc 3300
 35 aggtggaaaa gaggaaggcc ctccacaggc ataccctatt caaacagtaa atggagtacc 3360
 acaatatgta gcacttgacc caaaaatggg gtccattttc atggaaaagg caagagaagg 3420
 actaggaggg gaggaagttc aactatggtt tactgccttc tctgcaaat taacacctac 3480
 tgacatggcc acattaataa tggccgcacc aggtgcgct gcagataaag aaatattgga 3540
 tgaaagctta aagcaactga cagcagaata tgatgcgaca catccccctg atgctcccag 3600
 40 accattacc tattttactg cagcagaaat tatgggtata ggattaactc aagaacaaca 3660
 agcagaagca agatttgac cagctaggat gcagtgtaga gcatgggtatc tcgaggcatt 3720
 aggaaaattg gctgccataa aagctaagtc tcctcgagct gtgcagttaa gacaaggagc 3780
 taaggaagat tattcatcct ttatagacag attgtttgcc caaatagatc aagaacaaaa 3840
 45 tacagctgaa gttaagttat atttaaaaaca gtcattaagc atagctaattg ctaatgcaga 3900
 ctgtaaaaag gcaatgagcc accttaagcc agaaagtacc ctagaagaaa agttgagagc 3960
 ttgtcaagaa ataggctcac caggatataa aatgcaactc ttggcagaag ctcttacaaa 4020
 agttcaagta gtgcaatcaa aaggatcagg accagtgtgt tttaattgta aaaaaccagg 4080
 acatctagca agacaatgta gagaagtga aaaatgtaat aaatgtggaa aacctgggtca 4140
 50 tctagctgcc aaatgttggc aaggaaatag aaagaattcg ggaaactgga aggcggggcg 4200
 agctgcagcc ccagtgaatc aaatgcagca agcagtaattg ccatctgcac ctccaatgga 4260
 ggagaaacta ttggatttat aaattataat aaagtaggta cgactacaac attagaaaag 4320
 aggccagaaa tactttatatt tgtaaatgga tatctataa aatttttatt agatacagga 4380
 55 gcagatataa caattttaaa taggagagat tttcaagtaa aaaattctat agaaaatgga 4440

aggcaaaata tgattggagt aggaggagga aagagaggaa caaattatat taatgtācat 4500
 ttagagatta gagatgaaaa ttataagaca caatgtatat ttggtaatgt ttgtgtctta 4560
 gaagataact cattaatata accattattg gggagagata atatgattaa attcaatatt 4620
 5 aggttagtaa tggctcaata attttatccc gggtttttat agctaattag tcatttttctg 4680
 taagtaagta tttttattta atacttttta ttgtacttat gttaaāt 4727

<210> 7

10 <211> 4150

<212> DNA

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: predicted nucleotide sequence of vaccinia virus H6 promoter and altered FIV env, and vaccinia virus I3L promoter and FIV gag/pol in an expression cassette.

<400> 7

20

ttaatcaata aaaagaattc ctgcaggaat tcataaaaat cattcttctc cttctacttc 60
 aggcatgca attactgtgt atcctagtat cttgtggata caatttctta tacaatcaac 120
 caatgtaggt aacataaaa tcaataataa cactcctaāt cctattccca agatacctcc 180
 25 caatagtccc cttttccttc taggtttata ttccatgact tcctctggga ccactaagta 240
 atctggttgt tttaacaactt gatactgttc taaggattgt cgtaatcctg ctactgggtt 300
 ataccaattc cttaagatgc ctcgattgct aggacatgcc atttttagtac cactataact 360
 actactacta tttgtacaat tacaattcat ataccccat gacgatggca agtcagatgt 420
 acaagaccaa tttccagcaa tattatacat ttctacagct tttgtcatat tgaaatgcac 480
 30 aataaggcca tctaccttca tagtaaacc attttgtaaa gaacaattgt acattttatt 540
 tgaatacatg gtacaatcta caggattcgc acctgaaaca tctcgagtgt ttccacatgt 600
 atcaatgagc gaggtatcgg atcctacatt ccatctacat ctaattctaa accttgcttc 660
 agaatgatgt tttgatttat ttctatgaca tccaaactct atccaagctc ccgttacttc 720
 35 tccataatct cctgaacttc tcattgcaaa ggtaggttt tttgtgctat tgcactgtag 780
 agatattttc acctttttac tttccaaatc tggctctccac tcccatctat ttctttgttt 840
 ccatgacgag attgctctac gccatgatcc aggctgactc tgtgttcttt gacaatgaaa 900
 ctttaccttt gcctcttccc atttacaact gttataatag gccatttgat tccaccatcc 960
 acatttttgt atttcagggt cctgaatttg tgaagtattc cacatacatg tttgattagg 1020
 40 tccaaatgta taattgatca gtgggatttg taatgggtct gtacaatagc ttaattgttt 1080
 tgtaacttta ttgtacaaca tttttcctcc tgtagacat aatgatatat ttattttccc 1140
 ttgtaaccaa gtatctactc tatctaaata acactgataa tcagggtacta ttactgaaac 1200
 attataacat gtgttattag cacatcctga tggctcctgt atagtctcat tccatctttt 1260
 45 ccatattctg cctcttctac attgtctagt agcctttttg aataatgttg cccatatttc 1320
 tctagtccaa ttccccaagg taggtccctc tcgtatactt atatttgtct tagcttttag 1380
 atgtatcatt gccccaagaa agtcttgaca ggcgggttct tctgggtgcc aacagtcca 1440
 aaaaattatt tctgattctt ctactgggac tactaatggg ggaagtctcc atactacctg 1500
 50 agcgttggtt gtctgtgaat atattattaa tcctataaat aaaatcaggt acaagtcac 1560
 cgttcctagg caacatcgtc taccatattt tatattgtca gttgtaccct tctctctatt 1620
 attataacac tcttcttggg gtgcttctat atcaatgtca tgtcttaaag atcctaactt 1680
 atttcgatta ctaaatata tacaatatcc tatgaacgca tgaaccagg acaatacttg 1740

55

```

ttcatcagaa taccttaaaa atcttgctct tctaaactta cctgcatttc cttcttccag 1800
ttttacctct tgaatttcgt tccttagatc ttgtaactta ggttgtaata tgttacagta 1860
gttttgcttt tctttttctg ttattccagg taccctaaat gggtttactc ctggatttag 1920
5  tggtccttct tcactcattt gtgttgctat atcaaaatct aataactctt cagcttcttc 1980
tggtcctatc cattgtctat tggctgcaaa tccttctgcc attacgatac aaacttaacg 2040
gatatcgcga taatgaaata atttatgatt atttctcgct ttcaatttaa cacaaccctc 2100
aagaaccttt gtatttattt tcacttttta agtatagaat aaagaactgc agctaattaa 2160
10 ttaagctaca aatagtttcg ttttcacctt gtctaataac taattaatta aggatcccc 2220
gtaccggggc cccctcgcag gtcgacatcg atacatcatg cagtgggttaa acaaaaaacat 2280
ttttattctc aaatgagata aagtgaatat atatatcatt atattacaaa gtacaattat 2340
ttaggtttta tcatggggaa tggacagggg cgagattgga aaatggccat taagagatgt 2400
15 agtaatgttg ctgtaggagt agggggggaag agtaaaaaat ttggagaagg gaatttcaga 2460
tgggccatta gaatggctaa tgtatctaca ggacgagaac ctggtgatat accagagact 2520
ttagatcaac taagggttgt tatttgcatg ttacaagaaa gaagagaaaa atttggatct 2580
agcaagaaa ttgatatggc aattgtgaca ttaaagtctt ttgcggtagc aggacttttg 2640
aatatgacgg tgtctactgc tgctgcagct gaaaatatgt attctcaaat gggattagac 2700
20 actaggccat ctatgaaaga agcaggtgga aaagaggaag gccctccaca ggcatatcct 2760
attcaaacag taaatggagt accacaatat gtagcacttg acccaaaaat ggtgtccatt 2820
ttcatggaaa aggcaagaga aggactagga ggggaggaag ttcaactatg gtttactgcc 2880
ttctctgcaa atttaacacc tactgacatg gccacattaa taatggccgc accaggggtg 2940
25 gctgcagata aagaaatatt ggatgaaagc ttaaagcaac tgacagcaga atatgatcgc 3000
acacatcccc ctgatgctcc cagaccatta ccctatttta ctgcagcaga aattatgggt 3060
ataggattaa ctcaagaaca acaagcagaa gcaagatttg caccagctag gatgcagtgt 3120
agagcatggt atctcgaggc attaggaaaa ttggctgcca taaaagctaa gtctcctcga 3180
gctgtgcagt taagacaagg agctaaggaa gattattcat cttttataga cagattgttt 3240
30 gccaaatag atcaagaaca aaatacagct gaagttaagt tatattttaa acagtcatta 3300
agcatagcta atgctaatgc agactgtaaa aaggcaatga gccaccttaa gccagaaagt 3360
accctagaag aaaagttgag agcttgtcaa gaaataggct caccaggata taaaatgcaa 3420
ctcttggcag aagctcttac aaaagttcaa gtagtgcaat caaaaggatc aggaccagtg 3480
35 tgttttaatt gtaaaaaacc aggacatcta gcaagacaat gtagagaagt gaaaaaatgt 3540
aataaatgtg gaaaacctgg tcatctagct gccaaatgtt ggcaaggaaa tagaaagaat 3600
tcgggaaact ggaaggcggg gcgagctgca gcccagtgat atcaaatgca gcaagcagta 3660
atgccatctg cacctccaat ggaggagaaa ctattggatt tataaattat aataaagtag 3720
40 gtacgactac aacattagaa aagaggccag aaatacttat atttgtaaat ggatatccta 3780
taaaattttt attagataga ggagcagata taacaatttt aaataggaga gattttcaag 3840
taaaaaattc tatagaaaat ggaaggcaaa atatgattgg agtaggagga ggaaagagag 3900
gaacaaatta tattaatgta catttagaga ttagagatga aaattataag acacaatgta 3960
45 tatttggtta tgtttgtgtc ttagaagata actcattaat acaaccatta ttggggagag 4020
ataatatgat taaattcaat attagggttag taatggctca ataattttat cccgggtttt 4080
tatagctaat tagtcatttt tcgtaagtaa gtatttttat ttaatacttt ttattgtact 4140
tatgttaaat 4150

```

<210> 8

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> sequence not described in specification

<220>

<223> Description of Artificial Sequence: PCR primer used in a reaction with pMAW103 template, for construction of FIV expression plasmid pMAW103A.

5 <400> 8
atcatcaagc ttctgcagtt cttattcta tactta 36

<210> 9

<211> 79

10 <212> DNA

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of FIV env in a reaction with ptg6184 template.

<400> 9

aaattcttat atacagcttt cgctatgcaa gaattaggat gtaatcaaaa tcaattcttc 60 tgcaaaatcc ctctgggt 79

20 <210> 10

<211> 18

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of FIV env in a reaction with ptg6184 template.

<400> 10

30 cccatcgagt gcggctac 18

<210> 11

<211> 75

<212> DNA

35 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of FIV env.

40 <400> 11

gcagaagaat tgattttgat tacatcctaa ttctgcata gcgaaagctg tatataagaa 60
ttttccata gcttc 75

<210> 12

45 <211> 18

<212> DNA

<213> Artificial Sequence

<220>

50 <223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of FIV env.

<400> 12

aagttctggc aacccatc 18

55 <210> 13

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used to amplify the vaccinia virus H6 promoter and the 5' part of FIV env in a reaction with pMM108 template.

5 <400> 13
atcatcctgc agaagcttcc cgggttcttt attctatact t 41

<210> 14

<211> 36

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used to amplify the vaccinia virus H6 promoter and the 5' part of FIV env in a reaction with pMM108 template.

15 <400> 14
ctgcaaattcc ttctgccatt acgatacaaa cttaac 36

<210> 15

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used to amplify the 3' part of the vaccinia virus H6 promoter and the 5' part of FIV env in a reaction with pMM122 template.

25 <400> 15
30 cgtaaattt gtatcgtaat ggcagaagga ttgcagcc 39

<210> 16

<211> 18

<212> DNA

35 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used to amplify the 3' part of the vaccinia virus H6 promoter and the 5' part of FIV env in a reaction with pMM122 template.

40 <400> 16
cctcttgaat ttcgttcc 18

<210> 17

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used in a reaction with ALVAC template, for construction of insertion plasmid pC6L.

50 <400> 17
55 atcatcgagc tcgcggccgc ctatcaaaag tottaatgag tt 42

<210> 18

<211> 73

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used in a reaction with ALVAC template, for construction of insertion plasmid pC6L.

<400> 18

gaattcctcg agctgcagcc cgggtttta tagctaatta gtcattttt cgtaagtaag 60
tatttttatt taa 73

<210> 19

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used in a reaction with ALVAC template, for construction of insertion plasmid pC6L.

<400> 19

cccgggctgc agctcgagga attctttta ttgattaact agtcaaatga gtatatataa 60 ttgaaaaagt aa 72

<210> 20

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer used in a reaction with ALVAC template, for construction of insertion plasmid pC6L.

<400> 20

gatgatggta ccttcataaa tacaagttg attaaactta agttg 45

<210> 21

<211> 80

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence added to insertion plasmid pC6L in construction of pMM117.

<400> 21

gggggacatcct taattaatta gttagtagac aagggtgaaaa cgaaactatt ttagcttaa 60 ttaattagct gcaggaattc 80

<210> 22

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 5' PCR primer used to amplify the central part of FIV gag in a reaction with ptg8133 template.

<400> 22

caaaaatggt gtccatttc atggaaaagg caagagaagg ac 42

<210> 23

<211> 18
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <223> Description of Artificial Sequence: 3' PCR primer used to amplify the central part of FIV gag in a reaction with ptg8133 template.

10 <400> 23
 ctgctgcagt aaaatagg 18

<210> 24
 <211> 43
 <212> DNA
 15 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of the vaccinia virus I3L promoter and the 5' part of FIV gag in a reaction with ptg8133 template.

20 <400> 24
 cttctctgc ctttccatg aaaatggaca ccattttgg gtc 43

25 <210> 25
 <211> 38
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of the vaccinia virus I3L promoter and the 5' part of FIV gag in a reaction with ptg8133 template.

35 <400> 25
 caattatta ggttaatca tggggaatgg acaggggc 38

<210> 26
 <211> 42
 <212> DNA
 40 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of the vaccinia virus I3L promoter and the 5' part of FIV gag in a reaction with pMM100 template.

45 <400> 26
 cgcccctgtc cattcccat gattaaacct aaataattgt ac 42

50 <210> 27
 <211> 38
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of the vaccinia virus I3L promoter and the 5' part of FIV gag in a reaction with pMM100 template.

<400> 27
 atcatcgtcg acatcgatac atcatgcagt ggtaaac 38

<210> 28
<211> 18
<212> DNA
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence: 5' PCR primer used to amplify FIV protease in a reaction with pMM121 template.

10

<400> 28
caggacatct agcaagac 18

<210> 29
<211> 40

15

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 3' PCR primer used to amplify FIV protease in a reaction with pMM121 template.

20

<400> 29
gatgatcccg ggataaaaat tattgagcca ttactaacct 40

25

<210> 30
<211> 18
<212> DNA
<213> Artificial Sequence

30

<220>
<223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of FIV env in a reaction with pMM125#10 template.

35

<400> 30
tatgaattgt aattgtac 18

<210> 31
<211> 54
<212> DNA
<213> Artificial Sequence

40

<220>
<223> Description of Artificial Sequence: 3' PCR primer used to amplify the 3' part of FIV env in a reaction with pMM125#10 template.

45

<400> 31
gtagcataag gttaccgcgg ccgctaagct taggttacca tccctatagc agta 54

50

<210> 32
<211> 59
<212> DNA
<213> Artificial Sequence

55

<220>
<223> Description of Artificial Sequence: 5' PCR primer used to amplify the 3' part of FIV env in a reaction with pMM125#10 template.

<400> 32

<400> 37

atcatcgaat tcataaaaat cattctcttc ctctacttc 40

5 **Claims**

1. A vector comprising exogenous DNA encoding at least one FIV epitope, **characterized in that** the vector is a canarypox virus.
- 10 2. The vector of claim 1 **characterized in that** the canarypox virus is the ALVAC strain, or is a Rentschler vaccine strain obtained by (a) attenuation of a Rentschler vaccine strain through more than 200 serial passages on chick embryo fibroblasts, (b) subjecting a master seed therefrom to four successive plaque purifications under agar, and (c) amplifying a plaque clone through five additional passages.
- 15 3. The vector of any one of claims 1 to 2 **characterized in that** the DNA that encodes at least one FIV epitope encodes all or part of (a) Gag-Pol, (b) Gag-protease, (c) Env, Gag-Pol, or (d) Env, Gag-protease.
4. The vector of any one of claims 1 to 2 **characterized in that** the DNA that encodes at least one FIV epitope encodes all or part of Gag-Pol or Gag-protease.
- 20 5. The vector of any one of claims 1 to 2 **characterized in that** the DNA that encodes at least one FIV epitope encodes all or part of Env, Gag-Pol, or Env, Gag-protease.
- 25 6. The vector of claim 1 which is vCP242, vCP253, vCP255, or vCP329, said vector comprising exogenous DNA encoding at least one FIV epitope, wherein vCP242, vCP253, vCP255, or vCP329 are recombinants of the ALVAC strain, wherein vCP242 comprises DNA encoding Env, vCP253 comprises DNA encoding Gag-protease, vCP255 comprises DNA encoding Env, Gag-protease and wherein vCP329 comprises DNA encoding 97TM, Gag-protease.
- 30 7. The use of a vector as claimed in any one of claims 1 to 4 in admixture with a suitable carrier for the preparation of an antigenic, immunological or vaccine composition for inducing an antigenic or immunological or protective response in a feline animal.
8. The use of a vector as claimed in claim 5 or 6 in admixture with a suitable carrier for the preparation of an antigenic, immunological or vaccine composition for inducing an antigenic or immunological or protective response in a feline animal.
- 35 9. The use of a vector as claimed in any one of claims 1 to 4 for the preparation of a therapeutic composition for the treatment of seropositive feline animals in need of therapy to stimulate or boost the immune system against a homologous or heterologous strain of FIV.
- 40 10. A composition for inducing an immunological response comprises a vector as claimed in any one of claims 1 to 4 in admixture with a suitable carrier.
- 45 11. A composition for inducing an immunological response comprising a vector as claimed in claim 5 in admixture with a suitable carrier.
12. A composition for inducing an immunological response comprising a vector as claimed in claim 6 in admixture with a suitable carrier.
- 50 13. A method for expressing a gene product in a cell cultured in vitro comprising introducing into the cell a vector as claimed in any one of claims 1 to 6.

Patentansprüche

1. Vektor, der exogene DNA umfasst, die für mindestens ein FIV-Epitop kodiert, **dadurch** charakterisiert, dass der Vektor ein Canarypox-Virus ist.

2. Vektor nach Anspruch 1, **dadurch** charakterisiert, dass das Canarypox-Virus der ALVAC-Stamm oder ein Rentschler-Vakzine-Stamm ist, der durch (a) Attenuieren eines Rentschler-Vakzine-Stamms über mehr als 200 serielle Passagen auf Hühnerembryofibroblasten, (b) Unterziehen eines Originalsaatvirus davon gegenüber vier aufeinanderfolgenden Plaque-Aufreinigungen unter Agar und (c) Amplifizieren eines Plaque-Klons über fünf weitere Passagen erhalten wird.
3. Vektor nach einem der Ansprüche 1 bis 2, **dadurch** charakterisiert, dass die DNA, die für mindestens ein FIV-Epitop kodiert, für das gesamte oder einen Teil von (a) Gag-Pol, (b) Gag-Protease, (c) Env, Gag-Pol oder (d) Env, Gag-Protease kodiert.
4. Vektor nach einem der Ansprüche 1 bis 2, **dadurch** charakterisiert, dass die DNA, die für mindestens ein FIV-Epitop kodiert, für das gesamte oder einen Teil von Gag-Pol oder Gag-Protease kodiert.
5. Vektor nach einem der Ansprüche 1 bis 2, **dadurch** charakterisiert, dass die DNA, die für mindestens ein FIV-Epitop kodiert, für das gesamte oder einen Teil von Env, Gag-Pol oder Env, Gag-Protease kodiert.
6. Vektor nach Anspruch 1, der vCP242, vCP253, vCP255 oder vCP329 ist, wobei der Vektor exogene DNA umfasst, die für mindestens ein FIV-Epitop kodiert, wobei vCP242, vCP253, vCP255 oder vCP329 Rekombinanten des ALVAC-Stamms sind, wobei vCP242 DNA umfasst, die für Env kodiert, vCP253 DNA umfasst, die für Gag-Protease kodiert, vCP255 DNA umfasst, die für Env, Gag-Protease kodiert, und vCP329 DNA umfasst, die für 97TM, Gag-Protease kodiert.
7. Verwendung eines Vektors nach einem der Ansprüche 1 bis 4 im Gemisch mit einem geeigneten Träger für die Herstellung einer antigenischen, immunologischen oder Vakzine-Zusammensetzung zum Induzieren einer antigenischen oder immunologischen oder schützenden Reaktion in einem katzenartigen Tier.
8. Verwendung eines Vektors nach Anspruch 5 oder 6 im Gemisch mit einem geeigneten Träger zur Herstellung einer antigenischen, immunologischen oder Vakzine-Zusammensetzung zum Induzieren einer antigenischen oder immunologischen oder schützenden Reaktion in einem katzenartigen Tier.
9. Verwendung eines Vektors nach einem der Ansprüche 1 bis 4 zur Herstellung einer therapeutischen Zusammensetzung für die Behandlung von seropositiven katzenartigen Tieren, die einer Therapie bedürfen, um das Immunsystem gegenüber einem homologen oder heterologen Stamm von FIV zu stimulieren oder zu verstärken.
10. Zusammensetzung zum Induzieren einer immunologischen Reaktion, die einen Vektor nach einem der Ansprüche 1 bis 4 im Gemisch mit einem geeigneten Träger umfasst.
11. Zusammensetzung zum Induzieren einer immunologischen Reaktion, die einen Vektor nach Anspruch 5 im Gemisch mit einem geeigneten Träger umfasst.
12. Zusammensetzung zum Induzieren einer immunologischen Reaktion, die einen Vektor nach Anspruch 6 im Gemisch mit einem geeigneten Träger umfasst.
13. Verfahren zur Expression eines Genprodukts in einer in vitro kultivierten Zelle, das ein Einbringen eines Vektors nach einem der Ansprüche 1 bis 6 in die Zelle umfasst.

Revendications

1. Vecteur comprenant de l'ADN exogène codant au moins un épitope du VIF, **caractérisé en ce que** le vecteur est un virus canarypox.
2. Vecteur selon la revendication 1, **caractérisé en ce que** le virus canarypox est la souche ALVAC, ou est une souche vaccinale de Rentschler obtenue par (a) atténuation d'une souche vaccinale de Rentschler par plus de 200 passages en série sur des fibroblastes d'embryons de poulet, (b) soumission d'une semence initiale ainsi obtenue à quatre purifications successives sur plaque sous gélose et (c) amplification d'un clone de plaque par cinq passages supplémentaires.

3. Vecteur selon l'une quelconque des revendications 1 2 **caractérisé en ce que** l'ADN qui code au moins un épitope du VIF code tout ou partie de (a) Gag-Pol, (b) Gag-protéase, (c) Env, Gag-Pol ou (d) Env, Gag-protéase.
- 5 4. Vecteur selon l'une quelconque des revendications 1 à 2 **caractérisé en ce que** l'ADN qui code au moins un épitope du VIF code tout ou partie de Gag-Pol ou de Gag-protéase.
5. Vecteur selon l'une quelconque des revendications 1 à 2, **caractérisé en ce que** l'ADN qui code au moins l'un des épitopes du VIF code tout ou partie de Env, Gag-Pol ou Env, Gag-protéase.
- 10 6. Vecteur selon la revendication 1 qui est vCP242, vCP253, vCP255 ou vCP329, ledit vecteur contenant de l'ADN exogène codant au moins un épitope du VIF, dans lequel vCP242, vCP253, vCP255 ou vCP329 sont des recombinants de la souche ALVAC, dans lequel vCP242 comprend de l'ADN codant Env, vCP253 comprend de l'ADN codant Gag-protéase, vCP255 comprend de l'ADN codant Env, Gag-protéase et dans lequel vCP329 comprend de l'ADN codant 97TM, Gag-protéase.
- 15 7. Utilisation d'un vecteur selon l'une quelconque des revendications 1 à 4 en mélange avec un véhicule approprié pour la préparation d'une composition antigénique, immunologique ou vaccinale pour provoquer une réponse antigénique ou immunologique ou protectrice chez un animal félin.
- 20 8. Utilisation d'un vecteur selon la revendication 5 ou 6 en mélange avec un véhicule approprié pour la préparation d'une composition antigénique, immunologique ou vaccinale pour provoquer une réponse antigénique ou immunologique ou protectrice chez un félin.
- 25 9. Utilisation d'un vecteur selon l'une quelconque des revendications 1 à 4 pour la préparation d'une composition thérapeutique pour le traitement d'animaux félins séropositifs ayant besoin d'un traitement de stimulation ou de rappel du système immunitaire contre une souche homologue ou hétérologue du VIF.
- 30 10. Composition pour provoquer une réponse immunologique comprenant un vecteur selon l'une quelconque des revendications 1 à 4 en mélange avec un véhicule approprié.
- 35 11. Composition pour provoquer une réponse immunologique comprenant un vecteur selon la revendication 5 en mélange avec un véhicule approprié.
12. Composition pour provoquer une réponse immunologique comprenant un vecteur selon la revendication 6 en mélange avec un véhicule approprié.
- 40 13. Procédé pour exprimer un produit de gène dans une cellule cultivée *in vitro* comprenant l'introduction dans la cellule d'un vecteur selon l'une quelconque des revendications 1 à 6.

40

45

50

55




FIG. 1

FIG. 2 Nucleotide sequence of FIV *env* from Rhone Merieux. The FIV *env* start codon is at position 1 and the stop codon is at position 2569. Plasmid ptg6184, containing the FIV *env* coding sequence, was from Rhone Merieux. The FIV *env* coding sequence in ptg6184 was sequenced and the following differences with the sequence below were observed: position 1218 T is G in ptg6184 changing phe to leu; position 1220 G to A changes gly to glu; and position 2201 C to A change ala to glu.

```

1   ATGGCAGAAGGATTTGCAGCCAATAGACAATGGATAGGACCAGAAGAAGCTGAAGAGTTA
61  TTAGATTTTGATATAGCAACACAAATGAGTGAAGAAGGACCACTAAATCCAGGAGTAAAC
121 CCTTATAGGTACCTGGAATAACAGAAAAAGAAAAGCAAACTACTGTAACATATTACAA
181 CCTAAGTTACAAGATCTAAGGAACGAAATTCAGAGGTAAACTGGAAGAAGGAAATGCA
241 GGTAAGTTTAGAAGAGCAAGATTTTAAAGGTATTCTGATGAACAAGTATTGTCCCTGGTT
301 CATGCGTTATAGGATATTGTATATATTTAGGTAATCGAAATAAGTTAGGATCTTTAAGA
361 CATGACATTGATATAGAAGCACCACAGAAAGAGTGTTATAATAATAGAGAGAAGGGTACA
421 ACTGACAATATAAAATATGGTAGACGATGTTGCCTAGGAACGGTGACTTTGTACCTGATT
481 TTATTTATAGGATTAATAATATATTCACAGACAACCAACGCTCAGGTAGTATGGAGACTT
541 CCACCATTAGTAGTCCAGTAGAAGAAATCAGAAATAATTTTTTGGGACTGTTGGGCACCA
601 GAAGAACCCGCTGTCAGGACTTTCTTGGGGCAATGATACATCTAAAAGCTAAGACAAAT
661 ATAAGTATACGAGAGGGACCTACCTTGGGGCAATTGGACTAGAGAAATATGGGCAACATTA
721 TTCAAAAAGGCTACTAGACAATGTAGAAGAGGCAGAAATATGGAAAAGATGGAATGAGACT
781 ATAAAGGACCATCAGGATGTGCTAATAACACATGTTATAATGTTTCAGTAATAGTACCT
841 GATTATCAGTGTTATTTAGATAGAGTAGATACTTGGTTACAAGGGAAAATAAATATATCA
901 TTATGCTAACAGGAGGAAAAATGTTGTACAATAAAGTTACAAAACAATTAAGCTATTGT
961 ACAGACCCATTACAAATCCCACTGATCAATTATACATTTGGACCTAATCAAAATGTATG
1021 TGGAAATACCTCACAAATTCAGGACCTGAAATACCAAAATGTGGATGGTGGAATCAAATG
-1081 GCCTATTATAACAGTTGTAAATGGGAAGAGGCAAAGGTAAAGTTTCATTGTCAAAGAACA
1141 CAGAGTCAGCCTGGATCATGGCGTAGAGCAATCTCGTCATGGAAACAAAGAAATAGATGG
1201 GAGTGGAGACCAGATTTTGGAAAGTAAAAAGGTGAAAATATCTCTACAGTGCAATAGCACA
1261 AAAAACTTAACCTTTGCAATGAGAAGTTCAGGAGATTATGGAGAAGTAACGGGAGCTTGG
1321 ATAGAGTTTGGATGTCATAGAAATAAATCAAAACATCATTCTGAAGCAAGGTTTAGAATT
1381 AGATGTAGATGGAATGTAGGATCCGATACCTCGCTCATTGATACATGTGGAACACTCGA
1441 GATGTTTCAGGTGCGAATCCTGTAGATTGTACCATGTATTCAAATAAAATGTACAATTGT
1501 TCTTTACAAAATGGGTTTACTATGAAGGTAGATGACCTTATTGTGCATTTCAATATGACA
1561 AAAGCTGTAGAAATGTATAATATTGCTGGAATTTGGTCTTGTACATCTGACTTGCCATCG
1621 TCATGGGGGTATATGAATTGTAATTGTACAAATAGTAGTAGTATAGTGGTACTAAA
1681 ATGGCATGTCCTAGCAATCGAGGCATCTTAAGGAATTGGTATAACCCAGTAGCAGGATTA
1741 CGACAATCCTTAGAACAGTATCAAGTTGTAAAAACAACAGATTACTTAGTGGTCCCAGAG
1801 GAAGTCATGGAATATAAACCTAGAAGGAAAAGGGCAGCTATTATGTTATGTTGGCTCTT
1861 GCAACAGTATTATCTATTGTGCGGTGCAGGGACGGGGGCTACTGCTATAGGGATGGTAACA
1921 CAATACCACCAAGTTCTGGCAACCCATCAAGAAGCTATAGAAAAGGTGACTGAAGCCTTA
1981 AAGATAAACAACTTAAGATTAGTTACATTAGAGCATCAAGTACTAGTAATAGGATTAAAA
2041 GTAGAAGCTATGGAAAAATTTTTATATACAGCTTTCGCTATGCAAGAATTAGGATGTAAT
2101 CAAAATCAATTTTTCTGCAAAATCCCTCCTGGGTTGTGGACAAGGTATAATATGACTATA
2161 AATCAAACAATATGGAATCATGGAATATAAATTTGGGGGCATGGTATAACCAAACAAAA
2221 GATTTACAACAAAAGTTTTATGAAATAATAATGGACATAGAACAAAATAATGTACAAGGG
2281 AAAACAGGGATACAACAATTACAAAAGTGGGAAGATTGGGTAGGATGGATGGGAATATT
2341 CCACAATATTTAAAGGGACTATTGGGAGGTATCTTGGGAATAGGATTAGGAGTGTTATTA
2401 TTGATTTTATGTTTACCTACATTGGTTGATTGTATAAGAAATTGTATCCACAAGATACTA
2461 GGATACACAGTAATTGCAATGCCTGAAGTAGAAGGAGAAGAAATACAACCACAAATGGAA
2521 TTGAGGAGAAATGGTAGGCAATGTGGCATGTCTGAAAAAGAGGAGGAATGA

```

FIG. 3 Nucleotide sequence of FIV gag/pol coding sequences from Rhone Merieux. The gag start codon is at position 1 and the gag stop codon is at position 1414. The ribosomal frameshift site is near position 1255. The frameshift is -1 in relation to the gag open reading frame. The frameshift goes into the pol open reading frame. The pol stop codon is at position 4614. Plasmid ptg8133 from Rhone Merieux contains the FIV gag/pol coding sequences. Part of ptg8133 has been sequenced and the CG at positions 577-578 below is GC in ptg8133, changing the codon from arg to ala.

```

1  ATGGGGAATGGACAGGGGCGAGATTGGAAAATGGCCATTAAGAGATGTAGTAATGTTGCT
61  GTAGGAGTAGGGGGGAAGAGTAAAAAATTTGGAGAAGGGAATTTTCAGATGGGCCATTAGA
121 ATGGCTAATGTATCTACAGGACGAGAACCTGGTGATATACCAGAGACTTTAGATCAACTA
181 AGGTTGGTTATTTGCGATTACAAAGAAAGAGAAAAATTTGGATCTAGCAAAGAAATT
241 GATATGGCAATTGTGACATTAAAAGTCTTTGCGGTAGCAGGACTTTTGAATATGACGGTG
301 TCTACTGCTGCTGCAGCTGAAAATATGTATTCTCAAAATGGGATTAGACACTAGGCCATCT
361 ATGAAAGAAGCAGGTGGAAAAGAGGAAGGCCCTCCACAGGCATATCCTATTCAAAACAGTA
421 AATGGAGTACCACAATATGTAGCACTTGACCCAAAATGGTGTCCATTTTTATGGAAAAG
481 GCAAGAGAAGGACTAGGAGGGGAGGAAGTTCAACTATGGTTTACTGCCTTCTCTGCAAT
541 TTAACACCTACTGACATGGCCACATTAATAATGGCCCGACCAGGGTGGCTGCAGATAAA
601 GAAATATTGGATGAAAGCTTAAAGCAACTGACAGCAGAAATATGATCGCACACATCCCCCT
661 GATGCTCCAGACCATTACCCTATTTTACTGCGAGCAGAAATTATGGGTATAGGATTAAT
721 CAAGAACAACAAGCAGAAGCAAGATTTGCACCAGCTAGGATGCAGTGTAGAGCATGGTAT
781 CTCGAGGCATTAGGAAAATTGGCTGCCATAAAAGCTAAGTCTCCTCGAGCTGTGCAGTTA
841 AGACAAGGAGCTAAGGAAGATTATTCATCCTTTATAGACAGATTGTTTGCCCAATAGAT
901 CAAGAACAATAACAGCTGAAGTTAAGTTATATTTAAACAGTCATTAAGCATAGCTAAT
961 GCTAATGCAGACTGTAAAAGGCAATGAGCCACCTTAAGCCAGAAAGTACCCTAGAAAGAA
1021 AAGTTGAGAGCTTGTCAGAAAATAGGCTCACCAGGATATAAAATGCAACTCTTGCCAGAA
1081 GCTCTTACAAAAGTTCAAGTAGTGCAATCAAAGGATCAGGACCAGTGTGTTTTAATTGT
1141 AAAAAACCAGGACATCTAGCAAGACAATGTAGAGAAGTGAAAAAATGTAATAATGTGGA
1201 AAACCTGGTCATCTAGCTGCCAAATGTTGGCAAGGAAATAGAAAAGAAATTCGGGAACTGG
1261 AAGGCGGGGCGAGCTGCAGCCCCAGTGAATCAAATGCAGCAAGCAGTAATGCCATCTGCA
1321 CCTCCAATGGAGGAGAACTATTGGATTATATAAATTATAAAGTAGGTACGACTACAA
1381 CATTAGAAAAGAGGCCAGAAATCTTATTTTGTAAATGGATATCCTATAAAATTTTTAT
1441 TAGATACAGGAGCAGATATAACAATTTTAAATAGGAGAGATTTCAAGTAAAAAATTCTA
1501 TAGAAAATGGAAGGCAAAATATGATTGGAGTAGGAGGAGGAAAGAGAGGAAACAAATTATA
1561 TTAATGTACATTTAGAGATTAGAGATGAAAATTATAAGACACAATGTATATTTGGTAATG
1621 TTTGTGCTTAGAAGATAACTCATTAAATACAACCATTTATGGGGAGAGATAATATGATTA
1681 AATTCATATTTAGGTTAGTAATGGCTCAAATTTCTGATAAGATTCCAGTAGTAAAAGTAA
1741 AAATGAAGGATCCTAATAAAGGACCTCAAATAAAACAATGGCCATTAACAAATGAAAAAA
1801 TTGAAGCCTTAACAGAAATAGTAGAAAGACTAGAAAGAGAAGGGAAAGTAAAAAGAGCAG
1861 ATCCAAATAATCCATGGAATACACCAGTATTTGCTATAAAAAAGAAAAGTGGAAAATGGA
1921 GAATGCTCATAGATTTTAGAGAATTAACAAAACCTAAGTGAAGGAGCAGAGGTCCAGT
1981 TGGGACTACCTCATCTGCTGGGTACAAAATAAAAAACAAGTAACAGTATTAGATATAG
2041 GGGATGCATATTTACCATTCTCTTGATCCAGATTATGCTCCTTATACAGCATTTACTT
2101 TACCTAGGAAAAAATAATGCGGGACCAGGAAGGAGATTTGTGTGGTGTAGTCTACCACAAG
2161 GCTGGATTTTAAAGTCCATTGATATATCAAAGTACATTAGATAATATAACAACCTTTTA
2221 TTAGACAAAATCCTCAATTAGATATTTACCAATATATGGATGACATTTATATAGGATCAA
2281 ATTTAAGTAAAAGGAGCATAAAGAAAAGGTAGAAGAATTAAGAAAATTACTATTATGGT
2341 GGGGATTTGAACTCCAGAAGATAAATTACAGGAAGAACCCCATATACATGGATGGGT
2401 ATGAATTACATCCATTAAACATGGACAATAACAACAGAAACAGTTAGACATTCCAGAACGC
2461 CCACTCTAATGAATTGCAAAAATTAGCAGGAAAAATTAATTGGGCTAGCCAAGCTATTC

```

FIG. 3 (cont'd)

2521 CAGACTTGAGTATAAAAGCATTAACTAACATGATGAGAGGAAATCAAAACCTAAATTCAA
 2581 CAAGACAATGGACTAAAGAAGCTCGACTGGAAGTACAAAAGGCCAAAAAGGCTATAGAAG
 2641 AACAAGTACAACCTAGGATACTATGACCCAGTAAGGAGTTATATGCTAAATTAAAGTTTGG
 2701 TGGGACCACATCAAATAAGTTATCGAGTATATCAGAAGGATCAAGAAAAGATACTATGGT
 2761 ATGGAAAAATGAGTAGACAAAAGAAAAAGGCAGAAAATACATGTGATATAGCCTTAAGAG
 2821 CATGCTATAAGATAAGAGAAGAGTCTATTATAAGAATAGGAAAAGAACCAAGATATGAAA
 2881 TACCTACTTCTAGAGAAGCCTGGGAATCAAATCTAATTAATTCACCATATCTTAAGGCCCC
 2941 CACCTCCTGAGGTAGAATATATCCATGCTGCTTTGAATATAAAAGAGAGCGTTAAGTATGA
 3001 TAAAAGATGCTCCAATACCAGGAGCAGAAACATGGTATATAGATGGAGGTAGAAAACCTAG
 3061 GAAAAGCAGCAAAAGCAGCCTATTGGGACAGATACAGGAAAGTGGAAGTGATGGAATTAG
 3121 AAGGCAGTAATCAGAAGGCAGAAATACAAGCATTATTATTGGCATTAAAAGCAGGATCAG
 3181 AGGAGATGAATATTATAACAGATTCACAATATGCTATAAATATTATTCTTCAACAACCAG
 3241 ATATGATGGAGGGAATCTGGCAAGAAGTTTATAGAAATGGAGAAGAAAACAGCAATAT
 3301 TTATAGATTGGGTCCCAGGACATAAAGGTATTCCAGGAAATGAGGAAGTAGATAAGCTTT
 3361 GTCAAACAATGATGATAATAGAAGGGGATGGGATATTAGACAAAAGGTGAGAAGATGCGAG
 3421 GATATGATTTATTAGCTGCAAAAGAAAATACATTTATTGCCAGGAGAGGTAAAAGTAATAC
 3481 CAACAGGGGTAAAGCTAATGCTGCCTAAAGGACATTGGGGATTAATAATCGGAAAAGCT
 3541 CGATGGGGAGTAAAGGATTGGATGTATTAGGAGGAGTAATAGATGAAGGATATCGAGGTG
 3601 AAATTGGAGTAATAATGATTAATGTATCAAGAAAATCAATCACCTTAATGGAAACGACAAA
 3661 AGATAGCACAAATTAATAATACTGCCTTGTAACATGAAGTATTAGAACAAGGAAAAGTAG
 3721 TAAGGGATTCCAGAGAGAGGAGGCAATGGTTATGGGTCAACAGGAGTATTCTCCTCTTGGG
 3781 TTGACAGAATTGAGGAAGCAGAAATAAATCATGAAAAATTTCACTCAGATCCACAGTACT
 3841 TAAGGACTGAATTTAATTTACCTAAAATGGTAGCAGAAGAGATAAGACGAAAATGCCAG
 3901 TATGCAGAATCAGAGGAGAACAAGTGGGAGGACAAATTGAAAATAGGGCCTGGTATCTGGC
 3961 AAATGGATTGCACACACTTTGATGGCAAAATAATTCTTGTGGGTATACATGTGGAATCAG
 4021 GATATATATGGGCACAAATAATTTCTCAAGAACTGCTGACTGTACAGTTAAAGCTGTTT
 4081 TACAATTGTTGAGTGCTCATAATGTTACTGAATTACAAACAGATAATGGACCAATTTTA
 4141 AAAATCAAAGATGGAAGGAGTACTCAATTACATGGGTGTGAAACATAAGTTTGGTATCC
 4201 CAGGGAACCCACAGTCACAAGCATTAGTTGAAAATGTAATCATACATTAAAAGTTTGGGA
 4261 TTCGGAAATTTTTGCCTGAAACAACCTCCTTGATAATGCCTTATCTCTCGCTGTACATA
 4321 GTCTCAATTTTAAAAGAAGAGGTAGGATAGGAGGGATGGCCCCTTATGAATTATTAGCAC
 4381 AACAAGAATCCTTAAGAATACAAGATTATTTTTCTGCAATACCACAAAAATTGCAAGCAC
 4441 AGTGGATTATTATAAAGATCAAAAAGATAAGAAATGGAAGGACCAATGAGAGTAGAAT
 4501 ACTGGGGACAGGGATCAGTATTATTAAAGGATGAAGAGAAGGGATATTTTCTTATACCTA
 4561 GGAGACACATAAGGAGAGTTCAGAACCCTGCGCTCTTCTGGAAGGGGATGAGTGA

FIG. 4 Sequence comprised in the C6 donor plasmid pC6L. Plasmid pC6L contains the C6 insertion sites SmaI (position 409) and EcoRI (position 425).

```

1   GAGCTCGCGGCCGCCTATCAAAAAGTCTTAATGAGTTAGGTGTAGATAGTATAGATATTAC
61  TACAAAGGTATTCATATTTCTATCAATTCTAAAGTAGATGATATTAATAACTCAAAGAT
121 GATGATAGTAGATAATAGATACGCTCATATAATGACTGCAAATTTGGACGGTTACATTTT
181 TAATCATCACGCGTTCATAAGTTTCAACTGCATAGATCAAAATCTCACTAAAAAGATAGC
241 CGATGTATTTGAGAGAGATTGGACATCTAACTACGCTAAAGAAATTACAGTTATAAATAA
301 TACATAATGGATTTTGTATCATCAGTTATATTTAACATAAGTACAATAAAAAGTATTAA
361 ATAAAAATACTTACTTACGAAAAAATGACTAATTAGCTATAAAAAACCGGGCTGCAGCTC
421 GAGGAATTCCTTTTATTGATTAAGTAGTCAATGAGTATATATAATTGAAAAAGTAAAT
481 ATAAATCATATAATAATGAAACGAAATATCAGTAATAGACAGGAACGGCAGATTCTTCT
541 TCTAATGAAGTAAGTACTGCTAAATCTCCAAAATTAGATAAAAATGATACAGCAAATACA
601 GCTTCATTC AACGAATTACCTTTTAATTTTTTCAGACACACCTTATTACAACTAACTAA
661 GTCAGATGATGAGAAAGTAAATATAAATTTAACTTATGGGTATAATATAATAAGATTCA
721 TGATATTAATAATTTACTTAAACGATGTTAATAGACTTATTCATCAACCCCTTCAAACCT
781 TTCTGGATATTATAAAATACCGATTAAATGATATTAAAAATAGATTGTTTAAGAGATGTAAA
841 TAATTATTTGGAGGTAAAGGATATAAAATTAGTCTATCTTTCACATGGAAATGAATTACC
901 TAATATTAATAATTATGATAGGAATTTTTTAGGATTTACAGCTGTTATATGTATCAACAA
961 TACAGGCAGATCTATGGTTATGGTAAACACTGTAAACGGGAAGCAGCATTCTATGGTAAC
1021 TGGCCTATGTTTAAATAGCCAGATCATTTTACTCTATAAACATTTTACCACAAATAATAGG
1081 ATCCTCTAGATATTTAATATTATATCTAACAACAACAAAAAATTTAACGATGTATGGCC
1141 AGAAGTATTTTCTACTAATAAAGATAAAGATAGTCTATCTTATCTACAAGATATGAAAGA
1201 AGATAATCATTTAGTAGTAGCTACTAATATGGAAAGAAATGTATACAAAAACGTGGAAGC
1261 TTTTATATTAAATAGCATATTACTAGAAGATTTAAATCTAGACTTAGTATAACAAAACA
1321 GTTAAATGCCAATATCGATTCTATATTTTCATCATAACAGTAGTACATTAATCAGTGATAT
1381 ACTGAAACGATCTACAGACTCAACTATGCAAGGAATAAGCAATATGCCAATTATGTCTAA
1441 TATTTTAACTTTAGAACTAAAACGTTCTACCAATACTAAAAATAGGATACGTGATAGGCT
1501 GTTAAAAGCTGCAATAAATAGTAAGGATGTAGAAGAAATACTTTGTTCTATACCTTCGGA
1561 GGAAGAAGCTTTAGAACAACTTAAGTTTAATCAAACCTTGATTTTATGAAGGTACC

```


FIG. 5 Predicted nucleotide sequence of the vCP242 insertion. The H6 promoter starts at position 55. The FIV env start codon is at position 179, and the FIV env stop codon is at position 2749. Positions 1 through 54 and positions 2750 through 2879 flank the H6/FIV env expression cassette.

```

1   TTAATAAAAATACTTACTTACGAAAAATGACTAATTAGCTATAAAAACCCGGGTTCTTT
61  ATTCTATACTTAAAAAGTGAAAAATAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAA
121 AGCGAGAAATAATCATAAATTATTTTATTATCGCGATATCCGTTAAGTTTGATCGTAAT
181 GGCAGAAGGATTTGCAGCCAATAGACAATGGATAGGACCAGAAGAAGCTGAAGAGTTATT
241 AGATTTTGATATAGCAACACAAATGAGTGAAGAAGGACCACTAAATCCAGGAGTAAACCC
301 ATTTAGGGTACCTGGAATAACAGAAAAAGAAAGCAAACTACTGTAACATATTACAACC
361 TAAGTTACAAGATCTAAGGAACGAAATTCAAGAGGTAAAACTGGAAGAAGGAAATGCAGG
421 TAAGTTTAGAAGAGCAAGATTTTAAAGGTATTCTGATGAACAAGTATTGTCCCTGGTTCA
481 TGCGTTCTAGGATATTGTATATATTTAGGTAATCGAAATAAGTTAGGATCTTTAAGACA
541 TGACATTGATATAGAAGCACCCCAAGAGAGTGTGTATAATAATAGAGAGAAGGTTACAAC
601 TGACAATATAAAATATGGTAGACGATGTTGCCTAGGAACGGTGACTTTGTACCTGATTTT
661 ATTTATAGGATTAATAATATATTACAGACAACCAACGCTCAGGTAGTATGGAGACTTCC
721 ACCATTAGTAGTCCAGTAGAAGAATCAGAAATAATTTTTTGGGACTGTTGGGCACCAGA
781 AGAACCCGCTGTCCAGGACTTTCTTGGGGCAATGATACATCTAAAAGCTAAGACAATAT
841 AAGTATACGAGAGGGACCTACCTTGGGGAATTGGACTAGAGAAATATGGGCAACATTATT
901 CAAAAGGCTACTAGACAATGTAGAAGAGGCAGAATATGGAAGATGGAATGAGACTAT
961 AACAGGACCATCAGGATGTGCTAATAACACATGTTATAATGTTTCAGTAATAGTACCTGA
1021 TTATCAGTGTTATTTAGATAGAGTAGATACTTGGTTACAAGGGAAAATAAATATATCATT
1081 ATGTCTAACAGGAGGAAAAATGTTGTACAATAAAGTTACAAAACAATTAAGCTATTGTAC
1141 AGACCCATTACAAATCCCACTGATCAATTATACATTTGGACCTAATCAACATGTATGTG
1201 GAATACTTCACAAATTCAGGACCCGTGAATACCAAATGTGGATGGTGGAAATCAATGGC
1261 CTATTATAACAGTTGTAAATGGGAAGAGGCCAAAGGTAAAGTTTCATTGTCAAAGAACACA
1321 GAGTCAGCCTGGATCATGGCGTAGAAGAGCAGCAATCTCGTCATGGAACAAGAAATAGTGGGA
1381 GTGGAGACCAGATTTGGAAAGTAAAGGTGAAAATATCTCTACAGTGCAATAGCACAAA
1441 AAACCTAACCTTTGCAATGAGAAGTTCAGGAGATTATGGAGAAGTAACGGGAGCTTGGAT
1501 AGAGTTTGGATGTCATAGAAATAAATCAAAACATCATTCTGAAGCAAGGTTTAGAATTAG
1561 ATGTAGATGGAATGTAGGATCCGATACCTCGCTCATTGATACATGTGGAAACACTCGAGA
1621 TGTTCAGGTGCGAATCCTGTAGATTGTACCATGTATTCAAATAAAATGTACAATTGTTC
1681 TTTACAAAATGGGTTTACTATGAAGGTAGATGACCTTATTGTGCATTTCAATATGACAAA
1741 AGCTGTAGAAATGTATAATATTGCTGGAATTTGGTCTGTACATCTGACTTGCCATCGTC
1801 ATGGGGGTATATGAATTGTAATTGTACAAATAGTAGTAGTAGTTATAGTGGTACTAAAAT
1861 GGCATGTCCTAGCAATCGAGGCATCTTAAGGAATTGGTATAACCCAGTAGCAGGATTACG
1921 ACAATCCTTAGAACAGTATCAAGTTGTAAAACAACCAGATTACTTAGTGGTCCCAGAGGA
1981 AGTCATGGAATATAAACCTAGAAGGAAAAGGGCAGCTATTCATGTTATGTTGGCTCTGTC
2041 AACAGTATTATCTATTGTCCGTGCAGGGACGGGGCTACTGCTATAGGGATGGTAACCCA
2101 ATACCACCAAGTTCCTGGCAACCCATCAAGAAGCTATAGAAAAGGTGACTGAAGCCTTAA
2161 GATAAACAACTTAAGATTAGTTACATTAGAGCATCAAGTACTAGTAATAGGATTAAGT
2221 AGAAGCTATGGAAAAATTCCTATATACAGCTTTTCGCTATGCAAGAATTAGGATGTAATCA
2281 AATCAATTCCTCTGCAAAATCCCTCCTGGGTTGTGGACAAGGTATAATATGACTATAAA
2341 TCAAACAATATGGAATCATGGAAATATACTTTGGGGGAATGGTATAACCAAAACAAAAGA
2401 TTTACAACAAAAGTTTATGAAATAATAATGGACATAGAACAAAATAATGTACAAGGGAA
2461 AACAGGGATACAACAATTACAAAAGTGGGAAGATTGGGTAGGATGGATGGGAAATATTC
2521 ACAATATTTAAAGGGACTATTGGGAGGTATCTGGGAATAGGATTAGGAGTGTATTATT
2581 GATTTTATGTTTACCTACATTGGTTGATTGTATAGAAATTTGTATCCACAAGTATAGG
2641 ATACACAGTAATTGCAATGCCTGAAGTAGAAGGAGAAGAAATACAAACCAAAATGGAATT
2701 GAGGAGAAATGGTAGGCAATGTGGCATGTCTGAAAAAGAGGAGGAATGATGAAGTATCTC
2761 AGAATTCCTGCAGCCCGGGGGATCCTTAATTAATTAGTTATTAGACAAGGTGAAAACGAA
2821 ACTATTTGTAGCTTAATTAATTAGCTGCAGGAATCTTTTATTGATTAAGTACAGTCAA

```

FIG. 6 Predicted nucleotide sequence of I3L promoted FIV gag/protease expression cassette and flanking regions in vCP253. The I3L promoter begins at position 135. The gag start codon is at position 235 and the protease stop codon is at position 1648.

```

1   TTAATCAATAAAAAGAATTCCTGCAGCCCTGCAGCTAATTAATTAAGCTACAAATAGTTT
61  CGTTTTACCTTGTCTAATAACTAATTAATTAAGGATCCCCCGTACCGGGCCCCCCCCCTCG
121 AGGTCGACATCGATACATCATGCAGTGGTTAAACAAAAACATTTTTATTCTCAAATGAGA
181 TAAAGTGAAAATATATATCATTATATTACAAAGTACAATTATTTAGGTTTAATCATGGGG
241 AATGGACAGGGGCGAGATTGGAAAATGGCCATTAAAGAGATGTAGTAATGTTGCTGTAGGA
301 GTAGGGGGGAAGAGTAAAAAATTTGGAGAAGGGAATTCAGATGGGCCATTAGAATGGCT
361 AATGTATCTACAGGACGAGAACCCTGGTGATATACCAGAGACTTTAGATCAACTAAGGTTG
421 GTTATTTGCGATTTACAAGAAAGAAGAGAAAAATTTGGATCTAGCAAAGAAATTGATATG
481 GCAATTGTGACATTAAAAAGTCTTTGCGGTAGCAGGACTTTGAATATGACGGTGTCTACT
541 GCTGCTGCAGCTGAAAATATGTATTCTCAAATGGGATTAGACACTAGGCCATCTATGAAA
601 GAAGCAGGTGAAAAGAGGAAGGCCCTCCACAGGCATATCCTATTCAAACAGTAAATGGA
661 GTACCACAATATGTAGCACTTGACCCAAAAATGGTGTCCATTTTCATGGAAGGCAAGA
721 GAAGGACTAGGAGGGGAGGAAGTTCAACTATGGTTTACTGCCTTCTCTGCAAATTTAACA
781 CCTACTGACATGGCCACATTAATAATGGCCGCACCAGGGTGCCTGCAGATAAAGAAATA
841 TTGGATGAAAGCTTAAAGCAACTGACAGCAGAAATATGATCGCACACATCCCCCTGATGCT
901 CCCAGACCATTACCCTATTTTACTGCAGCAGAAATTATGGGTATAGGATTAAGTCAAGAA
961 CAACAAGCAGAAGCAAGATTTGCACCAGCTAGGATGCAGTGTAGAGCATGGTATCTCGAG
1021 GCATTAGGAAAATTGGCTGCCATAAAAAGCTAAGTCTCCTCGAGCTGTGCAGTTAAGACAA
1081 GGAGCTAAGGAAGATTATTCACTCTTTATAGACAGATTGTTTGCCCAAATAGATCAAGAA
1141 CAAAATACAGCTGAAGTTAAGTTATATTTAAAACAGTCATTAAGCATAGCTAATGCTAAT
1201 GCAGACTGTAAAAAGGCAATGAGCCACCTTAAGCCAGAAAGTACCCTAGAAGAAAAGTTG
1261 AGAGCTTGTCAAGAAATAGGCTCACCAGGATATAAAATGCAACTCTTGGCAGAAAGCTCTT
1321 ACAAAGTTCAAGTAGTGCAATCAAAAGGATCAGGACCAGTGTGTTTAAATTGTAAAAAA
1381 CCAGGACATCTAGCAAGACAATGTAGAGAAGTGAAAAAATGTAATAAATGTGGAAAACCT
1441 GGTCACTAGCTGCCAAATGTTGGCAAGGAAATAGAAAGAATTTCGGGAAACTGGAAGGCG
1501 GGGCGAGCTGCAGCCCCAGTGAATCAATGCAGCAAGCAGTAATGCCATCTGCACCTCCA
1561 ATGGAGGAGAACTATTGGATTTATAAATTATAATAAAGTAGGTACGACTACAACATTAG
1621 AAAAGAGGCCAGAAATACTTATATTTGTAAATGGATATCCTATAAAATTTTATTAGATA
1681 CAGGATCAGATATAACAATTTTAAATAGGAGAGATTTTCAAGTAAAAAATTCTATAGAAA
1741 ATGGAAGGCAAAATATGATTGGAGTAGGAGGAGGAAAGAGAGGAACAAATTATATTAATG
1801 TACATTTAGAGATTAGAGATGAAAATTATAAGACACAATGTATATTTGGTAATGTTTGTG
1861 TCTTAGAAGATAACTCATTAAATACACCATTATTGGGGAGAGATAATATGATTAAATTCA
1921 ATATTAGGTTAGTAATGGCTCAATAATTTTATCCCGGTTTTTATAGCTAATTAGTCATT
1981 TTTCGTAAGTAAGTATTTTTATTTAATACTTTTTATTGTACTTATGTAAAT

```

FIG. 7 Predicted nucleotide sequence of the H6 promoted FIV env/I3L promoted FIV gag/protease expression cassette and flanking regions in vCP255. The H6 promoter starts at position 129, the FIV env start codon is at position 253, and the FIV env stop codon is at position 2823. The I3L promoter starts at position 2830, the FIV gag start codon is at position 2930 and the FIV gag stop codon is at position 4282. The ribosomal frameshift site is near position 4184. The frameshift is -1 in relation to the gag open reading frame. The frameshift goes into the pol open reading frame. The stop codon for the protease gene is at position 4641. Positions 1 through 128 and positions 4642 through 4727 flank the H6 FIV env/I3L FIV gag/protease expression cassette.

```

1   TTAATCAATAAAAAGAATTCTCTGCAGCCCTGCAGCTAATTAATTAAGCTACAAATAGTTT
61  CGTTTTACCTTGTCTAATACTAATTAATTAAGGATCCCCGTACCGGGCCCCCCTCG
121 AGGTCGACTTCTTTATTCTATACTTAAAAAGTGAAAATAAATACAAAGGTTCTTGAGGGT
181 TGTGTTAAATTGAAAGCGAGAAATAATCATAAATTATTTTCATTATCGCGATATCCGTTAA
241 GTTTGTATCGTAATGGCAGAAGGATTTGCAGCCCAATAGACAATGGATAGGACCAGAAAGAA
301 GCTGAAGAGTTATTAGATTTTGATATAGCAACACAAATGAGTGAAAGAGGACCACTAAAT
361 CCAGGAGTAAACCCATTAGGGTACCTGGAATAACAGAAAAAGAAAAGCAAACTACTGT
421 AACATATTACAACCTAAGTTACAAGATCTAAGGAACGAAATTCAAGAGGTAAACTGGAA
481 GAAGGAAATGCAGGTAAGTTTAGAAGAGCAAGATTTTTAAGGTATTCTGATGAACAAGTA
541 TTGTCCTGTTTCATGCGTTCATAGGATATTGTATATATTTAGGTAATCGAAATAAGTTA
601 GGATCTTTAAGACATGACATTGATATAGAAGCACCCCAAGAAGAGTGTTATAATAATAGA
661 GAGAAGGGTACAACCTGACAATATAAAATATGGTAGACGATGTGCTTAGGAACGGTGACT
721 TTGTACCTGATTTTATTTATAGGATTAATAATATATTCACAGACAACCAACGCTCAGGTA
781 GTATGGAGACTTCCACCATTAGTAGTCCCAGTAGAAGAATCAGAAATAATTTTTTGGGAC
841 TGTGTTGGGCACCAGAAGAACCCGCTGTCAGGACTTTCTTGGGGCAATGATACATCTAAAA
901 GCTAAGACAAATATAAGTATACGAGAGGGACCTACCTTGGGGAATTGGACTAGAGAAATA
961 TGGGCAACATTATTCAAAAAGGCTACTAGACAATGTAGAAGAGGCAGAATATGGAAAAGA
1021 TGAATGAGACTATAACAGGACCATCAGGATGTGCTAATAACACATGTTATAATGTTTCA
1081 GTAATAGTACCTGATTATCAGTGTATTATTTAGATAGAGTAGATACTTGGTTACAAGGGAAA
1141 ATAAATATATCATTATGTCTAACAGGAGGAAAAATGTTGTACAATAAAGTTACAAAACAA
1201 TTAAGCTATTGTACAGACCCATTACAAATCCCACTGATCAATTATACATTGGACCTAAT
1261 CAAACATGTATGTGGAATACTTCACAAATTCAGGACCCCTGAAATACCAAAATGTGGATGG
1321 TGGAATCAAATGGCCTATTATAACAGTTGTAAATGGGAAGAGGCAAAGGTAAAGTTTCAT
1381 TGTCAAAGAACACAGAGTCAGCCTGGATCATGGCGTAGAGCAATCTCGTCATGGAAAACAA
1441 AGAAATAGATGGGAGTGGAGACAGATTTGGAAAAGTAAAAAGGTGAAAATATCTCTACAG
1501 TGCAATAGCACAAAAAACCTAACCTTTGCAATGAGAAGTTCAGGAGATTATGGAGAAGTA
1561 ACGGGAGCTTGGATAGAGTTTGGATGTCATAGAAATAAATCAAAACATCATTCTGAAGCA
1621 AGGTTTAGAATTAGATGTAGATGGAATGTAGGATCCGATACCTCGCTCATTGATACATGT
1681 GGAAACACTCGAGATGTTTCAGGTGCGAATCCTGTAGATTGTACCATGTATTCAAATAAA
1741 ATGTACAATTGTTCTTTACAAAATGGGTTTACTATGAAGGTAGATGACCTTATTGTGCAT
1801 TTCAATATGACAAAAGCTGTAGAAATGTATAATTTGCTGGAAATTGGTCTTGATCATCT
1861 GACTTGCCATCGTCATGGGGGTATATGAATTGTAATTGTACAAATAGTAGTAGTATTAT
1921 AGTGGTACTAAAATGGCATGTCCTAGCAATCGAGGCATCTTAAGGAATTGGTATAACCCA
1981 GTAGCAGGATTACGACAATCCTTAGAACAGTATCAAGTTGTAAAACAACCAGATTACTTA
2041 GTGGTCCCAGAGGAAGTCATGGAATATAAACCTAGAAGGAAAAGGGCAGCTATTCATGTT
2101 ATGTTGGCTCTTGCAACAGTATTATCTATTGTGCGGTGCAGGGACGGGGGCTACTGCTATA
2161 GGGATGGTAACCCAATACCACCAAGTTCTGGCAACCCATCAAGAAGCTATAGAAAAGGTG
2221 ACTGAAGCCTTAAGATAAACAACCTTAAGATTAGTTACATTAGAGCATCAAGTACTAGTA
2281 ATAGGATTAAAAGTAGAAGCTATGGAAAAATTCTTATATACAGCTTTCGCTATGCAAGAA
2341 TTAGGATGTAATCAAATCAATTCTTCTGCAAAATCCCTCCTGGGTTGTGGACAAGGTAT

```

FIG. 7 (cont'd)

2401 AATATGACTATAAATCAAACAATATGGAATCATGGAATATAA CTTTGGGGGAATGGTAT
 2461 AACCAAACAAAAGATTTACAACAAAAGTTTTATGAAATAATAATGGACATAGAACAAAAT
 2521 AATGTACAAGGGAAAACAGGGATACAACAATTACAAAAGTGGGAAGATTGGGTAGGATGG
 2581 ATGGGAAATATTCCACAATATTTAAAGGGACTATTGGGAGGTATCTTGGGAATAGGATTA
 2641 GGAGTGTTATTATTGATTTTATGTTTACCTACATTGGTTGATTGTATAAGAAATTGTATC
 2701 CACAAGATACTAGGATACACAGTAATTGCAATGCCTGAAGTAGAAGGAGAAGAAATACAA
 2761 CCACAAATGGAATGAGGAGAAATGGTAGGCAATGTGGCATGTCTGAAAAAGAGGAGGAA
 2821 TGAATCGATACATCATGCAGTGGTTAAACAAAAACATTTTATTCTCAAATGAGATAAAG
 2881 TGAAATATATATCATTATATTACAAAGTACAATTATTTAGGTTTAATCATGGGGAAATGG
 2941 ACAGGGGCGAGATTGGAAAATGGCCATTAAAGAGATGTAGTAATGTTGCTGTAGGAGTAGG
 3001 GGGGAAGAGTAAAAAATTTGGAGAAGGGAATTTTCAGATGGGGCCATTAGAATGGCTAATGT
 3061 ATCTACAGGACGAGAACCCTGGTGATATACCAGAGACTTTAGATCAACTAAGGTTGGTTAT
 3121 TTGCGATTTACAAGAAAGAAGAGAAAAATTTGGATCTAGCAAAGAAATTGATATGGCAAT
 3181 TGTGACATTAAAAGTCTTTGCGGTAGCAGGACTTTGAAATATGACGGTGTCTACTGCTGC
 3241 TGCAGCTGAAAATATGTATTCTCAAATGGGATTAGACACTAGGCCATCTATGAAAGAAGC
 3301 AGGTGGAAGAGGGAAGGCCCTCCACAGGCATATCCTATTCAAACAGTAAATGGAGTACC
 3361 ACAATATGTAGCACTTGACCCAAAATGGTGTCCATTTTCATGGAAAAGGCAAGAGAAGG
 3421 ACTAGGAGGGGAGGAAGTTCAACTATGGTTTACTGCTTCTCTGCAAATTTAACACCTAC
 3481 TGACATGGCCACATTAATAATGGCEGCACCAGGGTGGCTGCAGATAAAGAAATATTGGA
 3541 TGAAAGCTTAAAGCAACTGACAGCAGAATATGATCGCACACATCCCCCTGATGCTCCCAG
 3601 ACCATTACCCTATTTTACTGACAGCAAGTAATGGGTATAGGATTAAGTCAAGAACACA
 3661 AGCAGAAGCAAGATTTGCACCAGCTAGGATGCAGTGTAGAGCATGGTATCTCGAGGCATT
 3721 AGGAAAATTTGGCTGCCATAAAAGCTAAGTCTCCTCGAGCTGTGCAGTTAAGACAAGGAGC
 3781 TAAGGAAGATTATTCATCCTTTATAGACAGATTGTTTGCCCAAATAGATCAAGAACAAAA
 3841 TACAGCTGAAGTTAAGTTATATTTAAACAGTCAATTAAGCATAGCTAATGCTAATGCAGA
 3901 CTGTAAAAAGGCAATGAGCCACCTTAAGCCAGAAAGTACCCTAGAAGAAAAGTTGAGAGC
 3961 TTGTCAAGAAATAGGCTCACCAGGATATAAAATGCAACTCTTGGCAGAAGCTCTTACAAA
 4021 AGTTCAAGTAGTGCAATCAAAGGATCAGGACCAGTGTGTTTTAATTGTAAAAAACAGG
 4081 ACATCTAGCAAGACAATGTAGAGAAGTGAAAAAATGTAATAAATGTGGAAGAACCTGGTCA
 4141 TCTAGCTGCCAAATGTTGGCAAGGAAATAGAAAGAATTCGGGAACTGGAAGGCGGGGCG
 4201 AGCTGCAGCCCCAGTGAATCAAATGCAGCAAGCAGTAATGCCATCTGCACCTCCAATGGA
 4261 GGAGAAACTATTGGATTTATAAATTATAATAAAGTAGGTACGACTACACATTAGAAAAG
 4321 AGGCCAGAAATACTTATATTTGTAAATGGATATCCTATAAAATTTTTATTAGATACAGGA
 4381 GCAGATATAACAATTTTAAATAGGAGAGATTTTCAAGTAAAAAATTCTATAGAAAATGGA
 4441 AGGCAAAATATGATTGGAGTAGGAGGAGGAAAGAGAGGAACAAATTATATTAAATGTACAT
 4501 TTAGAGATTAGAGATGAAAATTATAAGACACAATGTATATTTGGTAATGTTTGTGTCTTA
 4561 GAAGATAACTCATTAATACAACCATTATTGGGGAGAGATAATATGATTAAATTCATATT
 4621 AGGTTAGTAATGGCTCAATAATTTTATCCCGGGTTTTTATAGCTAATTAGTCATTTTTCG
 4681 TAAGTAAGTATTTTTATTTAATACTTTTTATTGTACTTATGTAAAT

FIG. 8 Predicted nucleotide sequence of vCP329 insertion. The H6 promoter starts at position 2146. The coding sequence for FIV 97TM is from position 2022 to position 42. The I3L promoter starts at position 2253. The FIV gag start codon is at position 2353 and the pol stop codon is at position 3766.

```

1   TTAATCAATAAAAAGAATTCTGTCAGGAATTCATAAAAATCATTCTTCTCCTTCTACTTC
61  AGGCATTGCAATTACTGTGTATCCTAGTATCTTGTGGATACAATTTCTTATACAATCAAC
121 CAATGTAGGTAAACATAAAATCAATAATAACACTCCTAATCCTATTCCCAAGATACCTCC
181 CAATAGTCCCCTTTTCTTCTAGGTTTATATTCCATGACTTCCTCTGGGACCACTAAGTA
241 ATCTGGTGTGTTTACAACTTGATACTGTTCTAAGGATTGTCGTAATCCTGCTACTGGGTT
301 ATACCAATTCTTAAAGATGCCTCGATTGCTAGGACATGCCATTTTAGTACCACTATAACT
361 ACTACTACTATTTGTACAATTACAATTCATATACCCCATGACGATGGCAAGTCAGATGT
421 ACAAGACCAATTTCCAGCAATATTATACATTTCTACAGCTTTTGTATATTGAAATGCAC
481 AATAAGGTCATCTACCTTCATAGTAAACCCATTTTGTAAAGAACAAATTGTACATTTTATT
541 TGAATACATGGTACAATCTACAGGATTCGCACCTGAAACATCTCGAGTGTTCACATGT
601 ATCAATGAGCGAGGTATCGGATCCTACATTCCATCTACATCTAATTCTAAACCTTGCTTC
661 AGAATGATGTTTTGATTTATTTCTATGACATCCAACTCTATCCAAGCTCCCGTTACTTC
721 TCCATAATCTCCTGAACTTCTCATTGCAAAGGTTAGGTTTTTTGTGCTATTGCACGTAG
781 AGATATTTTCACTTTTACTTTCCAAATCTGGTCTCCACTCCCATCTATTTCTTTGTTT
841 CCATGACGAGATTGCTCTACGCCATGATCCAGGCTGACTCTGTGTTCTTTGACAATGAAA
901 CTTTACCTTTGCCCTCTTCCCATTACAACCTGTTATAATAGGCCATTGATTCACCATCC
961 ACATTTTGGTATTTTCAGGGTCTGGAATTTGTGAAGTATTCACATACATGTTTATTAGG
1021 TCCAAATGTATAATTGATCAGTGGGATTGTAAATGGGTCTGTACAATAGCTTAATTGTTT
1081 TGTAACCTTTATTGTACAACATTTTTCTCCTGTGTAGACATAATGATATATTTATTTCCC
1141 TTGTAACCAAGTATCTACTCTATCTAAATAACACTGATAATCAGGTACTATTACTGAAAC
1201 ATTATAACATGTGTTATTAGCACATCCTGATGGTCTGTTATAGTCTCATTCCATCTTTT
1261 CCATATTCTGCCTCTTCTACATTGTCTAGTAGCCTTTTTGAATAATGTTGCCCATATTTT
1321 TCTAGTCCAATCCCCAAGGTAGGTCCCTCTCGTATACTTATATTTGTCTTAGCTTTTAG
1381 ATGTATCATTGCCCCAAGAAAGTCCCTGACAGGCGGGTCTTCTGGTGCCCAACAGTCCCA
1441 AAAAATCTTTCTGATTCTTCTACTGGGACTACTAATGGTGGAAGTCTCCATACTACCTG
1501 AGCGTTGGTGTCTGTGAATATATTATTAATCCTATAAATAAAATCAGGTACAAAGTCAC
1561 CGTTCCTAGGCAACATCGTCTACCATATTTTATATTGTCAGTTGTACCCTTCTCTATT
1621 ATTATAACACTCTTCTTGGGGTGCTTCTATATCAATGTCATGCTTAAAGATCCTAACTT
1681 ATTTGATTACCTAAATATATACAATATCCTATGAACGCATGAACCAGGGACAATACTTG
1741 TTCATCAGAATACCTTAAAAATCTTGCTCTTCTAAACTTACCTGCATTTCTTCTCCAG
1801 TTTTACCTCTTGAATTTCTGTTCTTAGATCTTGTAACCTTAGGTTGTAATATGTTACAGTA
1861 GTTTTGCTTTTCTTTTCTGTTATTCCAGGTACCTTAAATGGGTTTACTCCTGGATTAG
1921 TGGTCTTCTTCACTCATTTGTGTTGCTATATCAAAATCTAATAACTCTTCAGCTTCTTC
1981 TGGTCTTATCCATTGTCTATTGGCTGCAATCCTTCTGCCATTACGATACAACTTAACG
2041 GATATCGCGATAATGAAATAATTTATGATTATTTCTCGCTTCAATTTAACACAACCTTC
2101 AAGAACCTTTGTATTTATTTTCACTTTTTAAGTATAGAATAAAGAACTGCAGCTAATTAA
2161 TTAAGCTACAAATAGTTTCGTTTTCACCTTGTCTAATAACTAATTAATTAAGGATCCCC
2221 GTACCGGGCCCCCCTCGAGGTCGACATCGATACATCATGCAGTGGTTAAACAAAACAT
2281 TTTTATTCTCAAATGAGATAAAGTGAAAATATATATCATTATATTACAAAGTACAATTAT
2341 TTAGGTTTAATCATGGGGAATGGACAGGGGCGAGATTGGAAAATGGCCATTAAAGAGATGT
2401 AGTAATGTTGCTGTAGGAGTAGGGGGGAAGAGTAAAAAATTTGGAGAAGGGAATTTTACA
2461 TGGGCCATTAGAATGGCTAATGTATCTACAGGACGAGAACCCTGGTGATATACCAGAGACT
2521 TTAGATCAACTAAGGTTGGTTATTTGCGATTTACAAGAAAGAAGAGAAAAATTTGGATCT
2581 AGCAAAGAAATTGATATGGCAATTGTGACATTAAAAGTCTTTGCGGTAGCAGGACTTTTG
2641 AATATGACGGTGTCTACTGCTGCTGCAGCTGAAAATATGTATTCTCAAATGGGATTAGAC
2701 ACTAGGCCATCTATGAAAGAAGCAGGTGGAAAAGAGGAAGGCCCTCCACAGGCATATCCT
2761 ATTCAAACAGTAAATGGAGTACCACAATATGTAGCACTTGACCCAAAAATGGTGTCCATT

```

FIG. 8 (cont'd)

2821 TTCATGGAAAAGGCAAGAGAAGGACTAGGAGGGGAGGAAGTTCAACTATGGTTTACTGCC
2881 TTCTCTGCAAATTTAACACCTACTGACATGGCCACATTAATAATGGCCGCACCAGGGTGC
2941 GCTGCAGATAAAGAAATATTGGATGAAAGCTTAAAGCAACTGACAGCAGAATATGATCGC
3001 ACACATCCCCCTGATGCTCCCAGACCATTACCCTATTTTACTGCAGCAGAAATTATGGGT
3061 ATAGGATTAACTCAAGAACAAGCAGAAGCAAGATTTGCACCAGCTAGGATGCAGTGT
3121 AGAGCATGGTATCTCGAGGCATTAGGAAAATTGGCTGCCATAAAAGCTAAGTCTCCTCGA
3181 GCTGTGCAGTTAAGACAAGGAGCTAAGGAAGATTATTCATCCTTTATAGACAGATTGTTT
3241 GCCCAAATAGATCAAGAACAAATACAGCTGAAGTTAAGTTATATTTAAACAGTCATTA
3301 AGCATAGCTAATGCTAATGCAGACTGTAAAAAGGCAATGAGCCACCTTAAGCCAGAAAGT
3361 ACCCTAGAAGAAAAGTTGAGAGCTTGTCAGAAATAGGCTCACCAGGATATAAAATGCAA
3421 CTCTTGGCAGAAAGCTCTTACAAAAGTTCAAGTAGTGCAATCAAAGGATCAGGACCAGTG
3481 TGTTTAAATTGTAAAAAACAGGACATCTAGCTGCCAAATGTTGGCAAGGAAATAGAAAGAAT
3541 AATAAATGTGGAAAACCTGGTCATCTAGCTGCCAAATGTTGGCAAGGAAATAGAAAGAAT
3601 TCGGGAAACTGGAAGGCGGGGCGAGCTGCAGCCCCAGTGAATCAAATGCAGCAAGCAGTA
3661 ATGCCATCTGCACCTCCAATGGAGGAGAACTATTGGATTTATAAATTATAATAAAGTAG
3721 GTACGACTACAACATTAGAAAAGAGGCCAGAAATACTTATATTTGTAAATGGATATCCTA
3781 TAAAATTTTATTAGATACAGGAGCAGATATAACAATTTTAAATAGGAGAGATTTTCAAG
3841 TAAAAAATCTATAGAAAATGGAAGGCAAAATATGATTGGAGTAGGAGGAGGAAAGAGAG
3901 GAACAAATTATATTAATGTACATTTAGAGATTAGAGATGAAAATTATAAGACACAATGTA
3961 TATTTGGTAATGTTTGTGTCTTAGAAGATAACTCATTAATACAACCATTATTGGGGAGAG
4021 ATAATATGATTAAATTCAATATTAGGTTAGTAATGGCTCAATAATTTTATCCCGGGTTTT
4081 TATAGCTAATTAGTCATTTTTCGTAAGTAAGTATTTTATTTAATACTTTTTATTGTACT
4141 TATGTTAAAT

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.